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Summary 
Despite the rich oral microflora, infections within the oral cavity are rare. Rapid 
wound healing within the oral mucosa occurs, potentially due to the presence of oral 
mucosa lamina propria-progenitor cells (OMLP-PCs). OMLP-PCs are a novel 
population of multipotent cells known to possess immunosuppressive properties, 
through contact-independent mediated mechanisms. Many immunomodulatory 
soluble factors are also documented to have dual functions as antimicrobials; leading 
to the hypothesis that OMLP-PCs possess antibacterial properties in addition to their 
published immunoregulatory actions. The aim of this study was to investigate the 
antibacterial properties of OMLP-PCs and to define the mechanisms of action. A 
further aim of this study was to determine whether the antibacterial potential of 
OMLP-PCs was affected during disease, specifically Graft Versus Host Disease 
(GVHD).    The antibacterial properties of OMLP-PCs were compared between cells 
isolated from healthy donors and patients with oral chronic GVHD. During this study it 
was determined that OMLP-PCs possess constitutive antibacterial properties against 
Gram positive and Gram negative bacteria which are mediated through the release of 
soluble factors. LL37 and Indoleamine 2,3-Dioxygenase are known to mediated the 
antibacterial properties of bone marrow-mesenchymal stem cells, however this study 
determined that these factors did not play a role in the OMLP-PCs antibacterial 
effects. It was established that osteoprotegerin, haptoglobin and prostaglandin E2 in 
part mediate the antibacterial effects of OMLP-PCs. For the first time, direct 
antibacterial properties of osteoprotegerin were demonstrated against Gram positive 
bacteria. Furthermore, OMLP-PCs isolated from GVHD patients did not display 
antibacterial properties. It was further established that the secretion of innate cell 
chemoattractants was dysregulated in OMLP-PCs isolated from GVHD patients 
compared to healthy controls. This finding demonstrates that during GVHD, the oral 
mucosa is unable to regulate the oral microflora and sufficiently recruit innate 
immune cells during infection.      
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1 General Introduction 
1.1 Oral Mucosa 
The oral mucosa is a vital structure within the oral cavity, involved in 
thermoregulation, maintaining electrolyte balance and acting as a barrier to micro-
organisms (Stephens and Genever, 2007). Macroscopically the tissue is structured 
into three distinct layers: the oral epithelium, the lamina propria and the submucosal 
fat layer (Fig. 1.1; Stephens and Genever, 2007). 
 Epithelium 1.1.1
The epithelium consists of stratified squamous cells, which are mainly keratinocytes 
in addition to a small number of melanocytes, Langerhans cells and Merkel cells. 
Within the oral cavity, two different types of epithelium exist; keratinised and non-
keratinised epithelium (Dawson et al., 2013). Keratinised epithelium shares structural 
similarities with skin epithelium, due to the equivalent functions in resisting shear 
stress and microbial defense. This type of epithelium is found within the gingiva and 
hard palate, whereas non-keratinised epithelium is found within the soft tissues such 
as the underside of the tongue and the buccal mucosa (Stephens and Genever, 
2007).  
 Lamina Propria  1.1.2
The lamina propria is the connective tissue layer, which can be further separated into 
two regions; the papillary and the reticular layers (Stephens and Genever, 2007). The 
papillary layer is located immediately below the epithelium, with an extracellular 
matrix (ECM) comprised of glycoproteins, glycosaminoglycans, elastic fibres, 
proteoglycans and collagen (type I and III). Fibroblasts are thought to primarily 
produce and re-organise the ECM (Stephens et al., 1996) however, since these 
studies the identification of a stem cell population within the lamina propria, so 
termed oral mucosa lamina propria progenitor cells (OMLP-PCs), has been 
demonstrated (Davies et al., 2010). Further studies are needed to confirm whether 
the ECM is truly made by the oral fibroblasts, or whether there is an involvement of 
the OMLP-PCs in tissue homeostasis within the lamina propria.  
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Fig. 1.1: The structure of the oral mucosa (Reproduced from Stephens and Genever, 2007). 
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A thick reticular layer lays beneath the papillary layer, with an ECM comprising thick 
bundles of type I collagen, in addition to elastic fibres, glycosaminoglycans, 
proteoglycans, glycoproteins and fibroblasts (Stephens and Genever, 2007). Immune 
cells such as dendritic cells (DCs; Hovav, 2014) and cells of the blood vessels such 
as pericytes are also found dispersed within the lamina propria (Stephens and 
Genever, 2007). 
 Submucosa 1.1.3
The submucosa separates the oral mucosa from the underlying muscle and bone. It 
is comprised of adipocytes and an extensive blood network, providing a nutrient 
supply and waste removal to the tissue. The submucosal layer also functions as an 
insulator, preventing excessive heat loss (Stephens and Genever, 2007).  
 
1.2 Oral Microflora 
 Bacteria   1.2.1
More than 700 different bacterial species have been identified within the human oral 
cavity (Aas et al., 2005), making the oral cavity the second most bacterially diverse 
region of the body after the colon (Consortium, 2012). The large number of different 
bacteria within the mouth is not surprising with its continuous exposure to the 
external environment, presenting the oral cavity as a major entry point for bacteria. 
The majority of bacteria are commensals however, some species found in the oral 
cavity are pathogenic outside the confinement of the oral environment, for example 
within the respiratory system (Parahitiyawa et al., 2010).  
It has been reported that over 60% of bacteria discovered within the oral cavity 
cannot yet be cultured in standard laboratory conditions, only being identified by 
molecular techniques (Dewhirst et al., 2010). It has been reported that an average of 
56 different bacterial species are dominant in one human mouth. Whilst previous 
studies have demonstrated that a wide range of bacteria reside within the oral cavity, 
distinct niches were shown to harbour specific species (Aas et al., 2005). For 
example, Streptococcus sanguinis and Streptococcus australis were only found 
residing on the soft tissues of the mouth and not on hard tissues such as the teeth 
(Aas et al., 2005).  The most commonly found bacteria within the oral cavity were 
Gemella, Granulicatella, Streptococcus and Viellonella species, with Streptococcus 
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mitis (S. mitis) the most common singular species (Aas et al., 2005). Streptococcal 
species have also been documented by others to be the most abundant species 
within the oral cavity (Norder Grusell et al., 2013, Dewhirst et al., 2010).  
Commensal bacteria play a role in the homeostasis of the oral cavity. These bacteria 
bind to the surfaces within the oral cavity, limiting the areas in which pathogenic 
bacteria can bind and subsequently colonise. However, disruptions in the commensal 
flora can occur through a change in diet, radiation or use  of antibiotics (Wade, 2013). 
For example, in the human gut the use of β lactam antibiotics increases the overall 
bacterial load. However, a decrease in the bacterial diversity is also noted, with a 
20% drop in the number of different bacterial taxa identified after antibiotic use. 
Furthermore, an increase in Bacteroides bacteria is reported, demonstrating the shift 
of the normal gut flora (Panda et al., 2014).  
The microflora of the oral cavity in a healthy individual is distinct from that in a patient 
with oral disease. Bacterial species, such as Treponema denticola and 
Porphyromonas gingivalis (P. gingivalis), are associated with periodontal disease. 
These species are identified within the oral cavity of patients with periodontal 
disease, but not found in those of healthy subjects (Aas et al., 2005).  Higher 
bacterial counts of Neisseria species and enterobacteria have also been noted in 
patients with periodontal disease, compared to healthy individuals (Vieira Colombo et 
al., 2015). A link between chronic inflammatory periodontitis caused by bacteria and 
a number of systemic diseases has been documented. Chronic periodontitis is 
reported to be associated with the incidence of chronic heart failure in men under the 
age of 60 (Dietrich et al., 2008). It is also thought that the oral cavity provides a 
reservoir for respiratory pathogens, with direct access to the respiratory organs.  
Indeed, patients with a history of chronic obstructive pulmonary disease have been 
associated with a greater number of periodontal tooth attachment loss (Scannapieco 
and Ho, 2001). The presence of periodontal disease has also been associated with 
increased systemic complications (such as Graft Versus Host Disease [GVHD], see 
section 1.9.7.1) following hematopoietic stem cell therapy (HSCT), with prior 
periodontal treatment hypothesised to improve patient oral outcome (Gürgan et al., 
2013). Dental caries is another oral condition associated with bacterial species, such 
as Streptococcus mutans (S. mutans). It was found that significantly higher levels of 
S mutans were present in children with caries, compared to healthy controls, in 
addition to S. mitis, Streptococcus oralis and Streptococcus pneumoniae species 
(Becker et al., 2002).   
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 Fungi  1.2.2
Candida species, predominantly Candida albicans (C.albicans), have long been 
identified within the oral cavity (Arendorf and Walker, 1979). Many different Candida 
species have been isolated from the oral cavity of healthy individuals including C. 
albicans, Candida parapsilosis, Candida tropicalis and Candida glabrata, with C. 
albicans making up over 70% of the Candida species within the oral cavity (Ng et al., 
2015). In addition to Candida, Aspergillus and Fusarium species have been identified 
in the oral cavity however, these are less abundant than the Candida species 
(Ghannoum et al., 2010).  Whilst Candida species colonise in the oral cavity as 
commensals, they can act as opportunistic pathogens causing disease.  Overgrowth 
of the fungus, particularly in immunocompromised individuals, can cause the 
inflammatory condition candidiasis (Patel et al., 2012).  
 
1.3 Bacterial Cell Wall Structure 
The cell wall provides the bacterial cell with shape, whilst preventing the occurrence 
of cell lysis by regulating internal osmotic pressure (Yount and Yeaman, 2013). It is 
this structure which divides bacteria into two groups: Gram positive and Gram 
negative bacteria (Yount and Yeaman, 2013).  
 Gram Positive Bacteria 1.3.1
The cell wall of Gram positive bacteria (Fig. 1.2, A) consists of polysaccharides 
covalently linked to  peptidoglycan (PGN) (Schäffer and Messner, 2005). Gram 
positive bacteria have long been further classified into groups by the presence of 
three specific polysaccharides; teichoic acid (Archibald et al., 1968), teichuronic acid 
(Ward, 1981) or other acidic or neutral polysaccharides which do not fall under the 
previous two categories (Araki and Ito, 1989). These polysaccharides are thought to 
play a role in several different cellular functions of the cell wall such as ion 
homeostasis, protein binding, folding of extracellular proteins and forming a physical 
barrier (Schäffer and Messner, 2005).  
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Fig. 1.2: Cell wall structure of a: Gram positive and b: Gram negative bacteria. (Reproduced from 
Cabeen and Jacobs-Wagner, 2005). 
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 Gram Negative Bacteria  1.3.2
Gram negative bacterial cell walls (Fig. 1.2, B) also contain a PGN layer, however it 
is much thinner, usually 1-2 layers thick, and in some cases is a simple monolayer 
(Labischinski et al., 1991). Surrounding the PGN is a lipopolysaccharide (LPS) outer 
layer in which either lipoproteins or β-barrel proteins are embedded (Yount and 
Yeaman, 2013). Escherichia coli (E. coli) are thought to have over 100 lipoproteins 
embedded within their LPS layer, however their function is not characterised (Silhavy 
et al., 2010). Numerous β-barrel proteins have been identified, however few been 
demonstrated to be essential for bacteria.  Deletion of outer membrane protein 
(OMP)-85 for example in Neisseria meningitidis results in a lack of lipids within the 
outer membrane layer demonstrating the role in OMP-85 in lipid transport (Genevrois 
et al., 2003). 
 Cell Wall Synthesis  1.3.3
The bacterial cell wall and its synthesis are targeted by antimicrobials such as β-
lactam antibiotics (e.g. penicillin). PGN is the cellular wall component which provides 
strength and rigidity (Cabeen and Jacobs-Wagner, 2005). This layer is formed by 
alternating N-acetylglucosamine and N-acetylmuramic acid molecules, linked by 
peptidyl bridges (Lovering et al., 2012). The cellular synthesis of PGN is highly 
complex (Fig. 1.3), involving numerous enzymatic reactions (Lovering et al., 2012).  
Although PGN is found in both Gram negative and Gram positive cell walls, the major 
component within Gram negative species is LPS (Wang and Quinn, 2010). LPS 
molecules are comprised of three components; lipid A, core polysaccharides and O-
antigen repeats (Wang and Quinn, 2010). Lipid A is located at the outer membrane 
and conveys the molecule’s hydrophobicity. Both the core polysaccharides and O-
antigen repeats are found on the surface of bacterial cells (Wang and Quinn, 2010).  
Whilst the PGN structure remains consistent between organisms of the same Gram 
classification, the LPS layers and the proteins embedded can vary greatly (Wang and 
Quinn, 2010).  LPS is a vital structure of Gram negative organisms and its synthesis 
has been studied to potentially target as part of antibiotic therapy (Fig. 1.4). 
Disruption in the bacterial cell wall can be fatal for bacteria causing cell lysis, proving 
an ideal target for natural and synthetic antimicrobials.  
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Fig. 1.3: PGN synthesis (Adapted from Katayama et al., 2003). 
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Fig. 1.4: LPS synthesis in E. coli. The enzymes for each reaction are shown in red (Reproduced from 
Wang and Quinn, 2010). 
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LPS synthesis commences in the bacterial cytoplasm from a uridine diphosphate -N-
acetylglucosamine (UDP-GlcNAc) molecule. This molecule is converted into UDP-
diacyl-GlcN by the addition of two 3-OH fatty acids chains, catalysed by the enzymes 
LpxA, LpxC and LpxD (Wang and Quinn, 2010). The hydrolysis of UDP-diacyl-GlcN 
by LpxH converts this molecule into Lipid X, which is then condensed along with 
residual UDP-diacyl-GlcN by LpxB to form disaccharide-1-P. The disaccharide 
molecule is then acted upon by several enzymes, which result in the formation of 
Kdo2-lipid A. These enzymes include the kinases LpxK, Kdt, LpxL and LpxM (Wang 
and Quinn, 2010). The core polysaccharide portion of the LPS is then added to the 
Kdo2-lipid A molecule at the inner membrane. The core polysaccharide is comprised 
of two sections; an inner core, which binds to the Kdo2-lipid A molecule, and an outer 
core which connects to the O-antigen repeats. Once the LPS molecule is 
constructed, it is transported to the outer membrane by a range of enzymes such as 
LptA-G. The roles of these enzymes include transportation of LPS across the 
membrane and ensuring correct LPS assembly at the outer surface (Wang and 
Quinn, 2010).   
 
1.4 Host Response to Bacterial Challenge  
Rapid cellular recognition of pathogenic bacteria is vital to initiate immune system 
defences as quickly as possible. Antigen receptors on the surface of adaptive 
immune cells, such as B and T lymphocytes, recognise pathogens. These antigen 
receptors are specific for separate pathogens and depend on the memory of previous 
infections. However, it can take days to activate adaptive immune cells and carry out 
sufficient bacterial clearance. It is therefore essential that the host is able to initiate a 
more rapid defence mechanism. These defences are carried out through innate 
immune cells, targeting pathogens in a non-specific manner (Fournier and Philpott, 
2005).  
 The Innate Immune System 1.4.1
The innate immune system results in the rapid release of inflammatory cytokines 
from cells such as neutrophils and macrophages. These cells also serve to 
phagocytose and kill invading pathogens (Fournier and Philpott, 2005). Residual 
components from the destruction of the pathogens are presented to cells of the 
adaptive immune system, which initiates the slower but more specific host defence.  
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1.4.1.1 Neutrophils 
Neutrophils are recruited to sites of infection by interleukin (IL)-8 chemotaxis resulting 
in the phagocytosis of pathogens. Once phagocytised, pathogens are killed by 
reactive oxygen species (ROS) and reactive nitrogen species (RNS) produced by the 
neutrophils (Fialkow et al., 2007). Additionally, neutrophils release granule proteins 
and chromatin, which form fibres known as neutrophil extracellular traps (NETs). 
NETs can directly bind Gram positive and Gram negative bacteria, inducing bacterial 
killing (Brinkmann et al., 2004).  
Neutrophils are recruited from the bone marrow during infection, where their life span 
is noticeably increased (Kim et al., 2011). Their mobilisation by the neutrophil 
recruitment cascade is a several stage process (Kolaczkowska and Kubes, 2013). 
During the initial step, neutrophils tether to the surface of endothelial cells within the 
blood vessels. Endothelial cells are primed for this adhesion by inflammatory 
mediators such as histamine, resulting in the increased surface expression of the 
adhesion molecules, P- and E-selectin. The neutrophils roll along the surface of the 
endothelial cells in the direction of the blood flow. Activation of neutrophils is induced 
during the rolling process and is facilitated by cytokines such as tumour necrosis 
factor (TNF)α and IL-1β. Once at the site of infection, neutrophils cease rolling and 
adhere to the endothelial cells. Chemokines, such as IL-8, provide a signal to the 
neutrophils to initiate the adhesion to the endothelial surface. Neutrophils migrate out 
of the vasculature into the site of infection through either a paracellular or 
transcellular mechanism. Paracellular migration involves neutrophils migrating 
between two endothelial cells at the cell-to-cell junction. Neutrophils can also migrate 
directly through an endothelial cell by transcellular migration, however this is less 
efficient (Burns et al., 2000). During this process endothelial cells send out micro-villi 
like projections which wrap around the neutrophils. Importantly, neutrophils are not 
internalised by endothelial cells, but are merely covered by and protected by the 
endothelium. The final stage is the migration of the neutrophils through the basement 
membrane, a process facilitated by their production of proteases, such as 
metalloproteinases (MMPs), which digest the ECM.   
1.4.1.2 Monocytes 
Monocytes have long been identified by their expression levels of CD14 and CD16 
(Passlick et al., 1989). The primary subset of monocytes, termed classical 
monocytes, display a CD14+CD16- surface expression, making up 90% of the total 
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monocyte population. The remaining 10% of monocytes is comprised of cells with an 
expression profile of CD14+CD16+, so termed non-classical monocytes (Ziegler-
Heitbrock and Hofer, 2013). The expression of these molecules gives some 
indication into their function. The ability for CD14 to acts as a co-receptor for toll-like 
receptor (TLR)4, facilitating LPS signalling is well reported (Wright et al., 1990).  
Whilst the function of CD16, an Fc receptor, is involved in innate immunity (Clarkson 
and Ory, 1988).  
Classical monocytes can kill bacteria through the production of ROS and the action 
of phagocytosis (Serbina et al., 2008). Monocytes are recruited from the blood 
stream during infection and inflammation to affected tissues (Shi and Pamer, 2011). 
Non-classical monocytes are a major source of pro-inflammatory cytokines such as 
TNFα. It has been reported that the depletion of CD16+ cells from peripheral blood 
mononuclear cells (PBMCs) significantly reduces the TNFα secretion induced by LPS 
by 64% (Belge et al., 2002). In additional to TNFα, the production of IL-1β and a 
reduced phagocytic phenotype has been documented within the non-classical 
population of monocytes (Cros et al., 2010).  
1.4.1.3 Macrophages 
Macrophages are ubiquitous throughout human tissue however, distinct populations 
are evident within different anatomical locations. For example, microglia, 
macrophages of the brain, display a different molecular signature to macrophages 
originating from the spleen (Butovsky et al., 2014). Macrophage populations have a 
high degree of plasticity, changing their gene expression profiles in response to a 
range of stimuli. The activation of macrophages results in either M1 (classical 
activation) or M2 (alternatively activated) macrophage populations, with distinct 
phenotypes. Interferon (IFN)-γ, LPS or TNFα stimulation to monocyte precursors or 
tissue-resident macrophages classically activates the cells into an M1 phenotype, 
which are defined by the secretion of pro-inflammatory cytokines such as TNFα, IL-
12 and IL-6.  Alternative activation of cells by IL-4 or IL-10 for example, results in an 
anti-inflammatory M2 phenotype, defined by the secretion of cytokines such as IL-10 
(Hume, 2015).  
M1 and M2 macrophages have distinct roles with M1 macrophages involved in 
bacterial defences and M2 in parasite infections (Hume, 2015). Phagocytosis is 
decreased in M2 macrophages compared to the classically activated M1 population 
(Varin et al., 2010), with M1 macrophages mediating mycobacteria killing through 
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nitric oxide (Herbst et al., 2011). Additionally it has been documented that during 
tuberculosis infection M1 macrophages can induce autpphagy (Matsuzawa et al., 
2012) whilst the M2 subset of cells decrease autophagy (Harris et al., 2007). It is 
thought that the M1 pro-inflammatory macrophages mediate the initial defence during 
bacterial infection through the induction of inflammation and phagocytosis, while the 
M2 macrophages predominate at a later stage in order to resolve the increased 
inflammation and prevent tissue damage (Sica et al., 2015).   
1.4.1.4 Dendritic Cells 
Dendritic cells (DCs) are phagocytic cells, which provide a link between the innate 
and adaptive immune system. Described as antigen presenting cells (APCs), DCs 
process and present antigens to T cells, activating the adaptive immune system 
(León et al., 2007, Hohl et al., 2009). In addition to the priming of T cells, DCs plays 
an important role within innate immunity by secreting inflammatory factors such as 
TNFα and IL-12 after LPS stimulation (Serbina et al., 2003).  
DCs can be differentiated from both classical and non-classical monocytes 
(Sánchez-Torres et al., 2001), generating different phenotypic DCs. DCs originating 
from the non-classical expressing CD16 monocytes are capable of driving larger T 
cell responses (such as T cell activation) compared to the classical CD16- monocyte 
derived DCs (Bajaña et al., 2007).  
 Toll-like Receptors 1.4.2
TLRs are responsible for identifying pathogenic bacteria by recognising common 
bacterial motifs know as pathogen associated molecular patterns (PAMPs; Fournier 
and Philpott, 2005). There have been 10 TLRs identified in humans (Blasius and 
Beutler, 2010) with all reported to be expressed in the oral cavity (McClure and 
Massari, 2014). TLR1, 2, 4, 5, 6 and 11 are expressed on the surface of cells which 
are capable of recognising microbial molecules. The intracellular expression of TLR3, 
7, 8 and 9 is found in cellular components such as lysosymes and endosomes, with 
the receptors adept at detecting microbial nucleic acid (Blasius and Beutler, 2010). 
The TLR recognition of bacteria is often dependent on the type of cell wall the 
bacterial organism displays, i.e Gram positive or Gram negative. 
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1.4.2.1 Gram Negative Bacterial Recognition by TLRs 
LPS on the surface of Gram negative bacteria, can induce a response by the human 
innate immune system via TLR signalling. TLR4 can become activated by LPS via 
CD14 on the surface of monocytes. LPS is thought to bind to LPS-binding protein, 
which then binds CD14 (Wright et al., 1990). CD14 bound LPS activates TLR4, 
activating the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-Kb) 
pathway (Fig. 1.5). Firstly, TLR4 associates with the adapter molecule Myd88 and IL-
1 receptor associated kinase (IRAK), before IRAK dissociates and activates TNF 
receptor associated factor 6 (TRAF6; Heumann and Roger, 2002). The activation of 
TRAF6 results in activation of the NF-Kb pathway; promoting pro-inflammatory 
cytokine expression (Barton and Medzhitov, 2003) or the c-Jun N-terminal 
kinase/stress-activated protein kinase (JNK/SAP) pathway (Heumann and Roger, 
2002). The apoptotic JNK/SAP pathway has been shown to be activated by Gram 
negative bacteria such as Legionella pneumophila (Welsh et al., 2004). 
Yang et al. demonstrated that is it the lipid A portion of LPS which activates TLR2, 
with lipid A alone resulting in activation comparable with LPS. The lipid A activation of 
TLR2 can induce the NF-Kb pathway, resulting in the production of pro-inflammatory 
cytokines (Yang et al., 1998). Gene expression of TLR2 has been demonstrated in a 
large variety of lymphoid tissues such as the spleen and lymph nodes and peripheral 
blood leukocytes, such as macrophages (Yang et al., 1998).  Gram negative bacterial 
infections vary in severity depending on the lipid A structure of the organism (Wang 
and Quinn, 2010).  Some bacteria synthesise lipid A molecules which are not well 
recognised by the human immune system, such as Helicobacter pylori (H. pylori; 
Suda et al., 2001), P. gingivalis (Darveau et al., 2004) and Chlamydia trachomatis 
(Heine et al., 2003), which prevents the host from clearing the bacterial infection 
effectively.  The structure of the lipid A molecule i.e. the number of phosphate groups 
and length of the fatty acids chains, dictates the degree of immune activation (Wang 
and Quinn, 2010). For example, E. coli is a potent activator of the innate immune 
system as it contains two phosphate groups and six fatty acids chains comprising of 
12-14 carbons (Fig. 1.4). The oral pathogen, P. gingivalis, is known to activate TLR2. 
It has been reported that this activation of TLR2 leads to increased receptor activator 
of NF-κB ligand (RANKL) and therefore increased osteoclast formation. The 
increased osteoclast formation leads to increased bone resorption, resulting in bone 
loss (Kassem et al., 2015b).   
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Fig. 1.5: LPS activation of the NF-kB pathway. After binding to LPS binding protein, LPS forms a 
complex with CD14 causing a further association, with TLR4.  This complex then interacts with Myd88 
and IRAK, before IRAK dissociates to activate TRAF-6. The activation of TRAF-6 leads to the activation 
of the NF-kB pathway which increases pro-inflammatory cytokine expression and cause the activation of 
the JNK/SAP pathway. The JNK/SAP pathway leads to apoptosis of host cells. Yellow stars represent 
the activation of components.  
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1.4.2.2 Gram Positive Bacterial Recognition by TLRs 
It is widely accepted that TLR2 has a broad range of recognition, recognising 
bacterial lipoproteins and PGN from the Gram positive staphylococcal species 
(Yoshimura et al., 1999). Yoshimura et al. demonstrated that the pattern of TLR2 
recognition was the same from whole Staphylococcus aureus (S. aureus) and the 
soluble PGN from the organism. Schröder et al., 2003 provided evidence that 
lipoteichoic acid (LTA) within the PGN layer of Gram positive species, in addition to 
PGN itself, activates TLR2 and subsequently the NF-kB pathway. In vivo studies 
have supported the evidence that TLR2 is the vital receptor in Gram positive 
recognition. Takeuchi et al., 1999 demonstrated that TLR2 deficient mice did not 
respond to PGN, in addition to TLR2 deficient macrophages, which displayed an 
impaired response to Gram positive species. Whilst TLR4 is involved in Gram 
negative recognition, it is not thought to be involved in the recognition of Gram 
positive species. TLR4 deficient mice did not show any impairment or abnormal 
responses to PGN (Takeuchi et al., 1999).  
1.4.2.3 Viral Recognition by TLRs 
TLR3 is the major TLR involved in viral innate immunity. The receptor recognises the 
double stranded RNA produced by most viruses. The activation of TLR3 by viral RNA 
leads to the activation of the NF-kB pathway through Myd88 signalling, resulting in 
the production of type 1 interferons (Alexopoulou et al., 2001). TLR7, 8 and 9 are 
also involved in viral innate immunity, with TLR7 and 8 able to recognise single 
stranded RNA, with the recognition of double stranded viral DNA provided for by 
TLR9. Similarly to the activation of TLR3, the activation for TLR7, 8 and 9 by viral 
nucleic acids leads to the activation of the NF-kB pathway (Xagorari and Chlichlia, 
2008). TLR2 and 4 have also been implicated in the innate recognition of viruses. 
Viral proteins from organisms such as the Epstein-Barr virus (Gaudreault et al., 2007) 
and respiratory syncytial virus (Kurt-Jones et al., 2000) have been reported to 
activate TLR 2 and 4 respectively.  
1.4.2.4 Flagella Recognition by TLRs 
Flagella are rod-like appendages, comprised of the molecule flagellin, which extend 
from the outer membrane of some bacteria. Flagellin is a bacterial virulence factor 
recognised by TLR5. Studies have shown that flagellin from both Gram positive and 
Gram negative bacteria are capable of activating TLR5, while depletion of the 
flagellin gene results in no TLR5 activation (Hayashi et al., 2001). Furthermore, the 
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induction of the flagellin gene in the non-flagellated E. coli results in activation of 
TLR5 (Hayashi et al., 2001).  Activation of the receptor leads to NF-kB dependant 
production of TNFα (Hayashi et al., 2001). In addition to cytokine production, it has 
been reported that flagellin activation of TLR5 leads to bone loss. The loss of bone 
demonstrated in murine bones was dependant on the increased RANKL: 
osteoprotegerin (OPG) ratio, which allows increased osteoclast (bone resorbing 
cells) formation leading to bone resorption/loss (Kassem et al., 2015a).   
 Other PAMP Receptors 1.4.3
TLRs are the major receptor family involved in the recognition of pathogens, however 
several other receptor groups have also been identified to play a role in pathogen 
recognition and innate immunity. Each of these receptor groups, like the TLRs, result 
in the activation of the NF- kB pathway.  
1.4.3.1 Nod-like Receptors 
When activated, Nod-like receptors (NLRs) form inflammasomes, which are caspase 
activating complexes and facilitate pro-IL-1β maturation (Martinon et al., 2002). NLRs 
can be activated by a variety of stimuli such as ROS, muramyl dipeptides 
(mycobacterium cell wall component), flagellin, PGN and viral RNA (Claes et al., 
2015), leading to activation of the NF-kB signalling pathway (Silva et al., 2010).    
1.4.3.2 RIG-I like Receptors 
RIG-I like receptors (RLRs) play a role in anti-viral immunity. Activation of RLRs by 
viral RNA leads to NF-kB activation and the production of type 1 IFN and the 
upregulation of antiviral gene expression (Yoneyama et al., 2004). The expression of 
RLRs is found on most mammalian cells at low levels.  Expression levels of RLRs 
are greatly increased by type 1 IFN during viral infection (Kang et al., 2004, Imaizumi 
et al., 2005) 
 
1.5 Antimicrobial Peptides  
Antimicrobial peptides (AMPs) are cationic proteins which provide a first-line defence 
against infection (Guaní-Guerra et al., 2010). There are several groups of AMPs (see 
below).  Whilst each class of AMPs differ in structure, they all share a fundamental 
principle that cationic and hydrophobic amino acids cluster in distinct domains 
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(Zasloff, 2002). This conveys the amphoteric nature of the molecules. It is thought 
that cationic AMPs interact with the negatively charged phospholipids on bacterial 
membranes (Guaní-Guerra et al., 2010), resulting in disruption to the bacterial 
membrane.  
 Mechanism of Action 1.5.1
Several methods of how AMPs disturb the bacterial membrane have been proposed 
(Fig. 1.6). Firstly, the barrel-stave method, where AMPs insert into the bacterial 
membrane, spanning the entire depth forming a pore. Similar to the barrel-stave 
method, the toroidal pore method sees the AMPs span the bacterial membrane, 
forming a pore. The main difference from the barrel-stave method is that the AMPs 
also associate with the bacterial lipids. The carpet model describes the AMPs coating 
the bacterial membrane, causing disruption to its structure. AMPs can also interact 
with the negatively charged bacterial membrane which causes a change in the 
electrical potential across the membrane in the molecular electroporation model. 
Finally, the sinking raft model describes when AMPs sink into the bacterial 
membranes causing the formation of pores, which leads to an increase in membrane 
permeability (Teixeira et al., 2012).  
 Cathelicidins 1.5.2
Cathelicidins can modulate the immune system in several ways.  They can exert a 
direct chemoattractive effect on immune cells such as monocytes and CD4+ T 
lymphocytes and are able to inhibit the transcription of pro-inflammatory cytokines.  
Cathelicidins are also capable of directly binding bacteria via LPS (Guaní-Guerra et 
al., 2010).  
LL37 is an α-helical protein and the only human cathelicidin (Zanetti, 2005). It is 
formed from a precursor protein known as hCAP18 (human cathelicidin precursor; 
(Bowdish et al., 2005) and is cleaved by serine proteases to form the active LL37 
(Zanetti, 2005). In sweat, LL37 can be further processed into smaller components 
which exert increased antimicrobial effects (Izadpanah and Gallo, 2005). LL37 
constitutively expressed by cells such as monocytes, natural killer (NK) cells, B and T 
cells and within tissues such as newborn skin and respiratory epithelia (Zanetti, 
2005). LL37 expression is also inducible in keratinocytes, nasal mucosal tissue,  
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Fig. 1.6: AMPs and their mechanism of action. A: Barrel-stave model. B: Carpet Model. C: Toroidal 
Pore Model. D: Molecular Electroporation Model. E: Sinking Raft Model (Reproduced from (Teixeira et 
al., 2012).  
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synovial membranes (Zanetti, 2005) and salivary glands by inflammation (Woo et al., 
2003) and the peptide is detected in the saliva and gingival crevicular fluid of the oral 
cavity (Gorr, 2009).  The peptide has an array of functions including the direct killing 
of microorganisms, chemotaxis and wound healing. LL37 is capable of directly 
binding LPS, inhibiting the LPS induced cellular responses usually seen in infection 
(Zanetti, 2005), including the release of pro-inflammatory agents such as TNFα and 
IL-6 (Ngkelo et al., 2012).  
LL37 has been demonstrated in vitro to provide an antimicrobial effect against Gram 
negative bacteria (such as Pseudomonas aeruginosa [P. aeruginosa], Salmonella 
typhimurium and E. coli [Zanetti, 2005]) and Gram positive bacteria (such as S. 
aureus, Staphylococcus epidermidis [S. epidermidis] and vancomycin resistance 
Enterococci [Zanetti, 2005]).  Although LL37 has demonstrated a wide range of 
antimicrobial effects, it has not been reported to be an active antifungal against 
organisms such as Candida (Zanetti, 2005).  Recently, LL37 has been implicated in 
the antibacterial effects of bone marrow derived mesenchymal stem cells (BM-MSCs; 
Krasnodembskaya et al., 2010). It is thought that upon exposure to both Gram 
positive and Gram negative bacteria, BM-MSCs release LL-37, which provides its 
direct effects on the microorganisms (Krasnodembskaya et al., 2010). The authors 
demonstrated that conditioned media (CM) from the BM-MSCs exposed to bacteria 
decreased the growth of bacteria, which was reversed when the medium was 
supplemented with an LL37 neutralising antibody.  
The dysregulation in oral LL37 is associated with some periodontal diseases.  
Patients with Morbus Kostman disease, which results in severe periodontitis, are 
deficient in saliva LL37 (Pütsep et al., 2002). Papillion-Lefèvre syndrome is another 
condition characterised by severe periodontitis. The syndrome is associated with a 
deficiency in the serine proteases which cleave hCAP18 into the antimicrobial LL37 
peptide. Whilst normal levels of hCAP18 precursor are produced, a limited amount is 
converted into the active LL37 (de Haar et al., 2006). 
It has also been reported that LL37 can aid in the wound healing process. One study 
demonstrated that in a mouse model of full thickness excisional wounds, 
encapsulated LL37 decreased the wound closure time by inducing cell migration at 
the wound site (Chereddy et al., 2014). The expression of IL-6 and vascular 
endothelial growth factor (VEGF), factors essential to wound healing progression, 
were found to be increased within the wound tissue in response to the encapsulated 
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LL37 treatment (Chereddy et al., 2014). Increased expression of VEGF has also 
been documented in dental pulp cells and periodontal ligament cells after LL37 
treatment (Khung et al., 2014, Kittaka et al., 2013). These studies suggest that in 
addition to its well-known antimicrobial properties, LL37 may also demonstrate 
wound healing properties.  
 Defensins 1.5.3
Defensins are peptides of 3.5-4.5 KDa and roughly 30 amino acids in length. They 
contain an antimicrobial c-terminal and have been found to be involved in the 
oxygen-independent killing of phagocytosed organisms (De Smet and Contreras, 
2005).  Defensins are also chemoattractants for immune cells such as monocytes 
and T lymphocytes (Guaní-Guerra et al., 2010).  Defensins contain six cysteine 
residues, which are highly conserved and form disulphide bonds stabilising the 
defensin structure (Guaní-Guerra et al., 2010). Human defensins can be divided into 
two major groups depending on the disulphide bond arrangment: α-defensins and β-
defensins. 
1.5.3.1 Αlpha-defensins  
Six α-defensins have been identified in humans, four of which are constitutively 
expressed in neutrophil granules. These defensins are referred to as human 
neutrophil peptides (HNP) 1-4 (Guaní-Guerra et al., 2010). HNP1-4 display broad 
spectrum antibacterial properties against Gram positive and Gram negative bacteria 
(Ericksen et al., 2005), in addition to antiviral effects against adenoviruses (Smith et 
al., 2010). These peptides are also chemoattractants and can cause the down 
regulation of pro-inflammatory cytokine expression (Guaní-Guerra et al., 2010).  
Human defensins (HD) 5 and 6 are constitutively expressed in Paneth cells of the 
small intestine. HD5 displays antibacterial properties against both Gram positive and 
Gram negative bacteria (Ericksen et al., 2005), whereas it was thought HD6 was not 
antibacterial. However, by mimicking the intestinal environment, studies have 
demonstrated that HD6 displays antibacterial activity against commensal bacteria of 
the gut (Schroeder et al., 2015). Within the oral cavity, α-defensins are found within 
the saliva (HNP1, 2, 3) and gingival crevicular fluid (HNP1, 2, 3, 4; Gorr, 2009).  
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1.5.3.2 Βeta-defensins 
There have been six β-defensins identified in humans, hBD1-6 (Guaní-Guerra et al., 
2010), with hBD1-4 more extensive studied. β-defensins are larger than the α-
defensins, approximately 40 amino acids in length, and are produced primarily by 
epithelial cells (Guaní-Guerra et al., 2010).  
Table 1.1 demonstrates the anatomical distribution of each β-defensin’s expression. 
These AMPs display a broad spectrum of antimicrobial activity against organisms 
such as Gram positive bacteria, Gram negative bacteria, yeast and some viruses 
(Dale and Fredericks, 2005). β-defensins also play a role in the immunomodulatory 
effects following bacterial invasion by inducing the production of inflammatory 
cytokines such as TNF-α and IL-1 in keratinocytes (Guaní-Guerra et al., 2010). 
Human BDs -1, -2 and -3 are detected in the oral fluids such as saliva and gingival 
crevicular fluid (Gorr, 2009), with the supressed levels of hBD-1 and -2 within the 
saliva associated with oral candidiasis (Tanida et al., 2003). 
 Lipocalin-2 1.5.4
The major expression of the Lipocain-2 gene is found within neutrophils, with lower 
expression reported in the renal tubular cells and hepatocytes (Cowland and 
Borregaard, 1997). Lipocalin-2 is released at sites of infection by neutrophils and 
functions to sequester the bacterial sideropheres (bacterial iron-binding compounds; 
(Goetz et al., 2002). This action of lipocalin-2 prevents iron-chelation by 
microorganisms resulting in iron-deprived bacteria. The growth of E. coli is inhibited 
20-fold in the presence of lipocalin-2, which can be reversed by the addition of iron 
(Goetz et al., 2002).  In vivo studies have demonstrated that lipocalin-2-deficient mice 
display greater bacterial infection compared with control mice (Flo et al., 2004).  
 Adrenomedullin 1.5.5
Adrenomedullin (ADM) is a cationic peptide containing one disulphide bond. It is 
proteolytically generated from a 185 amino acid pro-form into the mature 52 amino 
acid ADM (Khurshid et al., 2015). The peptide is detected in human saliva (Kapas et 
al., 2004) and gingival crevicular fluid (Lundy et al., 2006) and possesses diverse 
antibacterial properties. ADM displays antibacterial activity against Gram positive 
bacteria such as S. epidermidis and Gram negative bacteria such as Pseudomonas 
species (Gröschl et al., 2009). Gröschl et al. further demonstrated no antifungal 
activity of ADM against C. albicans (Gröschl et al., 2009).  
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Table 1.1: β-defensin distribution (Guaní-Guerra et al., 2010).  
 
β -
defensin 
 
Area of AMP 
production 
 
Expression 
 
Antimicrobial activity 
 
References 
hBD1 Epithelial cells 
of the 
respiratory and 
urinary tracts 
Constitutive Staphylococcus aureus1  
Escherichia coli1 
Enterococcus faecalis2 
Candida albicans3 
 Candida krusei3  
Candida parapsilosis3 
(Chen et al., 
2005)
1 
(Lee and Baek, 
2012)
2 
(Aerts et al., 
2008)
3 
(Harder et al., 
2000)
4
 
hBD2 Skin and 
urinary, 
gastrointestinal 
& respiratory 
epithelia 
Inducible by 
IL-1α, IL-
1β, TNFα, 
IFNγ, LPS 
Pseudomonas aeruginosa4 
Staphylococcus aureus1  
Escherichia coli1 
Entercoccus faecalis2 
Candida albicans3 
 Candida krusei3  
Candida parapsilosis3 
hBD3 Skin and found 
in saliva 
Inducible Staphylococcus aureus1 
Escherichia coli1 
Entercoccus faecalis2 
Candida albicans3 
 Candida krusei3  
Candida parapsilosis3 
hBD4 Testicles, 
stomach and 
uterus 
Inducible Enterococcus faecalis2 
hBD5 
hBD6 
 
Epididymis 
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 Statherin 1.5.6
Statherin is a 5.4kDa cationic peptide secreted by parotid and submandibular glands 
(Isola et al., 2008) and is found in saliva (Wilmarth et al., 2004) and gingival 
crevicular fluid (Pisano et al., 2005). Statherin displays antibacterial activity against 
anaerobic bacteria isolated from the oral cavity such as Peptostreptococcus strains 
(Kochańska et al., 2000)  and the fungus C. albicans (Johansson et al., 2000).   
 C-C motif ligand 28 (CCL28) 1.5.7
CCL28 is a peptide comprised of 128 amino acids secreted by salivary glands and 
detected in saliva (Khurshid et al., 2015). It has been reported that human CCL28 
demonstrates a diverse antimicrobial activity against the fungus C. albicans in 
addition to Gram positive bacteria (S. mutans, Streptococcus pyogenes [S. 
pyogenes] and S. aureus) and Gram negative bacteria (P. aeruginosa and Klebsiella 
pneumoniae [K. pneumoniae]; (Hieshima et al., 2003).  
 Azurocidin 1.5.8
Azurocidin is a 37KDa cationic peptide expressed in azurophil granules of neutrophils 
(Khurshid et al., 2015). Azurocidin displays potent antibacterial activity against Gram 
negative bacteria, potentially due to its affinity to LPS (Linde et al., 2000). 
Additionally, azurocidin can act as a chemoattractant to monocytes and 
macrophages leading to enhanced phagocytosis of microorganisms by these 
immune cells (Soehnlein and Lindbom, 2009). 
 Neuropeptides 1.5.9
The two neuropeptides, calcitonin gene related peptide and substance P, are both 
detected in human gingival crevicular fluid (Awawdeh et al., 2002) and saliva 
(Dawidson et al., 1997), whilst within the oral cavity neuropeptide Y and vasoactive 
intestinal peptide are exclusively found in saliva (Dawidson et al., 1997). These 
neuropeptides display diverse antimicrobial activities against the fungus C. alibicans, 
Gram positive bacteria E. coli, S. mutans and Enterococcus faecalis (E. faecalis), 
and Gram negative bacteria P. aeruginosa and Lactobacillus acidophilus (El Karim et 
al., 2008). S. aureus is not susceptible to any of these neuropeptides (El Karim et al., 
2008).  
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 Therapeutic Use of AMPs 1.5.10
Cationic AMPs have been identified in leukocytes and other host cells in most 
species. Their antimicrobial functions, which are often directed at multiple 
microorganisms, provides a foundation for developing AMP based therapeutics 
(Devocelle, 2012). AMP therapies can be used alone or in combination with 
antibiotics (Marr et al., 2006), providing a synergistic antimicrobial effect (Devocelle, 
2012). Whilst they display antimicrobial actions, they also demonstrate 
immunomodulatory properties such as modulating cytokine release (Zanetti, 2005). 
For example, it has been demonstrated that LL37 can act as a chemoattractant for 
immune cells such as mast cells (Bąbolewska and Brzezińska-Błaszczyk, 2015).  
Additionally, LL37 has been reported to decrease the production of the pro-
inflammatory cytokines TNFα and IL-17, while increasing the anti-inflammatory 
factors IL-10 and transforming growth factor (TGF)β in mycobacteria infected 
macrophages (Torres-Juarez et al., 2015). This demonstrates the ability of LL37 to 
modulate macrophages during infection. Maturation of langerhans cell-like DCs is 
potently induced by hBD3. Furthermore the expression of c-c chemokine receptor 
type 7 (CCR7), a mediator of chemotactic responses, is increased on the surface of 
langerhans cell-like DCs by hBD3 (Ferris et al., 2013). 
However, there are some obstacles, which must be overcome to ensure a positive 
outcome for AMP therapy. AMPs are rapidly degraded or excreted, resulting in a 
need for high initial doses to maintain therapeutic levels. This raises concerns 
regarding AMPs reaching toxic levels (Devocelle, 2012). If administrated orally, the 
peptides will encounter hydrolytic enzymes such as pepsin and trypsin through the 
digestive system. Similarly, if administered intravenously, proteases in the blood can 
also cause proteolytic degradation of the peptides (Haney and Hancock, 2013). 
Modifying AMPs to incorporate non-natural D-isomers of amino acids can alter the 
stereochemistry of the peptides, decreasing their susceptibility to proteases (Haney 
and Hancock, 2013). 
This has led to the development of synthetic AMPs as therapeutic agents, which are 
produced to provide effective antimicrobial action against a specific organism, whilst 
displaying low toxicity in humans at the therapeutic index (Fjell et al., 2012). There 
are currently over 15 different peptide-based therapies in clinical trials for anti-
infective and anti-inflammatory actions (Table 1.2; Devocelle, 2012).  
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Table 1.2: Antimicrobial peptides in clinical trials, (Adapted from (Fjell et al., 2012). 
Name Description Application Trial 
Phase 
Comments 
Pexignan Derived from frog skin Topical antibiotic III No advantage over 
current therapies 
Omiganan Cationic – derived from indolicidin Topical antiseptic for the prevention of catheter infections III Efficacy shown 
Omiganan Cationic – derived from indolicidin Acne II/III Efficacy shown 
Iseganan Derived from protegrin-1 Oral mucositis in patients undergoing radiation therapy III No advantage over 
current therapies 
Hlf1-11 Cationic- derived from lactoferrin Bacteraemia & fungal infections in immunocompromised patient 
who have had haematopoietic stem cell transplants 
I/II Efficacy shown 
XOMA 
629 
Derived from a bactericidal 
permeability-increasing protein 
Impetigo IIA - 
PAC-133 Derived from histatin -3 and -5 Oral candidiasis IIB Efficacy shown 
CZEN-002 Derived from α-melanocyte-
stimulating hormone 
Vulvovaginal candidiasis IIB Efficacy shown 
OP-145 Derived from LL-37 Chronic middle-ear infections II Efficacy shown 
Ghrelin Endogenous host-defence peptide Chronic respiratory infection and cystic fibrosis II Inflammation 
suppression 
PMX-3006 Mimetic of defensin Staphylococcus species skin infections II - 
Delmitide Derived from HLA 1 Inflammatory bowel disease II Efficacy similar to other 
therapies 
Plectasin Fungal defensin Microbial diseases Pre-
clinical 
Excellent efficacy in 
animal models 
HB1345 Synthetic lipohexapeptide Acne Pre-
clinical 
Promising pre-clinical 
studies 
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The majority of synthetic peptide therapies in clinical trials remain in phase II 
demonstrating efficacy against a range of applications such as acne, impetigo, oral 
candidiasis and chronic middle-ear infection (Devocelle, 2012). A synthetic peptide 
derived from LL-37, OP-145, has completed phase II clinical trials, demonstrating 
proof of efficacy against chronic bacterial mid-ear infection (Clinical trial reference 
number: ISRCTN84220089; (Fjell et al., 2012). Other synthetic peptides have 
progressed further into phase III trials. Omiganan, a peptide trialled as a topical 
antiseptic against catheter infections and acne treatment, has shown efficacy 
(Clinical trial reference numbers: NCT00231153; 
https://clinicaltrials.gov/ct2/show/NCT00231153?term=NCT00231153&rank=1 and 
NCT00608959; https://clinicaltrials.gov/ct2/show/NCT00608959?term=NCT00608959 
&rank=1 (ClinicalTrials.gov).  Omiganan, as a topical gel, had previously been shown 
ex vivo to express potent antimicrobial activity against Gram negative bacteria, Gram 
positive bacteria and yeast in a dose-dependent manner (Rubinchik et al., 2009). 
While Omiganan demonstrated positive results in phase II/III trials, Pexigana, a 
synthetic peptide derived from frog skin, has not demonstrated any advantage over 
currently used therapies as a topical antibiotic (Clinical trial reference numbers: 
NCT00563433; https://clinicaltrials.gov/ct2/show/NCT00563433?term=NCT00563433 
&rank=1   and NCT00563394; https://clinicaltrials.gov/ct2/show/NCT00563394 
?term=NCT00563394&rank=1  (ClinicalTrials.gov). 
 Antimicrobial peptide resistance 1.5.11
The antimicrobial activity of AMPs has been maintained over millions of years with 
very little bacterial resistance documented (Peschel and Sahl, 2006). AMPs target 
fundamental structures within bacterial cells, which are too costly to compromise in 
order to develop resistance (Gallo et al., 2002). For bacteria to display resistance to 
all AMPs, bacteria would need to redesign their membrane ensuring differences were 
conveyed in the composition (Zasloff, 2002). This is a pursuit too great for bacteria to 
undertake. However, several resistance mechanisms are displayed by bacteria to 
overcome the action of AMPs (Fig. 1.7). Partial resistance has been conveyed by 
bacteria, such as S. aureus and group A Streptococcus (Gallo and Nizet, 2008) by 
decreasing their membrane negative charge, preventing the binding of AMPs 
(Izadpanah and Gallo, 2005). Bacteria have also developed a proteolytic degradation 
resistance method. This type of resistance involves bacteria producing peptidases 
and proteases which aim to cleave linear AMPs such as LL37 (Peschel and Sahl, 
2006). S. pyogenes and P. gingivalis are examples of bacteria which produce such  
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Fig. 1.7: Bacterial mechanisms to convey AMP resistance. Bacteria can decrease their negative charge 
to prevent AMP binding, release enzymes which cause the degradation of AMPs, sequester AMPs to 
prevent AMP action and express efflux pumps which actively pump AMPs out of bacterial cells. 
(Reproduced from (Gallo and Nizet, 2008). 
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enzymes (Peschel and Sahl, 2006). The addition of disulphide bonds to an AMP 
structure can increase the peptide’s resistance to proteolytic degradation. S. aureus 
has also developed an exoprotein, staphylokinase, which binds and inactivates α-
defensins, while Neisseria gonorrhoeae and Neisseria meningitides express a 
multidrug exporter, of which LL37 is a substrate (Peschel and Sahl, 2006). 
1.6 Antimicrobial Proteins 
Antimicrobial proteins provide an additional component to the innate immune system, 
which act to reduce bacterial infection. They often co-exist with AMPs leading to 
speculation that they may act synergistically. These proteins demonstrate 
antimicrobial activity by either degrading a specific cellular component of the 
microorganism or limiting a vital compound needed for the microorganism’s survival 
(Janeway et al., 2005). 
 Histatins 1.6.1
Histatins are histidine-rich proteins present within human saliva, playing a vital role in 
limiting oral infections (De Smet and Contreras, 2005). The major histatins are 
histatin-1, -3 and -5, with all other histatins existing as degradation products of these. 
Histatins provide anti-fungal activity against Candida (Dale and Fredericks, 2005) in 
addition to antibacterial effects (De Smet and Contreras, 2005). They are thought to 
exert their antimicrobial actions via bacterial membrane independent methods. 
Histatin-5 enters the microbial cells by binding to a 67KDa histatin-binding protein 
found in bacterial membranes (Edgerton et al., 1998), resulting in cessation of the 
bacterial cell cycle. Cell respiration is inhibited, depleting adenosine triphosphate 
(ATP) and the formation of ROS is seen (De Smet and Contreras, 2005). The 
antifungal activity of histatin-5 is mediated through the protein’s ability to penetrate 
the cells of pathogens, disrupting intracellular processes such as mitochondrial ATP 
production (Luque-Ortega et al., 2008). Studies have demonstrated that the level of 
histatins in patient saliva is negatively associated with levels of Candida (Sugimoto et 
al., 2006). Histatin-5 has been reported to decrease C. albicans growth within human 
oral epithelium and reduce host cell apoptosis (Moffa et al., 2015), demonstrating the 
ability of histatin-5 to reduce C. albicans colonisation within the oral cavity.   
 Indolamine 2,3-dioxygenase 1.6.2
Indolamine 2,3-dioxygenase (IDO) is the rate limiting enzyme involved in tryptophan 
degradation. It is induced by IFNγ in several cells such as macrophages, fibroblasts 
  Chapter 1 General Introduction 
31 
 
(Hucke et al., 2004), some stem cell populations (Meisel et al., 2004, Davies et al., 
2012) and by LPS to display its antibacterial properties (O'Connor et al., 2009). The 
action of IDO at the site of infection leads to a depletion in the essential amino acid 
tryptophan; causing an inhibition of the growth of tryptophan-dependant 
microorganisms (Hucke et al., 2004). Such microorganisms affected include the 
pathogenic bacteria B streptococci, Enterococci (Hucke et al., 2004) and S. aureus 
(Schroten et al., 2001). IDO has been reported to provide protection against bacterial 
infection in human heart valve and vascular allografts (Saito et al., 2008). The 
allografts displayed a reduced proliferation of methicillin-resistant S. aureus, 
mediated by the induction of IDO.  
IDO has also been demonstrated to act in an immunomodulatory capacity.  It has 
long been reported that T cells are not capable of proliferating in a tryptophan 
deficient environment (Munn et al., 1999); therefore the depletion of tryptophan by 
IDO suppresses T cell proliferation, limiting the immune response. However, further 
studies have demonstrated that the metabolites generated by IDO result in selective 
apoptosis of T helper (Th)1, but not Th2, cells (Fallarino et al., 2003).  
The expression of IDO has been noted in several stem cell populations. Wada et al., 
reported that upon IFNγ stimulation, periodontal ligament stem cells, BM-MSCs and 
dental pulp stem cells significantly increased the expression of IDO. OMLP-PCs also 
demonstrate increased IDO expression upon exposure to allo-activated lymphocytes 
in addition to IFNγ (Davies et al., 2012).  It was further noted that these stem cell 
populations significantly decreased the proliferation of PBMCs in transwell 
experiments (Wada et al., 2009, Davies et al., 2012). These experiments 
demonstrated that the immunosuppressive properties of these stem cells are 
conveyed in part by a contact-independent manner, utilising soluble factors such as 
IDO (Wada et al., 2009). Several other studies have also reported IDO expression in 
BM-MSCs upon IFNγ stimulation, which mediates the cell’s ability to inhibit T cell 
proliferation (Meisel et al., 2004, Ryan et al., 2007). This IDO-mediated theory has 
been confirmed by the restoration in T cell proliferation with the addition of the IDO 
antagonist 1-methyl-L-tryptophan (English et al., 2013).  
IFNγ-induced IDO can be increased by the pro-inflammatory cytokines TNF-α and IL-
1 (Nisapakultorn et al., 2009, Shirey et al., 2006). Both TNF-α and IL-1β have been 
found at elevated levels in chronic periodontitis (Graves and Cochran, 2003), which 
has led to the notion that these cytokines cause further activation of IDO thereby 
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preventing an excessive immune response (Nisapakultorn et al., 2009). A similar 
theory of IDO-induced protection in periodontitis has also been proposed by 
Konermann et al., 2012.  The IDO expression in human periodontal ligament cells 
was seen to increase when exposed to inflammatory cytokines, specifically IFNγ and 
IL-1β by real-time PCR. It was proposed that periodontal ligament cells counteract 
the immune response in periodontitis by upregulating IDO. 
 Lysozyme 1.6.3
Lysozyme is 1,4-β-N-acetylmuramidase, which targets the PGN in bacterial cell 
walls. Lysozyme degrades the linkages between the N-acetylglucosamine and N-
acetylmuramic acid molecules within the PGN, compromising its structure (Ellison 
and Giehl, 1991). Due to the mechanism of action, Gram positive bacteria, with 
exposed PGN, are highly susceptible to lysozyme. Gram negative bacteria however, 
are reasonably resistant to lysozyme, as their PGN layer is not exposed and the 
lysozyme is unable to penetrate the outer membrane (Ellison and Giehl, 1991).  
Lysozyme is one of the dominant proteins found in human breast milk, providing 
antibacterial protection to an infant (Lönnerdal, 2003) and is additionally found within 
the fluids of the oral cavity such as saliva and gingival crevicular fluid  (Gorr, 2009).  
 Lactoferrin 1.6.4
Lactoferrin binds with high affinity to iron, a vital compound for bacteria (Ellison and 
Giehl, 1991). The chelation of iron by lactoferrin deprives bacteria of this essential 
compound. Bacterial biofilm formation by P. aeruginosa and B. cepacia has been 
shown to be stimulated by iron (Berlutti et al., 2005). Therefore, it has been 
suggested that lactoferrin chelation of iron inhibits the formation of bacterial biofilms 
(Jenssen and Hancock, 2009).  It has also been proposed that enzymatic cleavage of 
lactoferrin results in antibacterial peptides, active against a range of bacteria 
including some resistant to the lactoferrin protein itself (Tomita et al., 1991). The 
activity of these antibacterial peptides was conserved in the presence of increased 
iron, unlike lactoferrin, suggesting an alternative mechanism to iron chelation. This is 
further supported by the lack of iron-binding residues in the peptide structures 
(Bellamy et al., 1992). These peptides, namely lactoferricin, have been shown to 
provide antibacterial protection against a range of bacteria such as E. coli, K. 
pneumoniae, P. aeruginosa and S. aureus. Lactoferricin treatment of the above 
bacteria significantly decreases the bacterial growth compared to bacterial cultures 
alone. It is thought the peptides act in a bactericidal manner as they cause the 
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viability of E. coli to rapidly decrease (Tomita et al., 1991). Levels of lactoferrin are 
detected in the saliva and gingival crevicular fluid of the oral cavity (Gorr, 2009) 
Studies have shown that lactoferrin can provide lysozome with access to the PGN 
layer of Gram negative bacteria. Lactoferrin binds the LPS layer, removing it from the 
outer membrane (Ellison and Giehl, 1991). This allows lysozyme to degrade the 
linkages within the PGN layer, compromising the microorganism’s structure.   
 Calprotectin 1.6.5
Calprotectin is a calcium binding protein found in the cytoplasm of neutrophils, which 
is also capable of binding zinc (Clohessy and Golden, 1995). It is found to be 
increased in inflammatory conditions and in bacterial invasion it’s binding to zinc, a 
vital growth requirement for many microorganisms, is competitive thereby reducing 
the availability of this mineral to bacteria (Dale and Fredericks, 2005). Clohessy and 
Golden, 1995 demonstrated that calprotectin significantly inhibits the growth of the 
fungus C. albicans. This growth inhibition is reversed when zinc is supplemented into 
the culture medium, demonstrating the role of zinc chelation in calprotectin’s 
mechanism of action. Calprotectin has also been shown to display antimicrobial 
effects against S. aureus, S. epidermidis, E. coli and Klebsiella species (Brandtzaeg 
et al., 1995). 
 Haptoglobin 1.6.6
Haptoglobin is an acute phase glycoprotein produced by the liver. It is formed from 2 
alpha and 2 beta chains, with three possible isoforms; Hp1-2, Hp2-1 and Hp2-2 
(Sadrzadeh and Bozorgmehr, 2004). The variation in isoforms is a result of differing 
alpha chain configurations, thereby determining the level of activity displayed by the 
protein. It is the alpha-1 chain which conveys the greatest activity, with the Hp1-1 
isoform of haptoglobin demonstrating the highest activity level (Eaton et al., 1982).  
Haptoglobin is known to be both antibacterial and immunomodulatory. It is the ability 
of haptoglobin to bind haemoglobin, causing depletion in iron, which gives the protein 
its antibacterial functions. Specifically, haptoglobin’s antibacterial properties against 
iron-dependent E. coli have long been reported (Eaton et al., 1982). The production 
of TNFα and IL-12 by monocytes in response to LPS is suppressed by haptoglobin in 
vitro (Arredouani et al., 2005) and during inflammatory conditions, such as 
endometriosis, haptoglobin serum levels are elevated (Polak et al., 2015).  This 
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demonstrates the potential anti-inflammatory effects of haptoglobin. For critically ill 
patients suffering with sepsis, an association between increased haptoglobin plasma 
concentrations and a decrease in mortality has also been reported (Janz et al., 
2013). It is thought that haptoglobin binds excess free haemoglobin, preventing 
haemoglobin-induced tissue injury.  
 
1.7 Osteoprotegerin 
The main function of the glycoprotein OPG within bone remodelling process is well 
defined. OPG is a decoy receptor for RANKL. When bound to RANKL, OPG prevents 
the RANKL mediated osteoclast maturation, limiting the bone resorption phase of the 
bone remodelling process (Jin et al., 2015). The secretion of OPG from BM-MSCs 
has been reported, and it’s role thought to be involved in the bone remodelling 
process described above (Oshita et al., 2011). OPG is detected within the oral fluids 
of the human oral cavity, and is reported to be decreased in patients with 
periodontitis (Bostanci et al., 2007, Mogi et al., 2004, Liu et al., 2003, Balli et al., 
2015). However, each of the studies have analysed the data in relation to the 
RANKL:OPG ratio and its effect on bone remodelling. No study has investigated the 
potential involvement of OPG directly on periodontitis and bacterial infection.  
TNF-related apoptosis-inducing ligand (TRAIL) is also a ligand for OPG and known to 
induce apoptosis (Chaudhari et al., 2006) and necrosis (Jouan-Lanhouet et al., 
2012). The induction of apoptosis is mediated by the activation of death domain 
receptors -4 and -5 by TRAIL (Chaudhari et al., 2006) and suppressed by TRAIL 
binding of the decoy receptor OPG (Sandra et al., 2006). It has been reported that 
TRAIL decreases the OPG release from MSCs (Corallini et al., 2011), potentially 
through decreasing the phosphorylation of p38/mitogen-activated protein kinase 
(MAPK). It has been speculated that p38/MAPK may regulate OPG mRNA as a 
decrease in OPG by TRAIL can be mimicked by an inhibitor of p38/MAPK (Corallini 
et al., 2011).  
OPG has also been implicated in modulatory aspects of the immune system, 
although no correlation as to an antibacterial effect has been reported. TRAIL-
induced lymphocyte apoptosis is inhibited by OPG (Emery et al., 1998), whilst the 
regulation of B cell development is OPG dependent (Yun et al., 2001). OPG knock-
out mice demonstrate disruptions in B cell populations with increased proliferative 
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capacity of pro-B cells and an accumulation of transitional B cell populations. OPG 
has also been reported to play a role in monocyte chemotaxis, inducing their 
migration in a dose-dependent manner; a process which is inhibited by blocking the 
receptor syndecan-1 (Mosheimer et al., 2005).  
 
1.8 Prostaglandin E2 
Prostaglandin E2 (PGE2) is a lipid produced by immune cells during inflammation 
(Agard et al., 2013). A number of immunomodulatory effects of PGE2 have been 
reported.  Macrophage phagocytosis is inhibited by PGE2 in a dose-dependent 
manner (Aronoff et al., 2004), in addition to the inhibition of lymphocyte activation 
and proliferation (Kalinski, 2012) and NK cell proliferation (Sotiropoulou et al., 2006). 
A number of stem cell populations such as BM-MSCs (Aggarwal and Pittenger, 2005, 
Sotiropoulou et al., 2006) and the orally isolated periodontal ligament stem cells 
(Ding et al., 2010) and gingival stem cells (Su et al., 2011) have been reported to 
secrete PGE2 as an immunomodulatory mechanism. Both the BM-MSC mediated 
myeloid cell maturation and lymphocyte cell inhibition is dependent on the secretion 
of PGE2, with PGE2 blockade preventing these BM-MSC effects in vitro (Yañez et 
al., 2010). The production of PGE2 from BM-MSCs can be stimulated in vitro by 
direct co-culture with T lymphocytes. TNFα stimulation of BM-MSCs can further 
induce PGE2 production, with additional synergistic effects when in combination with 
IFNγ (Hegyi et al., 2012).  
The production of PGE2 within the oral cavity has been associated with the 
periodontitis. Elevated levels of PGE2, up to an average of 83ng/ml, are reported in 
the gingival crevicular fluid of patients with periodontitis (Preshaw and Heasman, 
2002). Furthermore, the inhibition of PGE2 production by the COX2 inhibitor Celeoxib 
reduced the symptoms of periodontitis. It has been reported that Celeoxib reduces 
gum bleeding after dental probing and improves tooth attachment, compared to a 
placebo in periodontal patients (Yen et al., 2008).   
The synthesis of PGE2 is controlled by cyclooxygenase (COX) enzymes and is 
regulated by a number of inflammatory stimuli including the bacterial-derived stimuli 
LPS (Agard et al., 2013). Both the COX1 and COX2 enzymes can synthesise PGE2 
from the precursor arachidonic acid (Fig. 1.8). Although the expression of COX1 is 
constitutive, the expression of COX2 is induced by inflammatory stimuli (Park et al., 
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2006). While both Gram positive and Gram negative bacteria are known to induce 
PGE2 synthesis through COX2, higher levels are induced in macrophages by the 
Gram negative group of bacteria (Hessle et al., 2003). However, the direct effects of 
PGE2 on bacterial growth are not well known. 
 
1.9 Stem Cells  
Stem cells are defined by their self-renewal capacity and ability to differentiate into 
specialised cell types (Fagan, 2013). Stem cells are found within embryonic tissues 
in addition to postnatal and adult tissues. Embryonic stem cells are found within the 
inner cell mass of a blastocyte during early embryonic development and are defined 
as pluripotent, with the potential to differentiate into each of the three germ layers 
(Fig. 1.9).  After embryogenesis, most organs contain multipotent tissue-specific stem 
cell populations which maintain each organ throughout a lifetime (Nisbet 2004).   It is 
the local environment, known as the stem cell nice, which dictates the self-renewal 
and differentiation properties of the tissue resident stem cells. After injury for 
example, signals within the stem cell niche initiate stem cell expansion and 
differentiation to replace damaged tissue (Sakaki-Yumoto et al., 2013). Adult stem 
cells are categorised into three groups; neural stem cells, mesenchymal stem cells 
(or mesenchymal stromal cells [MSCs]), and hematopoietic stem cells (Fig. 1.10). 
The neural stem cells give rise to cells on the central nervous system, whereas 
mesenchymal stem cells differentiate into cells of connective tissues. Hematopoietic 
stem cells are the cells which develop into the cells of the immune system such as 
neutrophils and T lymphocytes.   
There is an ethical debate surrounding the use of embryonic stem cell for scientific 
research, as human embryonic stem cells are harvested during embryonic 
development, preventing further embryo growth (Westphal, 2002). Due to the debate 
surrounding embryonic stem cells, much research has shifted towards the use of  
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Fig. 1.8: Production of prostaglandins (PG) from Arachidonic acid. Arachidonic acid is metabolised by 
either COX1 or COX2 to form PGH2. The metabolism of PGH2 by thromboxane (Tx) synthase produces 
TXA2, while the metabolism by specific PG synthase enzymes results in the production of PGI2, PGE2, 
PGD2 and PGF2 (Wang and Dubois, 2006).  
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Fig. 1.9: Embryonic stem cell development. Embryonic stem cells differentiate to form 
all three germ layers; the mesoderm, endoderm and ectoderm. Each of these germ 
layers develops further into the specialised cells and tissues of the human body.  
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Fig. 1.10: Adult stem cell differentiation pathway. A: The differentiation of neural stem cells into the 
specialised cells of the central nervous system, neurons, glia, astrocytes and oligodentrocytes.  B: 
Mesenchymal stem cells differentiation potential into the cells that comprise bone (osteoblasts), 
cartilage (chrondrocytes) and fat (adipocytes), C: Hematopoietic stem cell differentiation into immune 
cells. Hematopoietic stem cells have the capacity to differentiate into terminal cell types such as 
monocytes, neutrophils, T lymphocytes and B lymphocytes.  
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adult stem cells, or induced pluripotent stem (iPS) cells.  Adult stem cells can be 
retrieved from an array of tissues from a consenting donor, while iPS cells can be 
generated from cells taken from either the patient or a consenting donor.  Induced PS 
cells were first generated in 2006 from murine fibroblasts, by inserting pluripotent 
genes into the cellular genone (Takahashi and Yamanaka, 2006). The production of 
iPS cells has made a large impact on the stem cell field, nearly eliminating the need 
for embryonic stem cells.   
 Mesenchymal Stromal Cells 1.9.1
MSCs are defined by a distinct set of criteria established in 2006 by the International 
Society for Cellular Therapy. Firstly, cells must adhere to plastic under standard 
culture conditions and secondly express the following cell surface markers; CD105, 
CD73 and CD90. The lack of CD45, CD34, CD14 or CD11b, CD79α or CD19 and 
human leukocyte antigen (HLA) surface molecules expression is equally important to 
confirm the MSC classification (Dominici et al., 2006). The differentiation capability is 
the final set of criteria cells must meet, being able to differentiate into cells of the 
mesoderm lineage such as osteoblasts, adipocytes and chondroblasts (Dominici et 
al., 2006). 
Standardisation of MSC criteria was needed as MSC definitions prior to this were 
ambiguous and varied. Scientists had a range of opinions as to the characteristics of 
MSCs and the methods to isolate and expand the cells in culture (Dominici et al., 
2006). The defined criteria has allowed for standardisation of MSC research across 
different laboratories and countries. MSCs were first isolated from the bone-marrow 
(Friedenstein et al., 1968) and have remained the primary source of cells for 
research however, further MSC populations have been discovered in a range of 
tissues such as adipose (Rebelatto et al., 2008) and articular cartilage (Dowthwaite 
et al., 2004).  
Despite MSC populations from different sources sharing phenotypic characteristics 
such as a fibroblast-like morphology and expression of surface antigen markers 
(Jeon et al., 2015), differences in key properties between different MSC populations 
has been demonstrated. Rates of cell proliferation, in addition to a differential 
genomic (Chen et al., 2015a) and proteomic expression profile between populations 
has been reported, contributing to processes involving the regulation of apoptosis 
and oxidative stress responses, amongst others (Jeon et al., 2015).  
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 Oral Mucosa Lamina Propria-Progenitor Cells  1.9.2
OMLP-PCs were first isolated in 2010 from disease-free buccal mucosal biopsies. 
The OMLP-PCs were clonally derived, forming a homogeneous cell population 
displaying a fibroblast-like morphology (Davies et al., 2010). The clones were 
selected by differential adhesion to fibronectin before the expression of several stem 
cell markers was assessed. OMLP-PCs were found to have positive expression of 
the stem cell markers CD44, CD90, CD105 and CD166, but found not to express the 
hematopoietic markers CD34 and CD45. These findings confirm that the OMLP-PCs 
are not from a haematopoietic or fibrocyte origin (Davies et al., 2010). The OMLP-
PCs were found to stain positively for the neural crest markers Slug, Snail, Twist and 
Sox10, confirming their origin is of the neural crest. These progenitor cells are 
capable of differentiating down both mesenchymal and ectodermal lineages forming 
cells such as osteoblasts, adipocytes and chroncytes cells (Fig. 1.11; Davies et al., 
2010). A buccal mucosal biopsy is easy to obtain involving a minimally invasive 
procedure. The location of the biopsy allows for rapid healing after the process with 
little/no scar formation (Davies et al., 2010). This makes OMLP-PCs a viable option 
as a source of patient treatment.    
 Stem Cells and the Immune System 1.9.3
1.9.3.1 Immunomodulatory Properties of MSCs  
MSCs have been shown to possess immunomodulatory properties by manipulating 
cells of the immune system though the release of soluble factors (Fig. 1.12; Atoui and 
Chiu, 2012). MSCs modulate several subsets of T cell populations. The proliferation 
of pro-inflammatory cytokine secreting CD4+ and CD8+ T cells is inhibited by MSCs, 
whereas the expansion of the IL-10 producing T regulatory (T reg) cells is increased. 
IDO has been repeatedly reported to play a role in MSC immunosuppression. Once 
activated by IFNγ, MSCs release IDO resulting in the degradation of tryptophan 
(Ghannam et al., 2010a).  PGE2 is another factor thought to play a role in MSC 
immunosupression by inhibiting the mitogenesis of T cells. The production of PGE2 
by MSCs is also upregulated upon IFNγ activation (Ghannam et al., 2010a). It was 
shown that in murine MSCs, the production of nitric oxide was noted, which was 
thought to play a role in the inhibition of T cell proliferation. However, nitric oxide 
secretion could not be detected from human MSCs (Ghannam et al., 2010a). It has 
been proposed that murine MSCs increase nitric oxide in response to inflammatory  
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Fig. 1.11: OMLP-PC differentiation capacity. OMLP-PCs can differentiate down the chondrogenic 
lineage (A: aggrecan immunohistochemistry), form osteoblastic cells (B: Staining for calcium deposition) 
and adipogenic cells (C: Oil red staining of lipid  droplets). (Images reproduced from (Davies et al., 
2010). 
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Fig. 1.12: MSC inhibitory effect on immune cells (reproduced from (Djouad et al., 2009, Bassi et al., 
2011). MSCs are stimulated by cytokines, chemokines and TLR-ligands to produce immunomodulatory 
factors such as PGE2, IDO and IL-6. MSCs inhibit the proliferation and cytokine production from CD4
+
 
and CD8
+
 T cells.  The expansion of T reg cells and their production of the anti-inflammatory IL-10 in 
promoted by MSCs. The proliferation and differentiation of B cells is inhibited by MSCs and the 
maturation of DCs, in addition to their expansion and production of pro-inflammatory cytokines is also 
inhibited. Neutrophil respiratory burst and apoptosis is stimulated by MSCs, in addition to the inhibition 
of NK cell proliferation.     
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stimuli, while human MSCs respond by inducing IDO activity, demonstrating 
differential species specific responses (Meisel et al., 2011). Further T cell effects 
have been demonstrated, with the inhibition of CD4+ T cell differentiation into Th1 
effector cells by MSCs reported (Bassi et al., 2011, Ghannam et al., 2010b). The 
inhibition leads to a shift in the Th populations to an increase in the Th-2 phenotype. 
This therefore leads to decreased IFNγ production and increased IL-4 production, 
resulting in a more anti-inflammatory phenotype (Bassi et al., 2011).  Further 
differentiation by CD4+ T cells into the IL-17 producing Th17 cells has also been 
reported to be inhibited by MSCs, resulting in the lack of pro-inflammatory IL-22, 
TNFα and IFNγ production by these reduced populations of Th cells (Ghannam et al., 
2010b). 
The proliferation of B cells is inhibited by MSCs in addition to immunoglobulin (Ig) M, 
IgG and IgA production (Bassi et al., 2011). The reduction in Ig production by MSC 
conditioned media (CM) has been demonstrated, with the CC chemokine ligands 
(CCL) 2 and 7 identified in mediating Ig loss. Neutralisation of CCL2 has been 
reported to restore production, whereas only a partially restoration is observed by 
neutralising CCL7 (Rafei et al., 2008). 
DC differentiation, maturation and activation is inhibited by MSCs. This results in an 
altered secretome profile of DCs with increased anti-inflammatory IL-1 and 
decreased pro-inflammatory IL-12, TNFα and IFNγ production (Bassi et al., 2011). 
The effects of MSCs on DCs are established during both direct and transwell culture 
of MSCs with DCs, demonstrating the role of soluble factors (Chen et al., 2015b).  
The pro-inflammatory M1 phenotype of macrophages is altered by MSCs, shifting 
macrophage populations into the anti-inflammatory M2 phenotype (Dayan et al., 
2011, Nakajima et al., 2012, Melief et al., 2013). An increase in IL-10 was reported 
with M1 to M2 polarisation by MSCs (Dayan et al., 2011), mediated by MSC IL-6 
production (Melief et al., 2013). There is also evidence to suggest PGE2 mediates IL-
10 secretion from macrophage populations. Antagonists to the prostaglandin EP2 
and EP4 receptors inhibits the MSC mediated IL-10 production by macrophages 
(Németh et al., 2009). 
Overall MSCs have an immunosuppressive effect of the immune system, shifting to a 
more anti-inflammatory state by reducing pro-inflammatory cytokine production and 
increasing anti-inflammatory cytokines such as IL-10.  
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The oral cavity provides a reservoir of different MSC populations such as gingival 
mesenchymal stem cells, dental pulp-MSCs (DP-MSCs) and periodontal ligament 
stem cells. Like other MSC populations, the orally derived MSCs display 
immunomodulatory properties such as the ability to suppress PBMC proliferation 
(Zhang et al., 2009, Tomic et al., 2011, Wada et al., 2009). Furthermore, it has been 
demonstrated that the DP-MSC immunosuppression is mediated by TGFβ (Tomic et 
al., 2011) while each orally derived MSC population can be induced to express 
immunosuppressive factors such as IDO, by IFNγ (Zhang et al., 2009, Wada et al., 
2009).  Moreover, MSC populations, such as human salivary gland MSCs, 
demonstrate chemotactic effects, such as the ability to cause directed migration of 
neutrophils (Brandau et al., 2014).  
1.9.3.2 Immunosuppressive Properties of OMLP-PCs 
It has been found that the OMLP-PCs possess immunomodulatory properties. 
OMLP-PCs were demonstrated to significantly suppress the proliferation of 
peripheral blood lymphocytes in a dose- and contact-independent manner (Davies et 
al., 2012). Significant suppression of lymphocyte proliferation remained when 0.001% 
OMLP-PCs to responder cells was examined. The removal of OMLP-PCs from the 
lymphocyte co-culture restored the lymphocyte proliferation, demonstrating that 
OMLP-PCs do not induce anergy (unpublished data, personal communication with Dr 
L. Davies). It was shown that the lymphocyte proliferation was not simply suppressed 
via the induction of cell death by both trypan blue exclusion and annexin V staining. 
The contact-independent nature of the immunomodulation was established using 
Transwell systems, where the OMLP-PCs were physically separated from the 
responder cells, suggesting the importance of soluble factors. One such factor, IDO, 
has been investigated (Davies et al., 2012) due to its immunosuppressive effects 
against primary human T cells (Forouzandeh et al., 2008). The activity of the IDO 
protein was only reported in OMLP-PCs once the cells had been exposed to IFNγ, 
and was not constitutively expressed. 
 Antibacterial Properties of MSCs 1.9.4
MSCs from the bone-marrow and umbilical cord blood have been shown to exhibit 
direct antibacterial properties against a small range of both Gram positive and Gram 
negative bacteria (Krasnodembskaya et al., 2010, Sung et al., 2016). MSCs 
significantly reduced the number of bacterial colony forming units (CFU) of E. coli, P. 
aeruginosa and S. aureus compared to bacteria cultured in the absence of cells. It 
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was also investigated whether CM of MSCs would display the same antibacterial 
effect. It was shown that MSCs CM that had previously been exposed to bacteria 
significantly reduced the bacterial CFU. This effect was not seen from MSC CM from 
cells in standard culture in the absence of bacteria (Krasnodembskaya et al., 2010, 
Sung et al., 2016). This demonstrates that the MSCs do not constitutively display 
antibacterial properties, but upon bacterial exposure secrete an antibacterial agent(s) 
into the medium. An antibacterial factor, LL-37, was investigated as a potential 
mechanism of action. LL37 was observed to increase in BM-MSCs pre-exposed to E. 
coli by RT-PCR and ELISA (Krasnodembskaya et al., 2010). Animal studies have 
shown that in a model of bacterial-induced sepsis, MSCs increase bacterial 
clearance and upregulate LL37 secretion (Lee et al., 2011). Umbilical cord-MSCs 
have also demonstrated similar antibacterial effects in vitro, with hBD-2 explored as a 
potential mechanism. It has been reported that secreted levels of hBD-2 are 
increased from umbilical cord-MSCs after exposure to E. coli, which correlated with 
increased levels of TLR2 and TLR4 (Sung et al., 2016). A knockdown of TLR4 
eliminated the induction of hBD-2 and the antibacterial effects of the umbilical cord-
MSCs. The antibacterial effects of MSCs were restored by the addition of hBD-2 into 
the culture medium. This demonstrates the involvement of TLR4-mediated 
production of hBD-2 in the antibacterial effects of umbilical cord-MSCs.  
1.9.4.1 MSC Therapy for Bacterial Infections 
BM-MSCs express TLR1, 2, 3, 4, 5, 6 and 9 (Cho et al. 2006), demonstrating their 
ability to recognise bacterial stimuli and therefore respond to the infection. Animal 
studies using E. coli induced murine pneumonia have shown that overall MSCs 
reduce lung injury and improve survival (Gupta et al., 2012). Bacterial clearance was 
seen to increase with MSC treatment in addition to upregulating lipocalin-2 
production (Gupta et al., 2012). Ex vivo studies have also demonstrated the benefit 
of MSC therapy for bacterial infections. Lee et al., 2013 infused MSCs into human 
lungs after inducing E. coli associated pneumonia. A significant reduction in CFU/ml 
of E. coli within the alveolar fluid was seen after MSC therapy, which was not 
replicated by fibroblast infusion. Increasing the MSC dose further decreased the 
bacterial load, indicating a dose-dependent response. To assess whether the MSCs 
released antibacterial factors as a mechanism of action, the alveolar fluid exposed to 
MSCs and E. coli was tested for antibacterial properties. The fluid exposed to the 
bacteria significantly reduced the CFU/ml of E. coli, demonstrating MSCs had 
released factors into the surrounding environment. In addition to the secretion of 
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antibacterial agents, Lee et al., demonstrated increased levels of phagocytosis, 
indicating a further mechanism of bacterial clearance (Lee et al., 2013). Both human 
BM-MSCs and microvesicles derived these cells demonstrate increased survival of E 
coli induced-acute lung injury mice in a dose-dependent manner (Monsel et al., 
2015). The increased survival rate was associated with an increased monocyte 
phagocytosis, decreased bacterial load and a decrease of the pro-inflammatory 
cytokine TNFa. Similar effects of MSC treatment have been demonstrated for K. 
pneumoniae-induced acute lung injury (Hackstein et al., 2015). Increased murine 
survival was observed in combination with reduced aveolar pro-inflammatory 
cytokines such as TNFα, in addition to decreased IFNy and IL-17 secreting T cell 
subsets. Furthermore, both CM and extracellular vesicles derived from both human 
and murine BM-MSCs ameliorate the effects of the fungal Aspergillus hyphal extract, 
which otherwise induced a murine model representative of severe refractory asthma. 
Both lung inflammation and the CD4+ T cell Th2 and Th17 phenotype were reduced 
after the CM or extracellular vesicle treatment (Cruz et al., 2015). Similar effects of 
MSC extracellular vesicles on bacterial-induced conditions are yet to be examined.        
MSCs are now being evaluated in the treatment of sepsis in animal models. Sepsis is 
a condition in which the response to an infection is dysregulated within the host 
(Lombardo et al., 2015). This dysregulation leads to a disproportionally high pro-
inflammatory response due to the increase in activation of PAMP receptors such as 
TLRs. Therapies to successfully treat sepsis are not available, whilst the condition 
continues to become amongst the most comment causes of death amongst 
hospitalised patients (Mayr et al., 2014). The potential for MSCs in the treatment of 
P. aeruginosa induced sepsis has been explored.  Murine models of bacterial 
induced sepsis were infused with MSCs. The intravenous (IV) administration of 
MSCs significantly increased the survival of the mice while demonstrating a reduction 
in the numbers of bacteria within the blood (Krasnodembskaya et al., 2012). The 
reduction in bacterial numbers was attributed to increased phagocytosis of peripheral 
monocytes. The specific antiseptic mechanism of MSCs is not clearly defined, but 
MSCs are thought to contribute in several ways. The pro-inflammatory state of 
patients is facilitated by the apoptosis of many resolving immune cells (Kusadasi and 
Groeneveld, 2013). MSCs have been shown to reduce the apoptosis of neutrophils 
through IL-6 mediated mechanisms (Raffaghello et al., 2008), which could aid in the 
control of the pro-inflammatory state for septic patients. Studies have also shown that 
MSCs can effectively reverse the inflammatory position from a pro-inflammatory to an 
anti-inflammatory state. Németh and colleagues demonstrated that MSC infusion into 
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a murine model of sepsis significantly reduced the serum levels of the pro-
inflammatory cytokines TNFα and IL-6, both of which are known to be key in the 
development of sepsis (Németh et al., 2009). Furthermore, it was shown that the 
serum levels of the anti-inflammatory IL-10 were increased, even at 3 hours post 
MSC infusion. The study expanded to look at the influence of immune cells on the 
MSC antiseptic action. T, B and NK cells were not found to play a role however, 
when monocytes and macrophages were depleted, the MSC infusion failed to have 
an effect. It was also found that the monocytes and macrophages were the source of 
the anti-inflammatory IL-10 levels.  The authors found that bacterial LPS exposure 
activated the NF-kB pathway, which induced the production of COX2 dependant 
PGE2 from MSCs. The prostaglandin then modifies the macrophage secretome by 
reducing TNFα and IL-6 levels and increasing IL-10 (Németh et al., 2009).  
 MSCs as a cell-based therapy 1.9.5
There are currently almost 500 clinical trials which are registered to assess MSC-
based therapy (ClinicalTrials.gov). MSCs are thought to home to sites of injury, 
making them suitable candidates for cell-based therapies (Wei et al., 2013). The 
directed migration is thought to involve several cytokines and chemokines. For 
example, the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) found 
to be expressed on the surface of MSCs responds to the secretion gradient of 
stromal cell-derived factor-1 (SDF-1) from the sites of tissue damage. Over-
expression of the receptor in MSCs has been demonstrated to improve the cell 
engraftment at the site of injury (Cheng et al., 2008). It has also been reported that 
direct co-culture of H. pylori with BM-MSCs results in an increased BM-MSC surface 
expression of CXCR4, enhancing the migration of the cells towards a SDF-1a 
gradient (Fakhari et al., 2014). Another chemokine noted to be involved in MSC 
migration is macrophage inflammatory protein 1 alpha (MIP-1α) (Eseonu and De 
Bari, 2015). Cell migration assays have determined that MIP-1α, again secreted from 
sites of damage, significantly increases the migration of MSCs in vitro (Boomsma 
and Geenen, 2012).  
IV administration of MSCs has been demonstrated to be safe and allows for a large 
number of MSCs to be delivered. However, tracking studies have established that the 
overwhelming majority of infused MSCs migrate to the lungs (Assis et al., 2010, 
Fischer et al., 2009), with minimal numbers migrating to organs such as the heart 
and kidneys (Assis et al., 2010).  When infused into a rat model of myocardial 
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infarction, the small number of MSCs which migrated to the heart remained 7 days 
post infusion (Assis et al., 2010, Kraitchman et al., 2005). However, when infused 
into wild-type mice, infused MSCs were located in the lungs 1hr post infusion, with no 
viable MSCs detected in any other organ. Furthermore, infused MSCs were not 
detected in the lungs 24hrs post infusion, demonstrating their short longevity 
(Eggenhofer et al., 2012).  
The engraftment of IV infused MSCs has been investigated in the autopsy material of 
18 patients, all of which received MSC IV treatment (von Bahr et al. 2012). Autopsy 
material from just 8 patients was positive for donor MSC DNA, which was detected 
mostly within the lung, lymph nodes and intestine. The detection of MSC donor DNA 
was negatively correlated with the time from infusion, suggesting MSCs are cleared 
from the patient over time after the IV infusion MSC treatment demonstrating a 
limited engraftment long term. It was also reported that there was no correlation 
between MSC engraftment and treatment response, demonstrating that the MSC 
mechanism of action does not require MSC engraftment.    
Research involving MSCs has begun to focus on patient treatment. The 
overwhelming presence of infused MSCs in the lungs and the short longevity of the 
cells could limit their application (Eggenhofer et al., 2012), however MSC therapy has 
proven effective despite this for the treatment of conditions such as GVHD (see 
section 1.9.7.1). These stem cells are considered immunoprivileged due to their low 
expression of HLA I and HLA II and a lack of T cell stimulatory molecules (Lee et al., 
2011). The immunosuppressive nature of the cells could cause some concern if 
treating diseases unrelated to the immune system. However, suppression of the 
immune system by MSCs may not correlate to an increase in infections due to their 
additional antibacterial properties (Lee et al., 2011). Ease of delivery and the 
immunoprivilege properties make MSCs ideal drug candidates. 
 Post Hematopoietic stem cell transplantation Infections  1.9.6
HSCT is a treatment for conditions such as leukaemia and solid tumours (Passweg 
et al., 2014). However, HSCT transplantation can lead to the development of 
complications such as GVHD (see section 1.9.7.1) and increased infections (Kedia et 
al., 2013). The increase in infections is a result of the conditioning regimes (such as 
chemotherapy and radiation) prior to the HSCT, which target the immune cells of the 
bone marrow. Additionally, the patient is subjected to immunosuppressive treatment, 
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to prevent immune rejection of the transplant. This has further effects on the patient’s 
immune system, dampening its ability to fight infections. 
Neutropenia (decreased neutrophils) can result from HSCT, predisposing patients to 
increased infections. The majority of these infections are caused by bacteria (Young 
et al., 2015) and have the potential to be life threatening in this group of patients. 
Diverse oral bacterial infections have been documented post-HSCT, caused by 
microorganisms such as Gram positive cocci, and the Gram negative organisms K. 
pneumoniae and Enterobacter cloacae (Vavilov et al., 2015).  Fungal infections have 
also been reported in patients undergoing HSCT. The most common fungal 
infections within the oral cavity of these patients are caused by C. albicans, with 
patients receiving allogeneic HSCT more susceptible to fungal infections, compared 
to those who received an autologous HSCT (Markowski et al., 2015). Viral infections, 
particularly the reactivation of human herpes virus-6 (Shachor-Meyouhas et al., 2015, 
Inazawa et al., 2015) and Epstein–Barr virus (Inazawa et al., 2015) have also been 
reported in patients after HSCT.  
 MSCs in the Treatment of GVHD 1.9.7
1.9.7.1 Graft Versus Host Disease   
GVHD can develop in patients who have undergone a biological graft. The disease is 
defined by the Billingham criteria (Ferrara et al., 2009): 
1. The graft must contain cells which are capable of generating an immune 
response (i.e. immune-competent cells) 
2. The recipient must contain antigens which are not present in the graft donor 
3. The recipient must not be able to generate an effective immune response 
against the immune-competent cells from the donor 
 
GVHD arises from the transplantation of stem cells (haematopoietic) or bone marrow 
for the treatment of conditions such as leukaemia. T cells (the immune-competent 
cells) within the transplanted tissue will give rise to a reaction against the host’s 
tissue, often when a mismatch in the HLAs from the donor and recipient are detected 
(Ferrara et al., 2009, Loiseau et al., 2007).   
There are two types of GVHD, acute GVHD (aGVHD) and chronic GVHD (cGVHD). 
The acute condition normally manifests within 100 days of the transplantation, with 
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chronic GVHD presenting after 100 days and can last a lifetime (Jagasia et al., 
2015). The pathogenesis of GVHD, both acute and chronic is broken down into a 
model developed by Ferrara (Fig. 1.13; Ferrara and Reddy, 2006). Here it is thought 
that GVHD manifestation occurs in three stages. In the first stage, conditioning of the 
recipient by chemotherapy and/or radiotherapy prior to transplantation which leads to 
tissue damage and the release of bacterial products from the gut flora such as LPS. 
This in turn will cause the second stage of pro-inflammatory cytokine release and the 
migration of host antigen presenting cells to secondary lymphoid organs such as the 
lymph nodes. Finally, within the lymph nodes activated antigen presenting cells will 
present antigen to the donor T cells, leading to their proliferation and differentiation 
into effector cells. This will stimulate T cell production of IFNy and IL-2. These 
effector T cells will travel to the target tissues of the host, normally the skin, gut and 
liver and initiate cellular apoptosis as well as releasing pro-inflammatory cytokines to 
maintain the process (Ferrara and Reddy, 2006). 
Acute GVHD is reported to develop in 50-70% of patients undergoing allogenic 
transplants, whereas 30-50% develop the cGVHD (Margaix-Muñoz et al., 2015). The 
diagnosis of aGVHD is based on potential symptoms in up to three organs; the skin, 
the gastrointestinal (GI) tract and the liver. The skin is the most targeted organ during 
aGVHD, presenting with maculopapular rash, with the liver the most infrequently 
affected organ. The GI tract can also be affect during aGVHD, resulting in nausea, 
vomiting and diarrhoea (Harris et al., 2015).  
A larger number of organs may be affected during cGVHD (see Table 1.3) including 
the oral cavity (Socié and Ritz, 2014). The oral cavity is the second most commonly 
affected area in chronic GVHD patients, with in some cases being the only tissue 
affected (Margaix-Muñoz et al., 2015). One study found that 70% and 53% of 
patients who had undergone haematopoietic stem cell transplantation and bone 
marrow transplantation respectively, developed cGVHD with oral symptoms (Pavletic 
et al., 2005).  These symptoms include mucositis, gingivitis (bacterial infection) and 
pain. The pain leads to difficulty in the ability of patients to eat which in turn can lead 
to weight loss. Overall the oral component of the condition can severely decrease the 
quality of life for patients.  It has been reported that GVHD is associated with a 
reduction in AMPs within the intestine of mice. The secretion of α-defensins by 
intestinal Paneth cells regulates the microbial communities within the gut. It has also 
been reported that in a murine model of aGVHD, the Paneth cells are specifically  
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Fig. 1.13: Reproduced from (Ferrara and Reddy, 2006). The pathogenesis of GVHD. Tissue damage is 
caused by conditioning regimes such as chemotherapy, causing the release of products such as LPS. 
The release of the bacterial components cause the section of cytokines and the migration of APCs. 
APCs then present antigen to the donor T cells, resulting in T cell activation and proliferation leading to 
the development of T effector cells. This process stimulates the production of IFN-y and IL-2. The 
effector cells are then transported to target tissues where cellular apoptosis occurs. 
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Table 1.3: Tissue specific symptoms of cGVHD, a non-exhaustive list.  
 
Tissue site 
 
Symptoms 
 
Skin 
 
Maculopapular rash, Lichen planus-like rash, 
Erythema 
 
Nails 
 
Nail loss 
 
Gastrointestinal tract 
 
Diarrhoea, Vomiting, Loss of Weight 
 
Liver 
 
Increased Bilirubin 
 
Oral cavity 
 
Erythema, Gingivitis, Pain, Mucositis, Lichen 
planus-like rash 
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targeted, with dramatically less observed in the GVHD mice compared to controls. 
Furthermore, the loss in Paneth cells was associated with an increase in aGVHD 
severity in addition to a reduced secretion of α-defensins (Eriguchi et al., 2012). This 
may pre-dispose the gut changes in microflora. An increase in E. coli growth was 
demonstrated in the aGVHD mice, which was correlated to GVHD severity (Eriguchi 
et al., 2012). The effect of cGVHD on the secretion of AMPs and potential effects on 
microbial communities within the oral cavity is yet to be examined.  
Currently, conventional treatment of both aGVHD and cGVHD consists of steroids 
and an immunosuppressive drug such as cyclosporine a, but it has been reported 
that only two thirds of patients develop a complete response to this treatment (Dhir et 
al., 2014). It has long been known that patients with steroid refectory GVHD have a 
decreased survival rate compared to those who respond to steroids (Martin et al., 
1990).  Further treatment for GVHD patients who do not respond to steroids is given 
with drugs such as anti-TNFα antibodies (e.g. infliximab) and IL-2 receptor antibodies 
(e.g. daclizumab) (Dhir et al., 2014). However, the recommendations for treating 
GVHD from the American Society of Blood and Marrow Transplantation state that 
there is not enough evidence to support other treatments of GVHD other than 
steroids (Martin et al., 2012). 
1.9.7.1.1 Oral Chronic GVHD 
The oral cavity is the second most commonly affected organ during cGVHD, with 45-
83% of patients with reported oral involvement (Mays et al., 2013). Oral cGVHD is 
diagnosed by the presence of lichen-planus like changes characterised by 
‘hyperkeratotic (thickening) white lines and lacy-appearing lesions’ within the oral 
mucosa (Jagasia et al., 2015). Further symptoms of oral cGVHD include mucositis, 
gingivitis, erythema and pain, but are not used to diagnose the disease. Treatment 
for cGVHD often targets multiple organs affected by GVHD, with systemic treatment 
with corticosteroids the first-line therapy (Margaix-Muñoz et al., 2015). It has been 
reported that systemic treatment of cGHVD can result in oral improvements in 32% of 
patients (Inamoto et al., 2012). In patients where the cGHVD progresses despite 
corticosteroid treatment the disease is termed steroid-refractory. In steroid-refractory 
patients second-line treatments such as Rituximab may be used.  Rituximab 
treatment is well tolerated (Cutler et al., 2006), with one study reporting clinical 
improvements in the oral musocas in 6 out of 11 patients (Clavert et al., 2013). 
Extracorporeal photopheresis is also a second-line treatment for steroid-refractory 
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patients. Clinical improvements in oral cGVHD have been reported after 
extracorporeal photopheresis (Dall'Amico and Messina, 2002), with improvements 
potentially attributed to the apoptosis of neutrophils and a down regulation of the  
activation markers, CD16, CD54 and CD64, expressed on the surface of neutrophils 
(Franklin et al., 2015). Patients treated with extracorporeal photopheresis also 
display higher numbers of T regulatory cells and reduced numbers of CD4+ T cells 
and B cells (Zhu et al., 2015).  
Topical treatments can directly target the oral mucosa during cGVHD treatment. 
Topical treatments, such as the immunosuppressive drug tacrolimus, have 
demonstrated promise. One case study demonstrated that in 8 weeks the topical 
application of tacrolimus effectively relieved the mucosal symptoms in a 41 year old 
GVHD patient (Eckardt et al., 2004). It has also been reported that topical tacrolimus 
treatment in combination with an oral hygiene protocol may be an effective treatment 
for oral cGVHD  (Conrotto et al., 2014).  
1.9.7.2 MSC Therapy for GVHD 
MSC therapy in the treatment of both aGVHD and cGVHD has been explored. 
MSCs, from donors ranging from HLA-matched to HLA-mismatched, were 
transplanted in 55 patients with steroid refractory aGVHD in Sweden (Le Blanc et al., 
2008). Up to 70% of patients responded to the MSC treatment with no side effects 
seen throughout the study. The survival rate of steroid resistance GVHD patients was 
increased from 10% to 52% by the MSC therapy. The majority of responding patients 
required a single dose of MSCs from any donor however, some patients needed a 
second and potentially third dose to maintain the therapeutic benefits. There was no 
difference seen between the HLA-matched and HLA-mismatched MSCs, 
demonstrating MSCs in a practical therapy without the need for HLA-matching (Le 
Blanc et al., 2008). Furthermore, complete aberration of aGVHD has been 
documented in 6 out of 8 patients in another study (Ringdén et al., 2006). 
The MSC treatment for cGVHD has also been investigated. One study demonstrate 
that up to 74% of patients treated with MSCs display clinical improvements with no 
side effects, with a 2-year survival rate of 77.7%. This study also confirmed that the 
clinical benefits of MSCs are noted irrespective of donor (Weng et al., 2010). MSC 
therapy is well tolerated in patients with no side effects documented (Lucchini et al., 
2010, Zhou et al., 2010). A further study has demonstrated an arrest in cGVHD 
development in paediatric patients and a partial clinical response to MSC therapy in 2 
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out of 3 cGVHD patients, resulting in a decrease in the immunosuppressive 
treatment required. MSC therapy resulted in a decrease in the plasma levels of the 
pro-inflammatory cytokines TNFα and IFNγ (Lucchini et al., 2010). Improvements in 
the clinical scores of 4 patients have been documented in another study, with 
improvements skin sclerosis and joint mobility observed after MSC therapy (Zhou et 
al., 2010).  
Kordelas et al., have undertaken a novel approach to MSC therapy. With the 
knowledge that the MSC effects are mediated by the release of soluble factors, and 
not the cells directly, the authors isolated exosomes from MSC cultures to apply as a 
GVHD therapy. Due to their size, exosomes can be easily sterilised using filtration 
and do not necessitate the lengthy expansion times MSCs require as they are not 
self-replicating. Furthermore, exosomes can be isolated from immortilised MSC cell 
line cultures, which otherwise could not be used for a cell-based therapies. It was 
reported that the isolated MSC exosomes contained large quantities of the anti-
inflammatory molecules IL-10, TGFβ and HLA-G. Pro-inflammatory cytokine 
presence in the exosomes was limited to IFNγ and IL-8, with the absence of further 
molecules such as TNFα, IL-2 and IL-6. With the immunosuppressive properties of 
the exosomes was confirmed by the reduction in PBMC numbers, the application of 
exosomes to treat one GVHD patient was conducted. Exosome therapy did not 
cause any side effects and was well tolerated in the patient and resulted in a 
decrease in the numbers of pro-inflammatory cytokine secreting PBMCs. The clinical 
symptoms of GVHD improved within the patient after the treatment such as reduced 
diarrhoea volume. This study demonstrated the beneficial effects of MSCs even 
without the presence of MSCs directly (Kordelas et al., 2014).  
1.9.7.2.1 MSC Therapy for Oral GVHD 
A recent case study has demonstrated the efficacy of local MSC treatment in steroid-
refractory cGVHD (Garming-Legert et al., 2015). MSCs were locally injected into 3 
ulcerated areas of the buccal mucosa at day 0 and day 8 in a 59 year old male. 
Clinical improvements were reported at day 2, with a reduction in the ulceration 
wound and redness of the area and by day 16 the majority of the ulceration at the 
affected sites had dissolved. The healing capacity of the MSCs is thought to be 
mediated through soluble factors such as SDF-1, monocyte chemoattractant protein 
(MCP)-1 and IL-8, which were identified in the MSC secretome (Garming-Legert et 
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al., 2015). This is currently the only study to examine the effects of local MSC 
therapy to treat tissue-specific components of GVHD.  
The first line treatment of corticosteroids in the treatment of GVHD can prove 
ineffective against the oral symptoms. One study demonstrated that in group of 283 
patients with cGVHD, oral improvements were only observed in 32% of patients 
(Inamoto et al., 2012). This demonstrates the need for an oral specific treatment. 
Systemic MSC therapy has proven effective in treating cGVHD with oral involvement. 
One study demonstrated oral responses to MSC therapy in 15 out of 16 patients 
(Weng et al., 2010). With the known short longevity, localisation to the lungs 
(Eggenhofer et al., 2012) and lack of engraftment (von Bahr et al., 2012) of IV 
infused MSCs into the body, local MSC treatments may provide a more specific 
effect at the affected tissues.  The benefits of MSC treatment could be provided with 
local injections without the need for systemic infusion, reducing the number of cells 
needed.  
 Choosing an Appropriate Stem Cell Source 1.9.8
Autologous stem cell therapies, in which the donor and recipient are the same 
individual, has distinct advantages over allogeneic therapy, in which donor cells are 
harvested from a different individual to the recipient. Autologous therapy does not 
involve the need to identify HLA-matched samples, as the donor cells are native to 
the recipient (Champlin, 2003). This type of therapy does not require 
immunosuppressive treatment post-transplantation and therefore there is no risk of 
developing transplant rejection (Champlin, 2003).  The reagents and culture medium 
used during culture must be considered. Foetal calf serum (FCS) is a commonly 
used as a medium supplement during cell expansion in vitro. As a xenogenic 
material, the immunoprivileged nature of autologous stem cells could potentially be 
compromised, with the production anti-bodies directed at FCS demonstrated after 
MSC infusion (Sundin et al., 2007). Human-derived alternatives, such as human 
serum, may limit the effects on the immuneprivileged status of autologous stem cell 
therapies. However, if a patient displays a condition directly relating to the cell source 
or is genetic, autologous cells are not suitable. Transplantation of such cells would 
not result in clinical improvement as they would continue to develop the disease.  
Allogeneic cell sources overcome this problem, with cells taken from healthy donors. 
However, the cells are often HLA-matched to limit the immune response by the 
recipient and there is a risk of GVHD (Champlin, 2003). Allogeneic cell sources with 
  Chapter 1 General Introduction 
58 
 
low immunogenicity would overcome the problems faced by autologous and 
allogeneic therapies.  BM-MSCs display intermediate levels of HLA-I and low levels 
of HLA-II (Le Blanc et al., 2003). This limited expression of HLA molecules reduces 
their recognition by the donor immune system, and lowers the potential immune 
response to the donor cells by the recipient. MSCs are also able to evade the 
immune system by suppressing the activation and proliferation of a range of cellular 
components to the immune system (see section 1.9.3.1). This limits the immune 
response to the cells, potentiating their use as an allogeneic therapy. 
BM-MSCs are the gold standard adult stem cells for cell based therapies however, 
harvesting such cells is an invasive procedure causing the donor discomfort and pain 
for several days (Chen et al., 2013). A stem cell population has been identified within 
the oral mucosa (OMLP-PCs) with potential therapeutic value. OMLP-PCs are 
harvested by a minimally invasive procedure involving a biopsy from the oral mucosa 
(Davies et al., 2010). The procedure can be undertaken during routine dental 
procedures as the mucosa is easily accessible. It is also associated with rapid 
healing and a lack of scar formation, allowing rapid patient recovery with little 
discomfort and pain.  
A number of studies have demonstrated that the numbers of BM-MSCs decrease 
with age.  It has been hypothesised that the decrease in bone mass with age is 
related to the numbers of progenitor cells. In one study, cells from the bone marrow 
were harvested from 41 deceased patients ranging in ages (3yrs – 70yrs). The 
patients’ deaths had been as a result of traumatic injury and they had been otherwise 
healthy individuals. It was found that the number of BM-MSC colony forming units 
(CFU-F) decreased with age (D'Ippolito et al., 1999). These results have been 
echoed in numerous studies where the CFU-F of BM-MSC are seen to decrease with 
age (Nishida et al., 1999, Majors et al., 1997). (Stenderup et al., 2003) reported that 
BM-MSCs from older patients (68-81yrs) reached a senescent state faster than those 
from younger donors (18-29yrs). The decrease in proliferative capacity was not 
associated with a decrease in stem cell numbers with age. However, this study 
utilised the Stro-1 antibody to identify the BM-MSCs. This antibody may also identify 
non-stromal cells in the bone-marrow producing false-positive results. These studies 
have demonstrated that harvesting of BM-MSCs is limited by patient age. Finding an 
alternative stem cell source, which doesn’t decrease with age would be beneficial in 
harvesting optimal numbers of cells.  
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1.10 Rationale 
The oral cavity contains a rich microbiome, yet recurrent infections are rare 
(Parahitiyawa et al., 2010). A diverse and multifactorial microbial defence is essential 
to maintain a healthy oral homeostasis including the effects of innate immune cells 
and the secretion of antimicrobial factors. Antimicrobial factors are secreted in many 
areas of the oral cavity such as salivary glands and epithelial cells and are detected 
within the oral fluids such as saliva (Gorr, 2009). At least 45 different antimicrobial 
factors have been identified in the oral cavity, such as the defensins, histatins and 
LL37 (Gorr, 2009). It has been reported that BM-MSCs secret the antimicrobial 
peptide LL37, which has led to the investigation of the role of OMLP-PCs in oral 
defence.  MSCs have been reported to act as both an immunosuppressant 
(Ghannam et al., 2010a) and antibacterial (Krasnodembskaya et al., 2010) agent. 
OMLP-PCs share the immunosuppressive properties of MSCs (Davies et al., 2012), 
but the antibacterial qualities have yet to be investigated in OMLP-PCs.  
 
1.11 Hypothesis 
As OMLP-PCs are one of the key cells involved in the orchestration of oral 
homeostasis and repair, I hypothesize that such oral progenitors also exhibit 
antibacterial properties in addition to their immunosuppressive capabilities. 
 
1.12  Aims 
The overall objective of this study is to demonstrate the antibacterial properties of 
OMLP-PCs and their principal mechanisms of action. To achieve this objective the 
following aims will be addressed: 
 
1. Establish whether OMLP-PCs reduce the growth of both Gram positive and 
Gram negative bacteria in vitro. 
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2. Determine if OMLP-PCs require licensing by exposure to pro-inflammatory 
stimuli and/or bacterial products in order to exhibit antibacterial properties or 
whether their antibacterial properties are constitutive. 
 
3. Elucidate the mechanism of OMLP-PC antimicrobial action through 
investigation of the role of antibacterial factors produced by OMLP-PCs. 
                                
 
 
 
 
 
 
 
 
2. Investigating the 
Antibacterial Properties 
of OMLP-PCs 
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2 Investigating the Antibacterial Properties of OMLP-PCs  
2.1 Background 
Oral soft tissues are continually exposed to the external environment and are thus a 
critical entry point for potentially harmful bacteria (Parahitiyawa et al., 2010). 
Surprisingly chronic infections are rare, potentially due to antimicrobial factors 
secreted by resident cells within tissues such as the salivary glands (Gorr, 2009).  
Indeed, a decrease in specific antimicrobial factors has been linked with the onset of 
oral diseases such as periodontitis and deficiencies in the human cathelicidin protein 
LL37 (Pütsep et al., 2002). 
Wound healing within the buccal mucosa is preferential, potentially due to the 
presence of OMLP-PCs. In addition to their multipotency, OMLP-PCs have been 
demonstrated to possess potent immunosuppressive properties, significantly 
suppressing the proliferation of peripheral blood lymphocytes in a dose and contact-
independent manner (Davies et al., 2012). The contact-independent nature of this 
immunomodulation suggests the importance of soluble factors in mediating these 
effects. MSCs, from numerous sources including the bone marrow (BM-MSCs), have 
also been demonstrated to have inherent immunosuppressive properties, induced by 
exposure to IFNγ, a pro-inflammatory cytokine released by subsets of immune cells 
such as T helper cells (Ghannam et al., 2010). In contrast to OMLP-PCs, the 
immunosuppressive effects of BM-MSCs on T cell proliferation are thought to act via 
both contact-dependant and contact-independent methods, potentially suggesting 
different modes of action between the stem cell sources (Mezey, 2011). 
IDO is one of the major soluble factors repeatedly reported to play a role in stem cell 
mediated immunosuppression, including OMLP-PCs, BM-MSCs and gingival MSCs 
(GMSCs). The production of the IDO protein is not constitutively produced by these 
stem cell sources and is only secreted in response to IFNγ, (Davies et al., 2012, 
Ghannam et al., 2010, Zhang et al., 2009). 
Once activated by IFNγ, MSCs release IDO resulting in the degradation and 
depletion of tryptophan, thereby inducting T cell apoptosis (Ghannam et al., 2010) 
and the inhibition of T cell proliferation (Yang et al., 2009). Immunosuppressive 
factors, such as IDO, are also known to have prominent antibacterial actions; IDO 
inhibits tryptophan-dependent bacteria such as group B streptococci (Hucke et al., 
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2004) and E.coli (Barclay, 1985, Eaton et al., 1982) by the depletion of tryptophan. 
This knowledge has led to the hypothesis that stem cells can act with dual properties; 
displaying both immunomodulatory and antibacterial characteristics. However, limited 
studies have been reported with respect to the potential antibacterial properties of 
stem/progenitor cells. BM-MSCs have been demonstrated to exhibit antibacterial 
properties against a small range of both Gram positive and Gram negative bacteria 
(Krasnodembskaya et al., 2010). Within this study it was reported that BM-MSCs 
significantly reduced the number of bacterial colony forming units (CFU) of E. coli, 
Pseudomonas aeruginosa and Staphylococcus aureus compared to bacteria cultured 
in the absence of BM-MSCs. The authors demonstrated that CM produced from BM-
MSCs that had previously been exposed to bacteria, significantly reduced the 
bacterial CFU. This effect was not seen when CM was produced from BM-MSCs in 
standard culture in the absence of bacteria, suggesting that BM-MSCs do not 
constitutively display antibacterial properties, but upon bacterial exposure can be 
induced to secrete antibacterial factors; in this case LL37 (Krasnodembskaya et al., 
2010). LL37 has also been implicated in BM-MSC mediated antibacterial action in 
vivo, with animal studies using a model of bacterial-induced sepsis demonstrating the 
ability of BM-MSCs to increase bacterial clearance via upregulation of LL37 secretion 
(Lee et al., 2011).   
This Chapter therefore sought to investigate whether, similar to BM-MSCs, OMLP-
PCs display antibacterial properties in addition to their immunosuppressive qualities. 
Investigations were carried out to determine whether OMLP-PCs are constitutively 
antibacterial or whether bacterial and/or inflammatory priming is needed to exert 
suppressive effects against both Gram positive and Gram negative bacteria.  
 
2.1.1 Aims 
1. Establish whether OMLP-PCs possess antibacterial properties, acting against 
both Gram negative and Gram positive bacteria. 
2. Investigate OMLP-PC antibacterial mode of action and whether this is via 
contact dependant or independent mechanisms. 
3. Determine whether OMLP-PCs require bacterial or inflammatory priming to 
exert antibacterial actions against Gram positive and Gram negative bacteria. 
4. Investigate the response of OMLP-PCs to bacterial stimuli.  
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2.2 Materials and Methods 
All microbiology reagents were purchased from Oxoid (UK) and tissue culture 
reagents from Life Technologies Ltd (UK) unless otherwise stated. 
 
2.2.1 Maintenance of Oral Mucosa Lamina Propria Progenitor Cells 
(OMLP-PCs) and Enriched Oral Fibroblasts (EFs) 
OMLP-PCs were previously isolated and characterised by L. Davies (Cardiff 
University, UK; Davies et al., 2010). The study was approved by the local ethics 
committee and conducted in accordance with the Declaration of Helsinki. All donors 
provided written consent. Buccal mucosa biopsies from healthy patients undergoing 
orthognathic surgery were submerged in 70% (v/v) ethanol prior to enzymatic 
digestion for 16hrs at 4°C with 2mg/ml dispase II (Sigma, UK) in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 10% (v/v) foetal calf serum (FCS), 2mM 
L-glutamine and antibiotics/antimycotics (100 U/ml penicillin G, 100 µg/ml 
streptomycin sulphate and 0.25 µg/ml amphotericin B), herein referred to as 
complete medium. The epithelium layer was removed and further digestion into a 
single cell suspension was carried out in 1mg/ml collaganse A (Roche, UK) in 
complete medium for 16hrs at 37°C in a 5% CO2 humidified atmosphere. The single 
cell suspension was then washed in serum-free medium before plating (20mins at 
37°C)  onto tissue culture plastic coated with 10µM bovine plasma fibronectin 
(Sigma, UK) diluted in phosphate buffered saline supplemented with 1mM CaCl2 and 
1mM MgCl2 (PBS+). The cells that did not adhere to fibronectin after this 20mins 
were plated onto fibronectin as before for a further 40mins x2 to ensure all PCs were 
depleted, and the remaining cells which did not adhere to fibronectin were defined as 
EFs. The cells which adhered to the fibronectin from the first incubation of 20mins 
(OMLP-PCs) were cultured in complete medium until colonies formed from a single 
cell reached > 32 cells. Each colony was surrounded by a cloning ring and cells were 
removed from the plastic using 0.05% Trypsin-EDTA for 10mins at 37°C. The colony 
derived OMLP-PCs and the EFs were then expanded in complete medium.  
Cells in complete medium were frozen in 10% dimethyl sulphoxide (DMSO) for long 
term storage in liquid nitrogen. Upon removal from liquid nitrogen storage, cells were 
rapidly thawed in a 37°C waterbath before counting and seeding into a T75 flask as 
below.   
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The cell density of confluent flasks was recorded and the population doubling level 
(PDL) calculated for each OMLP-PC clone, using the formula below;  
 
𝑃𝐷𝐿 =  
𝑙𝑜𝑔10 (𝑐𝑜𝑛𝑓𝑙𝑢𝑒𝑛𝑡 𝑐𝑒𝑙𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 ) −  𝑙𝑜𝑔10 (𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑠𝑒𝑒𝑑𝑖𝑛𝑔 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 ) 
𝑙𝑜𝑔10 (2)
 
 
Cells were seeded at a density of 2x103 cells per cm2 in a T75 flask and trypsinised 
when they reached approximately 90% confluency. Cells were washed with 10ml 
PBS before adding 1ml 0.05% Trypsin-EDTA (Life Technologies Ltd., UK) & 
incubating at 37°C for 5mins. The cell suspension was combined with 7ml of 
complete medium and centrifuged at 500g for 5mins at room temperature. The 
medium was removed and the cell pellet re-suspended in 1ml of complete medium. 
Ten microlitres of the cell suspension was diluted 1:2 with trypan blue (to enable a 
viable cell count) and counted using a haemocytometer.  
2.2.2 Maintenance of Microbiological Stocks 
Enterococcus faecalis (E. faecelis; NCTC 775), Pseudomonas aeruginosa (P. 
aeruginosa; ATCC 15692) and Streptococcus pyogenes (S. pyogenes; NCTC 8198) 
were maintained on tryptone soya agar (TSA).  Proteus mirabilis (P. mirabilis; NCTC 
11938) was maintained on cysteine lactose electrolyte deficient (CLED) agar to 
prevent swarming of the bacteria. Bacteria were sub-cultured onto fresh agar plates 
weekly and stored at 4°C. Stocks of each bacterium were stored in Microbank™ 
cryovials (Pro-lab diagnostics, UK) at -80°C.  
2.2.3 Gram Staining 
Gram staining was performed regularly to ensure pure cultures. A loop of bacteria 
was heat fixed onto a glass slide before staining with crystal violet (1% w/v; Prolab 
diagnostics, UK) for 1min. Iodine solution (1% w/v iodine, 2% w/v potassium iodide; 
Prolab diagnostics: UK) was added to the bacteria for 30 seconds, followed by a 
rapid de-colouration step using acetone (Prolab diagnostics: UK). A final stain of 
fuschin (0.1% w/v fuschin, 1% v/v ethanol, 0.5% w/v phenol; Prolab diagnostics: UK) 
was added to the bacteria for 1 min before visualisation under a x100 lens oil 
emersion light microscope (Provis, Olympus, UK). 
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2.2.4 Determining Colony Forming Unit Concentration from Overnight 
Bacteriological Cultures 
Single colonies of bacteria (E. faecalis, P. aeruginosa, S. pyogenes and P. mirabilis) 
were grown in brain heart infusion (BHI) broth cultures overnight at 37°C (S. 
pyogenes also required 5% CO2; n=4 colonies per bacteria). At 16 and 23hrs, the 
cultures were serially diluted and a 50µl volume spiral plated (Whitely Automatic 
Spiral Plater, Don Whitely Scientific Limited, UK) onto TSA or CLED agar (P. 
mirabilis) and incubated at 37°C overnight.  The numbers of colonies on the agar 
plate were subsequently counted as per the manufacturer’s instructions and the total 
number of colonies/ml was calculated from the counting table (WASP 2 User Manual 
Section 15.1, Don Whitely Scientific Limited, UK). The dilution necessary to obtain 
150CFU units/ml was calculated from the colonies/ml value. 
2.2.5 Bacterial Growth Curves 
The growth profiles of E. faecalis, P. aeruginosa, S. pyogenes and P. mirabilis  was 
examined in BHI broth, Roswell Park Memorial Institute (RPMI) medium 
supplemented with  10% (v/v) or 20% (v/v) FCS and RPMI supplemented with 10% 
or 20% (v/v) FCS in combination with 5%, 10% and 20% (v/v) BHI. 
A single bacterial colony was grown overnight in 10ml (E. faecalis, P. mirabilis, P. 
aeruginosa) or 20ml (S. pyogenes) BHI medium as described in section 2.2.4. The 
bacterial culture was diluted in PBS to either a 0.5 McFarland standard (dilution of 
bacteria which has an absorbance of 0.08-0.1 at 600nm), before further diluting 1 in 
100, or to 150 CFU/ml into the range of media described above. The final dilutions 
were added to a 48 well plate in triplicate in a total volume of 0.5 ml per well. 
Respective sterile media was used as background controls for each condition. The 
microplate reader (SPECTROstar Omega, BMG-LABTECH or FLUOstar Optima, 
BMG-LABTECH, Germany) was warmed to 37°C before the plates were inserted. 
Before each reading, the plates were shaken for 20s before the absorbance was 
read at 625nm. Readings were taken every 30mins until the bacterial cultures had 
reached stationary phase (7-14hrs). 
2.2.6 Determining Cytotoxicity to BHI Using the LDH Cytotoxicity Assay 
Cellular lactate dehydrogenase (LDH) release from OMLP-PCs and EFs was used as 
a measure of cell death in response to incubation with BHI. LDH is a stable enzyme 
which is released from cells upon plasma membrane damage (Drent et al., 1996). 
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The LDH-Cytotoxicity Assay Kit (Abcam, UK) relies on LDH oxidising lactate, which 
produces nicotinamide adenine dinucleotide (NADH). The NADH then reacts with the 
WST substrate reagent to produce a colorimetric change. 
OMLP-PCs and EFs (n=3 independent donors; all with technical triplicates) were 
seeded at a density of 4x104 cells per well in a 96 well plate and left to settle 
overnight in complete medium. Subsequently, the CM was removed and the cells 
were incubated with 200µl of RPMI supplemented with 2mM L-glutamine, 10 or 20% 
(v/v) FCS and 5, 10 or 20% (v/v) BHI for 8.5hrs at 37ºC/5% CO2. The provided cell 
lysis solution was added to a further three wells of cells as ‘high’ controls. Medium 
was also incubated for 8.5hrs without the presence of any cells as a ‘low’ control.  
Subsequent to incubation, the medium was removed from the cells and stored in 
fresh 96 well plates at 4ºC overnight. The plates were then centrifuged at 126xg for 
5mins, before 10µl of medium from each well was transferred to a new 96 well plate 
in triplicate. One hundred microliters of the reaction buffer was added to each sample 
and incubated in the dark for 30mins. Ten microlitres of LDH was also added to 100µl 
of the reaction buffer and incubated for 30mins as a positive control. The absorbance 
of each well was read at 450nm and 650nm (reference wavelength). The following 
equation was used to determine the percentage of cytotoxic cells. 
𝐶𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 (%) =  
(𝑇𝑒𝑠𝑡 𝑠𝑎𝑚𝑝𝑙𝑒 𝑎𝑏𝑠 − 𝐿𝑜𝑤 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑎𝑏𝑠)
(𝐻𝑖𝑔ℎ𝑡 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑎𝑏𝑠 − 𝐿𝑜𝑤 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑎𝑏𝑠)
 𝑥 100 
 
2.2.7 Co-culture of OMLP-PCs or EFs and Live Bacteria 
OMLP-PCs (n=4 independent donors) at 24-30 PDs were treated +/-100 units/ml 
recombinant human interferon γ (rhIFNγ ; Sigma Aldrich, UK) for 7 days prior to co-
culture with bacteria. 
EFs (n=3 independent donors) and OMLP-PC +/- IFNγ (n=4 independent donors) 
were seeded into a 24 well plate at a density of 1x105 cells per well in RPMI 
supplemented with 10% (v/v) FCS and 2mM L-glutamine (no antibiotics were added 
to the medium). The cells were cultured at 37°C/5% CO2 overnight to allow 
adherence to the plate. Subsequent to adhesion, the medium was removed and 
exchanged for RPMI supplemented with 2mM L-glutamine, 10% (v/v) FCS and 20% 
(v/v) BHI +/- 150CFU bacteria. 
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The cells were co-cultured with the bacteria at 37°C/5% CO2 until the bacteria 
reached midlog phase (dependant on growth curves from 150 CFU/ml).  The CM was 
removed from the cells, serially diluted and spiral plated (onto TSA or CLED [P. 
mirabilis]) as outlined in section 2.2.4, and incubated overnight at 37°C before 
counting the bacterial colonies. The remaining CM was centrifuged at 14,000xg for 
2mins through a Nanosep MF centrifugal device (Pall, UK) to remove bacteria and 
stored at -80°C. 
2.2.8 Susceptibility Testing of CM from OMLP-PCs or EFs  
CM samples from OMLP-PCs and EFs generated in section 2.2.7 (90µl) were 
cultured with 100 CFU of each bacteria (in a 10µl volume of PBS) in a 96 well plate 
for 16hrs at 37°C/5% CO2. The CM was then serially diluted and spiral plated onto 
TSA or CLED (P. mirabilis) as outlined in section 1.2.5 and incubated overnight at 
37°C, before the colonies were counted.  
To examine whether the constitutive antibacterial properties of the CM could be 
diluted out, CM samples from OMLP-PCs were diluted 1:2 – 1:100 with RPMI + 10% 
(v/v) FCS + 20% (v/v) BHI supplemented with 2mM L-glutamine to a final volume of 
90µl. One hundred CFU of bacteria was added to the CM, incubated and analysed as 
above.  
2.2.9 Bacterial Viability Assessment with Live/Dead® BacLight™ 
Bacterial Viability Kit. 
Replicates of the above undiluted CM samples were incubated with 100 CFU 
bacteria as per section 2.2.8 and stained using the Live/Dead® BacLight™ Bacterial 
Viability Kit (Life Technologies, UK).  Briefly, cultures were centrifuged for 5mins and 
pellets washed in 0.85% w/v NaCl before re-suspending in 1ml of 0.85% w/v NaCl. 
Three microliters of the bacterial stain (1:1, part A: part B) was added to each culture 
for 15mins in the dark. Cultures were centrifuged and resuspended in 50µl 0.85% w/v 
NaCl before 5µl was mounted onto a poly-L-lysine coated glass slide under a glass 
coverslip using the mountant provided. Fluorescent bacteria were then visualised 
under a x100 lens oil emersion fluorescent microscope (Provis, Olympus, UK). Both 
live (green) and dead (red) bacteria were counted in a minimum of 3 fields of view 
per condition and percentage viability was calculated.  
 
                               Chapter 2 Investigating the Antibacterial Properties of OMLP-PCs 
69 
 
2.2.10 Assessment of OMLP-PCs responses to bacterial stimuli 
2.2.10.1 Generation of Bacterial Supernatant and Soluble Protein 
Extract 
A single bacterial colony was grown overnight in 10ml (E. faecelis, P. mirabilis, P. 
aeruginosa) or 20ml (S. pyogenes) BHI medium as described in section 2.2.4. 
Bacteria were diluted to 0.5 McFarland standard in BHI and a further 1:100 into 
200ml of BHI. Cultures were grown until midlog phase was reached (as assessed by 
BHI growth curve). 
2.2.10.2 Separation of Bacterial Supernatant 
Cultures were centrifuged at 17,000xg for 10mins to pellet the bacteria and the 
supernatant decanted. The supernatant was filter sterilised using a 0.22µm syringe 
filter (PVDF membrane, Elkay Laboratory Porducts Ltd, UK) before freezing in 
aliquots at -20°C for future use. 
2.2.10.3 Isolation of Soluble Bacterial Protein Fraction 
The bacterial protein was extracted from the pellet using the Qproteome® Bacterial 
Protein Prep Kit (Qiagen Ltd, UK). Briefly, the bacterial cell walls were disrupted by 
cell lysis using the provided detergent, allowing the release of the soluble bacterial 
protein from the cell. The bacterial cells and soluble protein were then centrifuged at 
14,000xg and therefore separated. The soluble protein fraction was then pelleted by 
centrifugation at 16,000xg and washed in ice cold acetone:water (4:1) before being 
re-suspended in 5ml sterile water. 
2.2.10.4 Quantification of Soluble Bacterial Protein 
The soluble bacterial protein was quantified using the Pierce® BCA Assay Kit 
(Thermo Scientific, UK). This assay is dependent on two reactions. The first is the 
reduction of Cu+ to Cu2+ by the peptide bonds within the protein sample.  Secondly, 
two bicinchoninic acid (BCA) molecules chelate with a Cu+ ion, forming a purple 
coloured product which absorbs light at a wavelength of 562nm. 
A standard curve was produced using known concentrations of bovine serum 
albumin (BSA; 0 - 2mg/ml). Both the standards and samples were incubated with the 
BCA solution (50:1, Reagent A:B) for 30mins at 37ºC before the absorbance was 
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read at 562nm (SPECTROstar Omega, BMG-LABTECH or FLUOstar Optima, BMG-
LABTECH, Germany). 
2.2.10.5 Visualisation of OMLP-PC Co-culture with Live Bacteria and 
Bacterial Products 
OMLP-PCs clones at 30-34 PDs (n=4 independent donors) or EFs at 30-34 PDs (n=3  
independent donors) were seeded at a density of 4x104 cells/well into a 12 well plate 
and left to settle overnight in complete medium.  The next day, medium was removed 
and the cells were washed with PBS before being incubated with 2ml RPMI 
supplemented with 2mM L-glutamine and 10% (v/v) FCS, +/- 50µg/ml of bacterial 
protein or +/- 20% (v/v) bacterial supernatant or +/- 20% (v/v) BHI +/- 300 CFU live 
bacteria.  Cells were incubated at 37°C/5% CO2 for 16hrs with images captured every 
20mins in 4 fields of view/well using the Multi Label Fluorescence (MLF) Cell IQ 
System (CM Technologies, Finland; Gen. 2.1). At the conclusion of these time lapse 
experiments CM were harvested and stored at -80°C until use. The cells were lysed 
in the cell lysis buffer (RA1) and stored at -80°C for later RNA extraction using the 
Illustra RNAspin Mini RNA isolation kit (GE Healthcare, Buckinghamshire, UK). 
Time-lapse images were combined and converted into videos using the Cell IQ 
lineage analyser software (CM Technologies, Finland; 4_v.ANA1.0_analyserdemo). 
Cell tracking was performed using an alternative version of the software: Cell IQ 
lineage analyser (4 ANA 01 TEST 2). Cells were tracked for 3hrs, as post 3hrs, live 
bacteria proliferated to the extent whereby visualising the cells was completely 
obstructed. Forty cells per well were manually tracked and the average speed over 
the 3 different clones tested (n=3 independent donors) was calculated by the Cell IQ 
lineage analyser software. The cell area of OMLP-PCs incubated with bacterial 
protein was also recorded using the Cell IQ lineage analyser software (CM 
Technologies, Finland; 4_v.ANA1.0_analyserdemo) after 16hrs in culture. A 
minimum of 40 cells were recorded per bacterial protein isolate or control medium.  
2.2.10.6 Boyden Chamber Migration Assay 
OMLP-PCs clones at 30-34 PDs (n=4 independent donors) or EFs at 30-34 PDs (n=3 
independent donors)  were serum starved in RPMI medium for 24hrs before seeding 
10,000 cells / cm2 onto a 10µg rat tail type 1 collagen (First Link, UK) coated insert 
(ThinCert™ cell culture insert for 24 well plate, Greiner Bio-One, UK). The lower well 
contained 1ml of either RPMI (control), RPMI + 10% (v/v) FCS (positive control), 
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RPMI + 50µg E. faecalis protein or RPMI + 50µg P. aeruginosa protein. Insert 
cultures were incubated at 37°C/5% CO2 for 20hrs before cells were fluorescently 
stained using 8µM Calcein-AM solution (Sigma Aldrich, UK) for 45mins at 37°C/5% 
CO2. Inserts were washed in PBS and submerged into a 20% (v/v) trypsin-PBS 
solution for 10mins at 37°C/5% CO2. Two hundred microliters of each sample was 
transferred to a black Nunc™ MicroWell™ 96-Well plate (Thermo Scientific, UK) in 
triplicate before the fluorescence was read at an excitation wavelength of 480nm and 
an emission wavelength of 520nm. The fluorescence of each well was compared to 
the fluorescence of the control wells.  
2.2.11 Statistical Analysis 
All statistical analysis was performed using SPSS statistics (IBM®, UK; Version 20). 
Variance analysis was performed using Levene’s test, where significant variability 
was assumed where P<0.05. Statistical analysis for comparing means was 
performed using a One-way ANOVA test with a post hoc Tukey test (where equal 
variance) or a Games-Howell test (where variances were unequal). Statistical 
significance was assumed where P<0.05.  
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2.3 Results  
2.3.1 OMLP-PCs and EFs in culture 
OMLP-PCs (n=4 independent donors) and EFs (n=3 independent donors) were 
expanded in complete media. Both cell types demonstrated a typical bipolar, 
fibroblast-like morphology at a PD 24-30 (Fig. 2.1 A-G). All OMLP-PC clones were 
previously phenotyped for their positive cell surface expression of CD44, CD90, 
CD105 and CD166 and negative expression of the haematopoietic markers CD45 
and CD34 (Davies et al., 2010). No variation in the growth profiles or gene 
expression was noted in cells derived from different patients, or during culture.   
2.3.2 Gram Staining of Bacteria 
Bacteria were Gram stained monthly to ensure purity of cultures. The PGN 
component within the cell wall of Gram positive bacteria, E. faecalis (Fig. 2.2 A) and 
S. pyogenes (Fig. 2.2 B), stained purple using crystal violet stain, whilst the LPS 
component of the cell wall of Gram negative bacteria, P. aeruginosa (Fig. 2.2 C) and 
P. mirabilis  (Fig. 2.2 D), stained pink with fuchsin.  
2.3.3 Bacteria Growth Curves: Growth Profiles of E. faecalis, S. 
pyogenes, P. aeruginosa and P. mirabilis  
The growth profiles for each bacterium were examined between 16 and 48hrs 
dependent on when the bacterial strain reached stationary phase. Further 
experiments would utilise the bacteria up to midlog phase, hence the complete 
growth profiles of each bacterium were examined to ensure transition from log into 
stationary phase. The growth of all bacteria was investigated in BHI and RPMI 
(supplemented with 2mM L-glutamine and 10 or 20% FCS) ±5, 10 or 20% BHI to 
establish an optimal growth medium supportive of both bacteria and OMLP-PCs/EFs. 
Each bacterium was added to the medium at both a 1:100 of a 0.5 McFarland 
standard and at 150 CFU/ml. To calculate 150 CFU of each bacteria, the total 
CFU/ml were determined. Bacterial cultures derived from a single CFU were taken at 
16 and 23hrs and spiral plated onto appropriate agar. Colonies were counted and the 
total CFU/ml calculated (Table 2.1). 
All bacteria displayed a standard sigmoidal growth pattern within each of the media 
tested. Each bacterium reached a higher optical density (OD) value within the RPMI  
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Fig. 2.1: Photomicrographs of each OMLP-PC clone and EF in culture. OMLP-PCs: (A) 17XV, (B) 11Li, 
(C) 2α (D) 1XXI and EFs: (E) XVI, (F) XXVIII, (G) XXI, PD 24-30. Bar = 10µm.  
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Fig. 2.2: Photomicrographs of bacteria showing Gram positive bacteria (A) E. faecalis, (B) S. pyogenes, 
and Gram negative bacteria (C) P. aeruginosa, (D) P. mirabilis. Bar = 50µm. 
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Table 2.1: Bacterial Counts at 16hrs and 23hrs 
Bacteria 16hrs bacterial count / ml 23hrs bacterial count / ml 
 
E. faecalis 
 
 
3.36 x 10
8 
(range: 2.8 x10
8
 – 4.05 x10
8
) 
 
3.62 x 10
8 
(range: 2.95 x10
8
 – 4.4 x10
8
) 
 
S. pyogenes 
 
 
1.99 x 10
8 
(range: 1.4 x10
8
 – 2.5 x10
8
) 
 
3.225 x 10
7 
(range: 2.7 x10
7
 –  3.45 x10
7
) 
 
P. aeruginosa 
 
 
2.71 x 10
9 
(range: 2 x10
9
 –  3.3 x10
9
) 
 
1.4 x 10
9 
(range: 1.2 x10
9
 – 1.7 x10
9
) 
 
P. mirabilis 
 
 
1.402 x 10
9 
(range: 1.06 x10
9
 – 1.6 x10
9
) 
 
2.05 x 10
9 
(range: 1.9 x10
9
 – 2.2 x10
9
) 
 
 
 
 
                               Chapter 2 Investigating the Antibacterial Properties of OMLP-PCs 
76 
 
media when supplemented with BHI suggesting a more supportive growth 
environment (Supplementary Data).  
The growth profiles for each bacterium in BHI alone and RPMI supplemented with 
2mM L-glutamine, 10% FCS and 20% BHI are shown in Fig. 2.3 - Fig. 2.10, with the 
time taken to reach each growth phase in each medium detailed in Table 2.2 (growth 
curves for all other media are provided in Supplementary Data). These growth curves 
demonstrate that E. faecalis, S. pyogenes, P. aeruginosa and P. mirabilis all display 
reproducible growth patterns in both BHI and supplemented RPMI + 20% BHI. All 
bacteria demonstrate a lag phase with absorbance values close to 0, which develops 
into a short log phase (as seen by the rapid increase in absorbance values) before 
reaching stationary phase. The absorbance values in this last phase remain relatively 
constant over the time period examined.  
2.3.4 Determining the Cytotoxicity of BHI to OMLP-PCs/EFs 
All bacteria demonstrated improved growth in RPMI (supplemented with 2mM L-
glutamine and 10% or 20% FCS) medium when further supplemented with BHI. The 
toxicity of BHI to OMLP-PCs and EFs was therefore examined to ensure that the BHI 
did not affect the viability of the mammalian cells. Cytotoxicity was measured using 
LDH as a marker – an active enzyme released upon cellular membrane damage.  
OMLP-PCs/EFs were incubated for 8.5hrs with the RPMI medium + 10% or 20% 
FCS, ±5, 10 or 20% BHI before percentage cytotoxicity was calculated. No significant 
cytotoxicity to the different media was observed within either cell type (P>0.05; Fig. 
2.11).  
Based on these findings, and those outlined in section 2.3.3, further experiments 
have utilised RPMI (supplemented with 2mM L-glutamine and 10% FCS) + 20% BHI 
as an optimal growth media for both bacterial and mammalian cells with each 
bacteria grown to the midlog point marked on the appropriate graphs (Fig. 2.3 - Fig. 
2.10),   
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Fig. 2.3: Growth profile of E. faecalis from an initial inoculation of 1:100 of a 0.5 McFarland Standard 
over 16hrs.  (A) BHI and (B) RPMI supplemented with 2mM L-glutamine, 10% FCS and 20% BHI. Data 
expressed as absorbance at 625nm +/- SD of the mean.  
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Fig. 2.4: Growth profile of E. faecalis from an initial inoculation of 150CFU over 16hrs.  (A) BHI and (B) 
RPMI supplemented with 2mM L-glutamine, 10% FCS and 20% BHI. *Midlog point used in future 
experiments. Data expressed as absorbance at 625nm +/- SD of the mean. 
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Fig. 2.5: Growth profile of S. pyogenes in (A) BHI and (B) RPMI supplemented with 2mM L-glutamine, 
10% FCS and 20% BHI over 16hrs from an initial inoculation of 1:100 of a 0.5 McFarland. Data 
expressed as absorbance at 625nm +/- SD of the mean. 
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Fig. 2.6: Growth profile of S. pyogenes in (A) BHI and (B) RPMI supplemented with 2mM L-glutamine, 
10% FCS and 20% BHI over 16hrs from an initial inoculation of 150 CFU. *Midlog point used in future 
experiments. Data expressed as absorbance at 625nm +/- SD of the mean. 
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Fig. 2.7: Growth profile of P. aeruginosa in (A) BHI and (B) RPMI supplemented with 2mM L-glutamine, 
10% FCS and 20% BHI over 24hrs from an initial inoculation of 1:100 of a 0.5 McFarland. Data 
expressed as absorbance at 625nm +/- SD of the mean. 
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Fig. 2.8: Growth profile of P. aeruginosa in (A) BHI and (B) RPMI supplemented with 2mM L-glutamine, 
10% FCS and 20% BHI over 24hrs from an initial inoculation of 150 CFU. *Midlog point used in future 
experiments. Data expressed as absorbance at 625nm +/- SD of the mean. 
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Fig. 2.9: Growth profile of P. mirabilis in (A) BHI and (B) RPMI supplemented with 2mM L-glutamine, 
10% FCS and 20% BHI over 48hrs from an initial inoculation of 1:100 of a 0.5 McFarland. Data 
expressed as absorbance at 625nm +/- SD of the mean. 
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Fig. 2.10: Growth profile of P. mirabilis  in (A) BHI and (B) RPMI supplemented with 2mM L-glutamine, 
10% FCS and 20% BHI over 48hrs from an initial inoculation of 150 CFU. *Midlog point used in future 
experiments. Data expressed as absorbance at 625nm +/- SD of the mean. 
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Table 2.2: Summary of the time in which each bacterium enters the different growth phases from both 
an initial inoculation of 1:100 of 0.5 McFarland standard and 150CFU in both media examined.  
 
Media and 
bacterial 
dilution 
 
BHI: 1:100 of 
0.5 McFarland 
standard 
RPMI: 1:100 of 
0.5 McFarland 
standard 
BHI: 150CFU RPMI: 150CFU 
 
 
Growth 
phase: 
 
 
Bacteria 
 
Log 
(hrs) 
 
 
Stationary 
(hrs) 
 
 
Log 
(hrs) 
 
 
Stationary 
(hrs) 
 
 
Log 
(hrs) 
 
 
Stationary 
(hrs) 
 
 
Log 
(hrs) 
 
Stationary 
(hrs) 
E. faecalis 2 5 3.5 5.5 6.5 8.5 6.5 8.5 
S. pyogenes 7 9.5 4 5.5 9.5 12 6 7.5 
P. aeruginosa 13 17.5 10 17 12 18 12 18 
P. mirabilis  3 5 3 5 7 10 8 11 
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Fig. 2.11: The effect of RPMI supplemented with 10% or 20% FCS +/- BHI 5%, 10% or 20% on the 
viability of OMLP-PCs (n=4 independent donors) and EFs (n=3 independent donors) as measured by 
the release of LDH from the cells. Percentage viability calculated from a positive control of lysed cells 
with 100% cytotoxicity. Data expressed as percentage cytotoxicity +/- SD of the mean. 
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2.3.5 OMLP-PCs Suppress the Growth of Gram positive and Gram 
Negative Bacteria in Co-culture. 
OMLP-PCs or EFs were co-cultured in direct contact with bacteria to determine 
whether oral mucosa cells possess antibacterial properties and whether this effect is 
specific to the PCs. Live bacteria (E. faecalis, S. pyogenes, P. aeruginosa, and P. 
mirabilis) were co-cultured with EFs or OMLP-PCs (pre-treated ± IFNγ for 7 days) for 
8, 7, 14 and 9hrs respectively to replicate the time required for each bacterium to 
normally reach midlog phase. Subsequently the CM (containing the bacteria) was 
aspirated and spiral plated onto agar to assess bacterial growth.  
Data within Fig. 2.12 is expressed as percentage bacterial growth compared to 
bacteria only controls (set at 100%). Bacterial growth in the presence of EFs did not 
significantly differ from control conditions (P>0.05; Fig. 2.12 A-D). In contrast OMLP-
PCs significantly decreased the percentage bacterium growth compared controls 
(P<0.01; Fig. 2.12 A-D). This effect was seen irrespective of pre-treatment with IFNγ 
or Gram classification (P<0.01; Fig. 2.12 A-D). 
2.3.6 OMLP-PCs Constitutively Suppress the Growth of Bacteria 
through the Release of Soluble Factors 
CM generated from section 2.2.7 was incubated with 100 CFU of each bacterium 
overnight (independent of the presence of any mammalian cells). Cultures were 
serially diluted and spiral plated onto agar before bacterial colonies were counted.  
CM from OMLP-PCs significantly decreased the growth of each bacterium (P<0.001), 
irrespective of whether this CM was derived from cells which had previously been 
stimulated by IFNy and/or bacterial exposure or not (Fig. 2.13 A, B and Fig. 2.14 A, 
B). Neither the CM from EFs (+/- bacterial exposure) or bacterial supernatants had 
any effect on bacterial growth (Fig. 2.13 A, B and Fig. 2.14 A, B). CM derived from 
OMLP-PCs which had previously been exposed to S. pyogenes had a further 
significant effect on decreasing bacterial growth (P<0.001; Fig. 2.13 B).  
2.3.7 OMLP-PC Secretome Reduces Bacterial Growth via a 
Bacteriostatic Mechanism 
CM generated from section 2.2.7 was incubated with 100CFU of each bacterium 
overnight. Cultures were stained using the Live/Dead® BacLight™ Bacterial Viability 
Kit. Bacteria were counted and percentage viability calculated. Fig. 2.15 – 2.18      
                               Chapter 2 Investigating the Antibacterial Properties of OMLP-PCs 
88 
 
 
 
 
 
    
    
Fig. 2.12: The effect of OMLP-PCs on the growth of bacteria in co-culture. The growth of (A) E. faecalis, 
(B) S. pyogenes, (C) P. aeruginosa and (D) P. mirabilis after incubation with OMLP-PCs (n=4) or EFs 
(n=3). Data expressed as percentage bacterial growth +/- SD of the mean with bacteria only controls set 
to 100%.  ** P<0.01 ***P<0.001 
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Fig. 2.13: The effect of CM from OMLP-PCs on the growth of Gram positive bacteria. The growth of (A) 
E. faecalis and (B) S. pyogenes after incubation with CM from OMLP-PCs (n=4), EFs (n=3) or bacterial 
supernatant (n=3). Data expressed as percentage bacterial growth +/- SD of the mean with bacteria only 
controls set to 100%. Statistics are compared to the bacteria only control unless otherwise stated. 
***P<0.001 
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Fig. 2.14: The effect of CM from OMLP-PCs on the growth of Gram negative bacteria. The growth of (A) 
P. aeruginosa and (B) P. mirabilis after incubation with CM from OMLP-PCs (n=4), EFs (n=3) or 
bacterial supernatant (n=3). Data expressed as percentage bacterial growth +/- SD of the mean with 
bacteria only controls set to 100%. Statistics are compared to the bacteria only control. ***P<0.001 
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Fig. 2.15: Percentage viability of E. faecalis after incubation with CM from OMLP-PCs. (A) Percentage 
of live (green) and dead (red) bacterial cells after incubation with CM derived from OMLP-PCs (n=4). 
Data expressed as percentage of bacterial cells +/- SD of the mean. Representative images (B) for E. 
faecalis incubated with CM from (i) OMLP-PCs, (ii) OMLP-PCs + IFNγ, (iii) E. faecalis primed OMLP-
PCs, (iv) E. faecalis primed OMLP-PCs + IFNγ, (v) no medium (E. faecalis only control).  
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Fig. 2.16: Percentage viability of S. pyogenes after incubation with CM from OMLP-PCs. (A) Percentage 
of live (green) and dead (red) bacterial cells after incubation with CM derived from OMLP-PCs (n=4). 
Data expressed as percentage of bacterial cells +/- SD of the mean. Representative images (B) for S. 
pyogenes incubated with CM from (i) OMLP-PCs, (ii) OMLP-PCs + IFNγ, (iii) S. pyogenes primed 
OMLP-PCs, (iv) S. pyogenes primed OMLP-PCs + IFNγ, (v) no medium (S. pyogenes only control). 
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 Fig. 2.17: Percentage viability of P. aeruginosa after incubation with CM from OMLP-PCs. (A) 
Percentage of live (green) and dead (red) bacterial cells after incubation with CM derived from OMLP-
PCs (n=4). Data expressed as percentage of bacterial cells +/- SD of the mean. Representative images 
(B) for P. aeruginosa incubated with CM from (i) OMLP-PCs, (ii) OMLP-PCs + IFNγ, (iii) P. aeruginosa 
primed OMLP-PCs, (iv) P. aeruginosa primed OMLP-PCs + IFNγ, (v) no medium  (P. aeruginosa only 
control). 
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Fig. 2.18:  Percentage viability of P. mirabilis after incubation with CM from OMLP-PCs. (A) Percentage 
of live (green) and dead (red) bacterial cells after incubation with CM derived from OMLP-PCs (n=4). 
Data expressed as percentage of bacterial cells +/- SD of the mean. Representative images (B) for P. 
mirabilis incubated with CM from (i) OMLP-PCs, (ii) OMLP-PCs + IFNγ, (iii) P. mirabilis primed OMLP-
PCs, (iv) P. mirabilis primed OMLP-PCs + IFNγ, (v) no medium (P. mirabilis only control). 
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demonstrate that the bacterial viability (live:dead ratio) was not adversely affected by 
exposure to CM derived from OMLP-PCs when compared to that of bacteria only 
cultures (P>0.05; Fig. 2.15 – Fig. 2.18) suggesting that suppression of bacterial 
growth by OMLP-PC CM occurs through a bacteriostatic rather than bacteriocidal 
effect. 
2.3.8 OMLP-PCs Antibacterial Factors are Dose Dependent 
CM samples derived from section 2.2.7 were diluted up to 1 in 100 into RPMI 
(supplemented with 2mM L-glutamine and 10% FCS and 20% BHI). Diluted samples 
were incubated with 100CFU of each bacterium for 16hrs before spiral plating onto 
agar and colonies counted.  
Undiluted CM from OMLP-PCs (+/- IFNy, +/- bacterial exposure) significantly 
decreased the growth of each bacterium as in section 2.3.6 (P<0.01; Fig. 2.19 – Fig. 
2.22), with medium derived from OMLP-PCs exposed to S. pyogenes further 
decreasing the growth of S. pyogenes (Fig. 2.20). Bacterial growth continued to be 
significantly decreased when the CM samples were diluted 1 in 2 and 1 in 5 (P<0.01), 
however further dilutions of 1 in 10 and 1 in 100 of the samples did not cause a 
significant effect on bacterial growth (P>0.05; Fig. 2.19 – Fig. 2.22), confirming the 
dose-dependent effect of the OMLP-PCs.  
2.3.9 OMLP-PCs Respond to Bacterial Stimuli 
2.3.9.1.1 OMLP-PCs Reduce Their Migratory Speed When Exposed to 
Live Bacteria or Bacterial Supernatant 
OMLP-PCs were incubated for 16hrs with bacterial protein, bacterial supernatant or 
live bacteria, with images of OMLP-PCs (n=4) or EFs (n=3) taken every 20mins to 
investigate the behaviour of the cells when cultured with live bacteria or their 
products. The migratory speed of the cells was determined (Fig. 2.23 – Fig. 2.26).  
Cells were tracked over a 3hr period as after this time, the view of those incubated 
with bacteria were obstructed by dividing bacteria. No notable changes in cell  
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Fig. 2.19: The effect of a dilution series of CM from OMLP-PCs on the growth of E. faecalis. Percentage 
of E. faecalis after incubation with CM (n=3) from undiluted to 1 in 100. Data expressed as percentage 
bacterial growth +/- SD of the mean with E. faecalis only controls set to 100%, represented by the red 
dotted line. All statistics compared to E. faecalis only control. **P<0.01. 
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Fig. 2.20: The effect of a dilution series of CM from OMLP-PCs on the growth of S. pyogenes. 
Percentage of S. pyogenes after incubation with CM (n=3) from undiluted to 1 in 100. Data expressed as 
percentage bacterial growth +/- SD of the mean with S. pyogenes only controls set to 100%, 
represented by the red dotted line. All Statistics compared to S. pyogenes only control unless otherwise 
stated. *P<0.05, **P<0.01, ***P<0.001. 
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Fig. 2.21: The effect of a dilution series of CM from OMLP-PCs on the growth of P. aeruginosa. 
Percentage of P. aeruginosa after incubation with CM (n=3) from undiluted to 1 in 100. Data expressed 
as percentage bacterial growth +/- SD of the mean with P. aeruginosa only controls set to 100%. 
Statistics compared to P. aeruginosa only control. ***P<0.001. 
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Fig. 2.22: The effect of a dilution series of CM from OMLP-PCs on the growth of P. mirabilis. 
Percentage of P. mirabilis after incubation with CM (n=3) from undiluted to 1 in 100. Data expressed as 
percentage bacterial growth +/- SD of the mean with P. mirabilis only controls set to 100%. Statistics 
compared to P. mirabilis only control. ***P<0.001. 
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Fig. 2.23: Migratory speed of cells after incubation with E. faecalis stimuli. Cell speed of OMLP-PCs 
(n=4) (A) and EFs (n=3) (B) after incubation with E. faecalis protein, live E. faecalis or E. faecalis 
supernatant. BHI media was used as a control for both live E. faecalis and E. faecalis supernatant 
samples. Data expressed as cell speed +/- SD of the mean. *P< 0.05 
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Fig. 2.24: Migratory speed of cells after incubation with S. pyogenes stimuli. Cell speed of OMLP-PCs 
(n=4) (A) and EFs (n=3) (B) after incubation with S. pyogenes protein, live S. pyogenes or S. pyogenes 
supernatant. BHI media was used as a control for both live S. pyogenes and S. pyogenes supernatant 
samples. Data expressed as cell speed +/- SD of the mean. *P<0.05, ** P<0.01 
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Fig. 2.25: Migratory speed of cells after incubation with P. aeruginosa stimuli. Cell speed of OMLP-PCs 
(n=4) (A) and EFs (n=3) (B) after incubation with P. aeruginosa protein, live P. aeruginosa or P. 
aeruginosa supernatant. BHI media was used as a control for both live P. aeruginosa and P. aeruginosa 
supernatant samples. Data expressed as cell speed +/- SD of the mean. *P<0.05, *** P<0.001 
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Fig. 2.26: Migratory speed of cells after incubation with P. mirabilis stimuli. Cell speed of OMLP-PCs 
(n=4) (A) and EFs (n=3) (B) after incubation with P. mirabilis protein, live P. mirabilis or P. mirabilis 
supernatant. BHI media was used as a control for both live P. mirabilis and P. mirabilis supernatant 
samples. Data expressed as cell speed +/- SD of the mean. *P< 0.05. 
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morphology were observed over the culture period when cells were incubated in 
control media, RPMI supplemented with 2mM L-glutamine and 10% (v/v) FCS. 
OMLP-PCs moved significantly slower when exposed to live bacteria up to this 3hr 
time period (P<0.05; Fig. 2.23 – Fig 2.26), whereas the EFs did not display any 
changes to their speed (P>0.05).  
OMLP-PCs moved significantly slower when exposed to bacterial supernatant, 
irrespective of the bacteria Gram classification of the bacteria (P<0.05; Fig. 2.23 – 
Fig 2.26), while EFs remained at a constant speed compared to the control (P>0.05).  
Irrespective of the bacteria utilised, oral cells incubated with bacterial protein 
appeared to migrate towards and directly interact with this protein (Supplementary 
Data Stick: Movie 1-4).  Over time, the majority of the bacterial protein appeared to 
become associated with the OMLP-PCs rather than remain free within the medium 
(Fig. 2.27 – Fig. 30). This effect was observed irrespective of whether bacteria were 
Gram positive (E. faecalis and S. pyogenes) or Gram negative (P. mirabilis and P. 
aeruginosa). The speed of OMLP-PC movement did not significantly alter when 
exposed to bacterial protein (P>0.05), with the exception of protein extracted from P. 
aeruginosa (P<0.001) (Fig. 2.23 – Fig 2.26). This suggests that OMLP-PCs respond 
to factors secreted by OMLP-PCs rather than the intracellular soluble proteins of the 
bacteria examined here. 
2.3.9.1.2 Bacterial Protein Does Not Affect the Cell Area of OMLP-PCs  
While the migratory speed of OMLP-PCs did not change in response to bacterial 
protein, the morphology appeared to change. The cell area of OMLP-PCs was 
therefore recorded after 16 hours in culture. It was demonstrated that OMLP-PCs did 
not change their cell area in response to bacterial protein isolated from Gram positive 
or Gram negative bacteria (Fig. 2.31). 
2.3.9.2 OMLP-PCs Do Not Migrate Towards Bacterial Protein 
It was hypothesised that OMLP-PCs may migrate towards bacterial protein after 
analysis presented in section 2.3.9.1 Boyden chamber analysis was therefore carried 
out to assess the migration of the cells towards Gram positive (E. faecalis) and Gram 
negative (P. aeruginosa) bacterial protein.  
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Neither OMLP-PCs nor EFs displayed any migration towards the bacterial protein 
utilising this system (Fig. 2.32). A positive control of 10% FCS was used, which 
significantly increased the migration of the EFs but not the OMLP-PCs. The OMLP-
PCs baseline migration was comparable to levels induced by FCS in the EFs (Fig. 
2.32). This suggested that OMLP-PCs were inherently more migratory at baseline 
compared to the EFs.  
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Fig. 2.27: Micrograph images of OMLP-PCs in (A) control media or (B) with protein extracted from E. faecalis (B) over a time course of 16 hours. OMLP-PCs appeared to 
remain healthy with no considerable changes in morphology when incubated with bacterial protein. OMLP-PCs physically interacted with protein extracted from E. faecalis, and 
by 16 hours the majority of protein was interacting with the OMLP-PCs and was not free within the medium. Bar = 10µM. 
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Fig. 2.28: Micrograph images of OMLP-PCs in (A) control media or (B) with protein extracted from S. pyogenes (B) over a time course of 16 hours. OMLP-PCs appeared to 
remain healthy with no considerable changes in morphology when incubated with bacterial protein. OMLP-PCs physically interacted with protein extracted from S. pyogenes, 
and by 16 hours the majority of protein was interacting with the OMLP-PCs and was not free within the medium. Bar = 10µM. 
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Fig. 2.29: Micrograph images of OMLP-PCs in (A) control media or (B) with protein extracted from P. aeruginosa (B) over a time course of 16 hours. OMLP-PCs appeared to 
remain healthy with no considerable changes in morphology when incubated with bacterial protein. OMLP-PCs physically interacted with protein extracted from P. aeruginosa, 
and by 16 hours the majority of protein was interacting with the OMLP-PCs and was not free within the medium. Bar = 10µM. 
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Fig. 2.30: Micrograph images of OMLP-PCs in (A) control media or (B) with protein extracted from P. mirabilis (B) over a time course of 16 hours. OMLP-PCs appeared to 
remain healthy with no considerable changes in morphology when incubated with bacterial protein. OMLP-PCs physically interacted with protein extracted from P. mirabilis, 
and by 16 hours the majority of protein was interacting with the OMLP-PCs and was not free within the medium. Bar = 10µM.
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Fig. 2.31: The effect of bacterial protein on OMLP-PC area. Area of OMLP-PCs (n=3) after incubation 
with bacterial protein isolated from E. faecalis, S. pyogenes, Paeruginosa or P. mirabilis, +/- SD of the 
mean. 
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Fig. 2.32: The effect of bacterial protein on directional cell migration. OMLP-PCs (n=3) and EFs (n=3) 
migration after incubation with E. faecalis protein or P. aeruginosa protein. FCS was used as a positive 
control. Data expressed as a percentage of cells compared to migratory OMLP-PCs in control media +/- 
SD of the mean. 
 *P< 0.05 
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2.4 Discussion 
BM-MSCs display both immunosuppressive (Ghannam et al., 2010) and antibacterial 
(Krasnodembskaya et al., 2010) properties. Potentially, these properties may be 
common to many stem and PC populations. The recent discovery that OMLP-PCs 
display immunosuppressive qualities (Davies et al., 2012) has led to the 
investigations in this Thesis into the potential antibacterial properties of OMLP-PCs.  
Cells from the oral cavity provide promising potential as antimicrobial cells as the 
mouth is constantly rich in a dynamic population of micro-organisms (Parahitiyawa et 
al., 2010).  It is clear that there must be an antimicrobial strategy in the oral cavity to 
prevent recurrent infections. Several cell populations have already been identified to 
play a role (e.g. oral epithelial cells and the salivary gland) by secreting antibacterial 
factors (Gorr, 2009). However, due to the diversity in the microbial population of the 
mouth the secretion of multiple antimicrobial peptides or proteins is likely. The 
secretion of LL37 by BM-MSCs (Krasnodembskaya et al., 2010) suggests that 
OMLP-PCs may also secrete an antimicrobial agent(s) to aid in oral defences.  
This study aimed to investigate the antibacterial properties of OMLP-PCs in host 
defence. Investigations have focussed on determining whether OMLP-PCs decrease 
the CFU of bacteria, while further studies will concentrate on potential antibacterial 
factors released by these cells. 
The growth of bacteria in tissue culture medium was demonstrated to be limited 
compared to growth in the standard microbiology medium BHI. To increase the 
growth of bacteria, BHI was supplemented to the RPMI tissue culture medium, which 
in some cases restored the growth of bacteria to a level comparable to that seen in 
BHI medium. It was important to assess the effect of the BHI supplementation on 
OMLP-PC and EF viability as later experiments involved co-culturing the cells with 
bacteria. The addition of 5, 10 or 20% BHI to the RPMI medium did not cause any 
significant cytotoxicity to either the OMLP-PCs or EFs. This demonstrated that RPMI 
supplemented with BHI medium could be utilised in the later co-culture studies.  
The first aim of the study, to establish whether OMLP-PCs decrease the growth of 
Gram positive and Gram negative bacteria was addressed. The study demonstrated 
that OMLP-PCs act in an antibacterial manner by reducing the growth of both Gram 
positive and Gram negative bacteria, a phenomenon not replicated by the EFs. The 
EF cells were used as a control cell type; illustrating that the OMLP-PCs actively 
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decrease the growth of bacteria and do not simply decrease the bacterial numbers 
due to depletion of nutrients within the culture media. The lack of antibacterial 
properties of the EFs also demonstrates that this is not a property of all cells within 
the buccal mucosal, and despite the rich microbial environment from which they 
originate, it is a property specific to the OMLP-PCs.  
The decrease in bacterial growth by OMLP-PCs was seen irrespective of pre-
treatment with IFNγ. The IFNγ stimulation is required to activate the 
immunosuppressive activity of MSCs through the induction of IDO (Ghannam et al., 
2010), while IDO is also induced by IFNγ in OMLP-PCs (Davies et al., 2012). This 
observation demonstrates that the induction of IDO from OMLP-PCs does not 
contribute to the antibacterial properties. Furthermore this study begins to address 
the third aim of this chapter: to determine whether OMLP-PCs require inflammatory 
or bacterial priming to exert antibacterial actions against Gram positive and Gram 
negative bacteria. It was demonstrated that the inflammatory stimulus IFNγ was not 
required for OMLP-PCs to display the antibacterial properties, nor was exposure of 
bacteria to OMLP-PCs. This illustrates that OMLP-PCs are constitutively 
antibacterial, a mechanism differing from that of the BM-MSCs, which only display 
antibacterial properties upon exposure to bacteria (Krasnodembskaya et al., 2010). It 
is possible that the constitutive mechanism of OMLP-PCs may be a consequence of 
in vivo priming to the cells, due to the rich microbiome from which the cells originate.  
The contact independent antibacterial mechanism of OMLP-PCs was confirmed 
when it was demonstrated that the CM samples retained the constitutive antibacterial 
properties of the cells. These studies confirm that OMLP-PCs secrete antimicrobial 
factors, confirming a similar mechanism to the BM-MSCs (Krasnodembskaya et al., 
2010). While pre-stimulation of the cells to IFNγ or previous bacterial exposure was 
not required for the CM of OMLP-PCs to demonstrate antibacterial properties, 
OMLP-PCs exposed to S. pyogenes demonstrated enhanced antibacterial properties 
within the CM. Streptoccocal species are hugely prevalent within the oral cavity (Aas 
et al., 2005), with exposure of the cells to such bacteria possible in situ. This may 
explain the heightened response of the OMLP-PCs to S. pyogenes, as cells may 
recognise this genus. Further investigations could fully evaluate the effects of 
bacteria commonly found in the oral cavity on the antibacterial properties of OMLP-
PCs.  
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Importantly, these studies demonstrate that the antibacterial properties of OMLP-PCs 
can be lost through dilution. CM samples were diluted up to 1 in 100. It was found 
that CM samples retained their antibacterial properties when diluted up to 1 in 5, but 
beyond this the antibacterial effect was not observed. This illustrates the dose-
dependent antibacterial mechanism of OMLP-PCs, a phenomenon which has yet to 
be investigated within the CM of BM-MSCs.  
It has also been demonstrated during this study that the antibacterial properties of 
OMLP-PCs are of a bacteriostatic mechanism and not bactericidal. By staining 
bacterial cultures with LIVE/DEAD® fluorescent dyes it was determined that the 
number of dead bacterial cells did not increase when bacterial cultures were 
incubated with the CM derived from OMLP-PCs. From this it can be concluded that 
the overall effect of the soluble factors released by OMLP-PCs is a bacteriostatic 
effect.  
To address the forth aim live bacteria, bacterial supernatant and bacterial protein 
were incubated with OMLP-PCs for 16hrs and migratory cell speed was determined 
using time-lapse microscopy. The time-lapse photomicrographs of the OMLP-PCs 
incubated with live bacteria, bacterial supernatant and bacterial protein demonstrated 
no morphological changes to the cells over time suggesting they remained healthy 
throughout the incubation period. Some interesting findings were made with respect 
to the cells incubated with the bacterial protein.   
The Cell-IQ system utilised as part of these investigations is able to capture Z-stacks 
of cells, however there was an extensive build-up of bacterial protein on the cells. 
Therefore, analysis using a suitable Z stack range could not be performed to 
evaluate the protein from its outer surface down to the cell membrane. It was 
therefore not possible to determine whether the protein was bound to the cell 
surface, or had become internalised by the cells. Further investigations are warranted 
to delineate the fate of this protein, such as the use of scanning electron microscopy 
to visualise if the protein is internalised or bound to the surface of OMLP-PCs. Whilst 
the morphology of OMLP-PCs exposed to bacterial protein did not notably change 
over time, there were some differences compared to the morphology of OMLP-PCs 
cultured in the absence of stimuli. However, this was not manifested by any change 
in cell area, yet the cells incubated with bacterial protein appeared thinner and longer 
with some cells sending out processes to interact with the protein in the surrounding 
environment. This suggests that the OMLP-PCs can rapidly respond to the presence 
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of bacterial proteins, adapting their shape to permit direct interaction with this 
exogenous agent. The mechanism by which the OMLP-PCs ‘sense’ the protein has 
yet to be explored.  One candidate pathway is via Phosphoinositide-3-Kinase (PI3K) 
signalling which has been implicated in microbial killing by neutrophils (Kulkarni et al., 
2011). Neutrophils engulf the microbes exposing the micro-organisms to 
antimicrobial proteins such as lysozyme and lactoferrin and reactive oxygen species 
(ROS; Moraes and Downey, 2003). However, it was noted that the production of the 
ROS was inhibited following PI3K inhibition (Kulkarni et al., 2011).  Furthermore, 
animal studies have demonstrated that mice deficient in PI3K display impaired ROS 
production in response to bacterial LPS (Hirsch et al., 2000). Recently, it has been 
reported that the PI3K isoform, p110γ, is the major form of the enzyme involved in 
ROS production (Nigorikawa et al., 2012). Superoxide production cannot be induced 
by PI3K in p110γ knock-out mice (Nigorikawa et al., 2012). These studies illustrate 
the importance of PI3K in the host defence against bacterial infection. PI3K could 
potentially be involved in recognising the bacterial protein which may cause 
downstream effects in aiding bacterial clearance. Repeating the experiments using a 
PI3K inhibitor could confirm its involvement in the behaviour of OMLP-PCs in 
response to the bacterial protein, while immunocytochemistry could also been used 
to localise the transport and production of PI3K.  
The speed of the OMLP-PC migration significantly decreased when exposed to live 
bacteria or bacterial supernatant from both Gram positive and Gram negative 
bacteria, but not in response to isolated intracellular bacterial protein. This suggests 
that OMLP-PCs respond to factors secreted by OMLP-PCs, rather than the 
intracellular bacterial proteins examined here. The decrease in migratory speed after 
bacterial stimuli could be a result of cells transferring resources into antibacterial 
mechanisms rather than migration. Further investigations will determine if the OMLP-
PCs release antimicrobial factors in response to bacterial stimuli.   
Neither the migration of OMLP-PCs nor EFs increased when exposed to bacterial 
protein. A positive control of 10% FCS was used to stimulate the migration of each 
cell type. The migration of the EFs significantly increased upon FCS exposure; 
however the OMLP-PCs migration was not altered. The baseline migration of the 
OMLP-PCs was comparable to the FCS stimulated migration of EFs, suggesting 
OMLP-PCs are inherently more migratory at baseline compared to EFs. This could 
potentially be a result of in vivo priming of the OMLP-PCs, having already been 
stimulated to migrate by the presence of bacteria or bacterial products in situ. 
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Throughout this Thesis chapter it has been demonstrated that EFs cannot respond to 
bacterial stimuli or display antibacterial properties despite the rich microbial 
environment from which both EFs and OMLP-PCs originate, hence the in situ priming 
having no effect on EFs. Higher concentrations of FCS could be used to assess the 
maximal migratory potential of the OMLP-PCs and examine whether the migratory 
potential of OMLP-PCs is greater than the EFs at all FCS concentrations. 
   
2.4.1 Conclusion 
The aim of this study was to investigate the antibacterial properties of OMLP-PCs. 
Work within this chapter demonstrated that OMLP-PCs are antibacterial, reducing the 
growth of both Gram positive and Gram negative bacteria. Furthermore, it was 
established that neither inflammatory nor bacterial stimuli was required to induce this 
property, illustrating the constitutive antibacterial nature of the cells.  
The antibacterial properties of the OMLP-PCs were retained within the CM of the 
cells, indicating that antibacterial factors are released by the PCs into the culture 
medium. This effect was dose-dependent, with dilutions of the CM beyond 1 in 5 not 
displaying any antibacterial properties. The antibacterial mechanism was further 
investigated, with confirmation of the bacteriostatic effect by OMLP-PCs 
demonstrated using live/dead staining of the bacterial cultures. The antibacterial 
response of the CM was enhanced when the cells were previously exposed to S. 
pyogenes. This could be a result of OMLP-PC recognition of the Streptococcal 
genus, as these bacteria are a dominant genus within the oral cavity   
This chapter has determined that OMLP-PCs are antibacterial through the release of 
antimicrobial factors, a property scarcely investigated in stem cell/PC populations. 
Further investigations have focussed on the soluble factors released by OMLP-PCs 
and their potential antibacterial effects against Gram positive and Gram negative 
bacteria.    
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3 Elucidating the Soluble Mechanisms Mediating the 
Antibacterial Effects of OMLP-PCs 
 
3.1 Background 
The immunosuppressive properties of OMLP-PCs are mediated through the cellular 
release of soluble factors (Davies et al., 2012). Many of the identified 
immunomodulatory factors are known to additionally demonstrate antibacterial 
effects, leading to the hypothesis that OMLP-PCs possess both immunosuppressive 
and antibacterial properties through the secretion of such factors. This hypothesis 
has been demonstrated to some extent for BM-MSCs, with the secretion of IDO 
(Krampera et al., 2006) and LL37 (Krasnodembskaya et al., 2010) documented.  
IDO is an enzyme capable of degrading tryptophan, an essential factor for 
tryptophan-dependant bacteria such as Group B Streptococci, Enterococci (Hucke et 
al., 2004) and Staphylococcus aureus (Schroten et al., 2001). IDO activity is 
undetected in resting OMLP-PCs, but with high levels of IFNγ can be induced 
(Davies et al., 2012). IDO induction in response to bacterial exposure is yet to be 
investigated. 
LL37 is an AMP constitutively expressed in immune cells such as monocytes and 
natural killer cells (Zanetti, 2005), and inducible in areas such as the salivary glands 
by inflammation (Woo et al., 2003). LL37 directly binds LPS on the surface of 
bacteria, supressing LPS-induced host responses, such as pro-inflammatory 
cytokines release, during infection (Zanetti, 2005). It has been reported that LL37 
demonstrates antibacterial properties against a range of bacteria such as the Gram 
positive S. aureus and vancomycin resistance enterococci and Gram negative E. coli 
and P. aeruginosa  (Zanetti, 2005). It has also been reported that the secretion of 
LL37 is induced by bacteria in BM-MSCs, which partially mediated the antibacterial 
properties of BM-MSCs described in this study (Krasnodembskaya et al., 2010).   
The role of OPG is well known within bone remodelling, acting as a decoy receptor 
for RANKL. The binding of OPG to RANKL prevents osteoclast maturation and 
therefore slows the bone resorptive phase of the process (Jin et al., 2015). This 
glycoprotein has been identified within the secretome of BM-MSCs, but is not thought 
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to play a role in the BM-MSC-mediated immunosuppression (Le Blanc et al., 2004). 
OPG has also been identified as a decoy receptor for TRAIL. TRAIL induces 
apoptosis (Chaudhari et al., 2006) through the activation of death domain receptor, 
with apoptosis suppressed when TRAIL is bound to OPG (Sandra et al., 2006). The 
decrease of OPG within the oral cavity has been well documented during 
periodontitis, a condition associated with the bacterium Porphyromonas gingivalis 
(Bostanci et al., 2007, Mogi et al., 2004, Liu et al., 2003). However, each study has 
investigated the levels of OPG in relation to the bone remodelling process, rather 
than examining any potential antibacterial effect. 
Another glycoprotein, haptoglobin, is known to possess both antibacterial and 
immunomodulatory properties (Sadrzadeh and Bozorgmehr, 2004). Three forms of 
haptoglobin have been identified within humans, Hp1-1, Hp1-2 or Hp2-2, dependant 
on the chains present. Comprising of two α and two β chains, the isoform of the α 
chain dictates the form and the level of activity. The presence of the α1 chain leads to 
a higher activity level, with the Hp1-1 form displaying the greatest level of activity. 
The antibacterial mechanism of haptoglobin is through effective binding of 
haemoglobin and therefore depletion of iron (Eaton et al., 1982), which is an 
essential environmental factor for many bacteria and fungi (Barclay, 1985). 
Production of haptoglobin by the liver and its presence within plasma during 
inflammation is well known (Huntoon et al., 2008) however, the secretion by a 
stem/progenitor cell population has yet to be reported.       
A factor known to be secreted from stem cell populations is PGE2, a lipid produced 
by COX enzymes (Park et al., 2006), which demonstrates immunomodulatory 
properties, with immune cells the primary source during inflammation (Agard et al., 
2013). Whilst PGE2 is known to inhibit innate cell functions such as the phagocytosis 
of macrophages, direct effects of PGE2 on bacterial growth are less reported. In 
addition to its effect on innate immune cells, PGE2 is able to suppress the activation 
and proliferation of T cells (Kalinski, 2012). The synthesis of PGE2 is regulated by a 
number of inflammatory stimuli including the bacterial-derived stimuli LPS (Agard et 
al., 2013). Whilst both Gram positive and Gram negative bacteria are known to 
induce PGE2 expression in macrophages, higher levels are induced by the Gram 
negative group of bacteria (Hessle et al., 2003). The secretion of PGE2 is well 
documented from stem cell populations, with BM-MSCs (Aggarwal and Pittenger, 
2005, Sotiropoulou et al., 2006), periodontal ligament stem cells (Ding et al., 2010) 
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and gingival stem cells (Su et al., 2011) reported to secrete PGE2, which plays a role 
in the immunomodulation of these cell types.  
The aim of this chapter is to begin to elucidate the antibacterial mechanism of action 
of OMLP-PCs. Previously, it was demonstrated within chapter 2 that OMLP-PCs 
mediate their antibacterial effects through contact independent mechanisms i.e. the 
release of soluble factors. Furthermore, it was demonstrated that these factors are 
constitutively secreted. This chapter aims to identity the proteins within the OMLP-PC 
secretome which play a role in the antibacterial effects. The antibacterial activity of 
identified factors was also assessed with reference to and secreted concentration 
required to elicit an effect. Additionally, blocking of the identified factors within the 
secretome has been used to further validate the role of each factor in the OMLP-PC 
mediated antibacterial effects.  
 
3.1.1 Aims 
1. To investigate the potential antibacterial factors expressed and secreted by 
OMLP-PCs  
2. To examine the antibacterial activity of identified factors 
3. Establish whether blocking specific antibacterial factors inhibits the 
antibacterial properties of OMLP-PCs 
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3.2 Materials and Methods 
 
3.2.1 Investigation of mRNA Expression of Antimicrobial Factors in 
OMLP-PCs 
3.2.1.1 RNA Isolation  
RNA was isolated from OMLP-PCs after co-culture experiments described in section 
2.2.7 using the Illustra RNAspin Mini RNA isolation kit. The RNA isolation method 
used is shown in Fig. 3.1. Briefly, cells were directly added to the cell lysis buffer 
provided and stored at -80ºC until required. The lysed cells were passed through an 
RNAspin Mini Filter at 11,000xg for 1 min, to reduce viscosity. The RNA binding 
conditions were altered by adding 70% ethanol, before the RNA was bound to a silica 
membrane. Salts were removed from the membrane using the Membrane Desalting 
Buffer provided, allowing DNase to effectively remove contaminating DNA. Finally, 
the membrane was washed 3 times before the RNA was eluted in 100µl of RNase-
free water. The RNA was then quantified using a NanoVue (28-9232-16; GE 
Healthcare, UK) and the quality assessed by evaluation of the A260/A280 and 
A260/A230 ratios.  
3.2.1.2 cDNA Synthesis 
cDNA was synthesised from 0.5µg of total RNA. RNA was added to 1µl random 
hexamer primers (Promega Ltd, Southampton, UK) and incubated at 70°C for 5mins. 
The RNA and primer mix was supplemented with 1µl RNasin, 1µl Moloney murine 
leukemia virus reverse transcriptase, 5µl reverse transcriptase buffer and 5µl 
deoxynucleotide triphosphates (dNTPS; Promega, Southampton, UK). The reaction 
volume was made up to 50µl with DNase-free water (Sigma Aldrich, UK) and 
incubated at 25°C for 10mins, 42°C for 1hr followed by 95°C for 5mins (Unocyclyer, 
VWR, UK). 
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Fig. 3.1: RNA Isolation: 1: Cell lysis. 2: Cells filtered to reduce viscosity. 3: The binding conditions 
altered using 70% ethanol to allow RNA binding. 4: RNA bound to membrane. 5: Membrane desalted. 6: 
Contaminating DNA digested using DNase. 7: Membrane is washed and dried. 8: RNA eluted using 
RNase-free water. 
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3.2.1.3 Quantitative Polymerase Chain Reaction (qPCR)  
Three µl of diluted cDNA (1 in 5) was added to 10 µmol of both forward and reverse 
primers and 4.75µl of Fast SYBR® Green Master Mix (Life Technologies Ltd, Paisley, 
UK). The volume of each well was made up to 10µl with DNase-free water. Water 
was used as a negative control. Primers were designed using basic local alignment 
search tool (BLAST) from NCBI (http://blast.ncbi.nlm.nih.gov/) and purchased from 
MWG Biotech (Germany). Primer sequences are outlined in table 3.1 
The PCR was carried out using a standard PCR reaction protocol, with an initial 
denaturation at 95°C, followed by 40 cycles of 95°C for denaturation for 3s and 
annealing/extension 60°C for 30s (ABI 6000 Prism, Life Technologies Ltd, UK). 
Data was analysed using the Δ ΔCT method, by which each sample was compared 
to its own β-actin level, before being compared to the control sample group. 
3.2.2 Investigation of the Secretion of Antimicrobial Factors in OMLP-
PCs 
Conditioned media (CM) samples were generated from section 2.2.7. 
3.2.2.1 Quantification of IDO Activity in Conditioned Media from OMLP-
PCs 
The concentration of the IDO metabolite, L-kynurenine was determined as a measure 
of IDO activity. The method used was adapted from Mahanonda et al., 2007. Briefly, 
300µl CM from the experiments outlined in section 2.2.7 was mixed with 150µl of 
30% (v/v) trichloroacetic acid and centrifuged for 5 minutes at 8000xg. Seventy-five 
µl of each supernatant was added to 75µl of Ehrlich’s reagent (20mg/ml p-
dimethylbenzaldehyde [Sigma Aldrich, UK] dissolved in pure glacial acetic acid 
[Sigma Aldrich, UK]) in a 96 well plate in triplicate. The absorbance of each well was 
read at 490nm (Microplate autoreader EL311, Bio-Tek Instruments, USA). 
Concentrations of L-kynurenine in each sample were determined using a standard 
curve produced using known concentrations of L-kynurenine (0-100µM; Sigma 
Aldrich, UK) prepared in unconditioned medium pre-centrifuged at x8000g with 30% 
(v/v) trichloroacetic acid.  
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Table 3.1: Primer sequences for qPCR reactions.  
Primer target Primer sequence 
β-actin 
(housekeeping 
gene) 
F: AGG GCA GTG ATC TCC TTC TGC ATC CT 
R: CCA CAC TGT GCC CAT CTA CGA GGG GT 
 
IDO 
F: GCG ATG TTG GAA ATA GCT TC 
R: CAG GAC GTC AAA GCA CTA AA 
 
LL37 
F: CTG CTG GGT GAT TTC TTC C 
R: TCT GTC CTG GGT ACA AGA TTC C 
 
OPG 
F:GAA GGG CGC TAC CTT GA GAT 
R:GCA AAC TGT ATT TCG CTC TGG 
 
COX2 
F:CTT CAC GCA TCA GTT TTT CAA G 
R: TCA CCG TAA ATA TGA TTT AAG TCC AC 
 
RANKL 
F: TGA TTC ATG TAG GAG AAT TAA ACA GG 
R: GAT GTG CTG TGA TCC AAC GA                   
 
TRAIL 
F:GC TCT GGG CCG CAA AAT 
R:GCT CTG GGC  CGC AAA AT 
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3.2.2.2 Quantification of OPG Secretion in Conditioned Media from 
OMLP-PCs 
Secreted levels of OPG were determined using an enzyme-linked immunosorbent 
assay (ELISA: R&D systems, UK), and was performed as per the manufacturer’s 
protocol. A 96 well microplate was coated with 100µl of the capture antibody (2µg/ml) 
in PBS, covered and incubated overnight at room temperature. Each well was 
washed for a total of three times using the wash buffer provided (0.05% Tween® 20 
in PBS, pH 7.2-7.4). Wells were subsequently blocked with the supplied Reagent 
Diluent (1% bovine serum albumin [BSA], pH 7.2-7.4, 0.2µm filtered) for 1hr at room 
temperature. The microplate was washed as before, followed by the addition of 100µl 
of sample (diluted 1 in 5) or standard (0-4ng/ml) for 2hrs.  The wells were washed 
before the addition of 100µl detection antibody (200ng/ml diluted in reagent diluent 
and 2% heat inactivated normal goat serum) for a further 2hrs. After washing, 100µl 
of the supplied Streptavidin-horseradish peroxidase (HRP) (diluted 1 in 40) was 
added to each well for 20mins in the dark. A final wash step was applied before 100µl 
of the substrate solution (1:1 Part A [H2O2]: Part B [Tetramethylbenzidine]) was 
added for 20mins in the dark. Fifty µl of stop solution (2N H2SO4) was added to each 
well before the absorbance at 450nm, with a reference wavelength of 540nm was 
determined (SPECTROstar Omega, BMG-LABTECH or FLUOstar Optima, BMG-
LABTECH, Germany). Concentrations of OPG were determined using a standard 
curve of OPG provided. The data was linearised by plotting the log of OPG 
concentrations against the log of the absorbance values. Concentrations were read 
using the equation of the line and data re-transformed and compared to an OPG 
standard of known concentrations. 
3.2.2.3 Quantification of Secreted PGE2 in Conditioned Media from 
OMLP-PC 
The secretion of PGE2 from OMLP-PCs and EFs was determined using a 
Prostaglandin E2 Parameter Assay Kit (R&D Systems, UK), as per the 
manufacturer’s protocol. CM samples (150µl) generated in section 2.2.7 and PGE2 
standard provided (0-2500pg/ml) were incubated with 50µl of the provided primary 
antibody for 1hr with agitation. Non-specific binding wells were included containing 
only the provided calibrator diluent (a buffered protein base with preservatives), in 
which the standards were diluted. Fifty µl of the PGE2 conjugate was added directly 
to each sample (excluding the non-specific binding wells) and incubated for a further 
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2hrs on an orbital shaker at 500 revolutions per minute (RPM). Each well was 
washed thoroughly with the wash buffer provided (0.05% Tween® 20 in PBS, pH 7.2-
7.4) before 200µl of the substrate solution (1:1 Part A [H2O2]: Part B 
[Tetramethylbenzidine]) was added, and incubated for 30mins in the dark. After the 
30mins incubation, 100µl stop solution (2N H2SO4) was added and the absorbance of 
each well recorded at 450nm and 540nm (SPECTROstar Omega, BMG-LABTECH or 
FLUOstar Optima, BMG-LABTECH, Germany). Concentrations of PGE2 were 
determined using a standard curve of PGE2 provided. The data was linearised by 
plotting the mean absorbance of each standard on a linear y-axis and the log of the 
concentration on the x-axis. Concentrations were read using the equation of the line 
and data re-transformed and compared to a PGE2 standard of known 
concentrations. 
3.2.2.4 Western Blot Analysis of OPG and Haptoglobin Secretion from 
OMLP-PCs 
3.2.2.4.1 Protein Quantification by Bicinchoninic Acid Protein Assay 
The protein content of CM samples generate from section 2.2.7 were determined by 
bicinchoninic acid (BCA) protein assay (Pierce; ThermoFisher Scientific, UK). Briefly, 
25µl of CM was added to 200µl of working reagent, prepared according to the 
manufacturer’s protocol (50:1 Part A [sodium carbonate, sodium bicarbonate, 
bicinchoninic acid and sodium tartrate in 0.1M sodium hydroxide]: Part B [4% cupric 
sulphate]). Samples were incubated at 37°C for 30mins before the absorbance was 
read at 562nm (SPECTROstar Omega, BMG-LABTECH or FLUOstar Optima, BMG-
LABTECH, Germany). The concentration of protein in each sample was determined 
using a standard linear curve of albumin standards provided, diluted in unconditioned 
media.  
3.2.2.4.2 Protein Separation by Polyacrylamide gel electrophoresis 
CM (25µg total protein) was combined with x3 Laemmli sample buffer (0.125M Tris, 
0.004% Bromophenol Blue, 20% Glycerol, 4% Sodium dodecyl sulfate [SDS], pH 
6.8). Where sample reduction was required, 10% 2β-mercaptoethanol was added to 
the above and samples incubated at 96°C for 5mins. (Note: to separate native 
proteins neither SDS nor 2β-mercaptoethanol was added). The 25 µg samples were 
then separated through a 4–15% Mini-PROTEAN® TGX™ Gel (Biorad, UK) at 200V 
for 45mins (Mini-PROTEAN® Tetra Vertical Electrophoresis Cell, Biorad UK) in 
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running buffer (25mM Tris [Sigma Aldrich, UK]), 192mM Glycine [Fisher Scientific, 
UK], 0.1% Sodium dodecyl sulfate [SDS; Sigma Aldrich, UK]). Pre-stained 
Kaleidoscope molecular weight standards (10-250kDa; BioRad, UK) were loaded 
(8µl) to compare samples.  Gels were subsequently carried forward for Western blot 
analysis (see section 3.2.2.4.4).   
3.2.2.4.3 2 Dimensional-Polyacrylamide Gel Electrophoresis 
CM samples (180µg) from section 2.2.7 were processed through a 2D Clean-Up Kit 
(GE Healthcare, UK). Briefly, proteins were precipitated using the precipitant and co-
precipitant provided and centrifuged at 12,000xg for 5mins. The proteins were then 
washed in the ice-cold wash buffer provided and pellets air-dried. Pellets were re-
suspended in 116µl of 7M Urea, 2M Thiourea, 2% 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate [CHAPS] followed by 1% 
Bromophenol Blue, 2µl immobilized pH gradient [IPG] buffer (GE Healthcare, UK) 
and 6.25µl 50nM Dithiothreitol (DTT).   
Samples (180µg) were pipetted into the strip holder and the Immobiline DryStrip pH 
3-10, 7 cm (GE Healthcare, UK) placed on top. The sample and Immobiline® 
DryStrip were coated in Immobiline® DryStrip cover fluid (GE Healthcare, UK) and 
placed onto the Isoelectric Focussing Unit (GE healthcare, UK) and the following 
protocol applied: rehydration at 20°C for 12hrs, step & hold 500V 1hr, gradient 1000V 
2hrs, step & hold 1000V 1hr, gradient 8000V 2hrs  and step & hold 8000V 8hrs.  
The Immobiline DryStrip was equilibrated in 4.5ml 1x NuPAGE LDS Sample Buffer 
(Life Technologies, UK) supplemented with 0.5ml 1x NuPAGE Sample Reducing 
Agent (Life Technologies, UK) for 15mins with agitation. The Immobiline DryStrip was 
then added to 5ml of an alkylating solution of 1x NuPAGE LDS Sample Buffer 
supplemented with 23.2mg/ml Iodoacetamide for 15mins with agitation.  
The Immobiline DryStrip was then inserted into the well of a NuPAGE® Novex® 4-
12% Bis-Tris ZOOM® Protein Gel (1.0 mm, IPG well: Life Technologies, UK). A 
rhOPG standard (R&D Systems, UK; 30ng) and pre-stained Kaleidoscope molecular 
weight standards (BioRad, UK) were mixed and added to the control well as a guide. 
Proteins were separated through the gel at 200V for 50mins. Gels were carried 
forward for western blot analysis (see section 3.2.2.4.4).   
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3.2.2.4.4 Western Blot Detection of OPG and Haptoglobin 
Western blot analysis was carried out on gels from sections 3.2.2.4.2 and 3.2.2.4.3. 
Samples loaded were transferred onto a Polyvinylidene fluoride (PVDF: GE 
Healthcare, UK membrane) for OPG detection, or a nitrocellulose membrane 
(Hybond™ECL™; GE Healthcare, UK) for haptoglobin detection, at 15V for 30mins 
(Trans-Blot® SD Semi-Dry Transfer Cell, Biorad UK). The membranes were 
subsequently blocked for 1hr in blocking buffer (Tris buffered saline [TBS], 0.2% (v/v) 
Tween®20, 5% (w/v) skimmed milk powder) with agitation. The membranes were 
probed with the primary antibody (OPG: Monoclonal Human Osteoprotegerin/ 
TNFRSF11B Antibody, 0.1µg/ml; R&D Systems and Haptoglobin: Polyclonal Rabbit 
Anti-Human Haptoglobin, 1.2µg/ml; Dako, UK) diluted in blocking buffer for 1hr at 
room temperature (OPG) or overnight at 4°C (haptoglobin). The membranes were 
washed in the blocking buffer before incubation with secondary antibody (OPG: HRP 
Conjugated Polyclonal Rabbit Anti-Goat Antibody, 25µg/ml; Dako, UK, Haptoglobin: 
HRP Conjugated Polyclonal Swine Anti-Rabbit, 0.1µg/ml: Dako, UK) in blocking 
buffer for 1hr at room temperature. The membranes were washed in TBS before 
development using ECL™ Prime and exposure to Hyperfilm (GE Healthcare). 
3.2.3 Examining the Level of Antimicrobial Activity of OPG, Haptoglobin 
and PGE2  
RhOPG (0-100ng/ml; R&D Systems, UK), haptoglobin from pooled human plasma 
(0-1µg/ml; Sigma Aldrich, UK) or 0-100ng/ml PGE2 (Cambridge Bioscience, UK) 
were incubated with 150CFU/ml of Gram positive (E. faecalis or S. pyogenes) or 
Gram negative (P. aeruginosa or P. mirabilis) bacteria for 7-14hrs (established 
midlog for each bacteria). Bacterial cultures were serially diluted and spiral plated 
(Don Whitley Scientific Limited, UK) onto TSA or CLED (P. mirabilis) agar and 
incubated at 37°C overnight. The number of colonies grown on the agar plates was 
counted and bacterial CFU/ml was calculated from the manufacturer’s counting table 
(WASP 2 User Manual Section 15.1, Don Whitely Scientific Limited, UK). 
It was also investigated whether OPG in combination with haptoglobin or PGE2 had 
an additive or synergistic effect against bacterial growth. OPG (10ng/ml) and 
haptoglobin (1ng/ml) or PGE2 (10ng/ml) were incubated with the above Gram 
positive and Gram negative bacteria for 7-14hrs. Cultures were serially diluted before 
spiral plating onto appropriate agar, and the colonies counted.   
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Furthermore, the antibacterial potential of OPG against oral specific bacterial strains 
was examined. S. salivarius and S. oralis were isolated from the oral mucosa of 
patients with oral squamous cell carcinoma at the Dental Hospital of University 
Hospital Wales after local research ethical approval and in accordance with the 
Declaration of Helsinki. OPG (0-100ng/ml) was cultured with 100CFU of either S. 
salivarius or S. oralis for 16hrs at 37ºC/5%CO2. Bacterial cultures were serially 
diluted and spiral plates onto TSA. The number of colonies grown on the agar was 
counted, and CFU/ml determined as above.  
3.2.3.1 Viability of Bacterial Cultures after Incubation with OPG, 
Haptoglobin or PGE2  
Bacteria from section 3.2.3 were stained using the LIVE/DEAD® BacLight™ Bacterial 
Viability Kit (Life Technologies) as per the manufacturer’s instructions after incubation 
with rhOPG, haptoglobin or PGE2. Briefly, bacterial cultures were pelleted by 
centrifugation at 14,000xg for 1min and re-suspended in 0.85% (w/v) NaCl or 70% 
isopropanol (negative control) and incubated for 1hour at room temperature. 
Bacterial cultures were again centrifuged at 14,000xg for 1min and re-suspended in 
1ml 0.85% (w/v) NaCl before incubating with 3µl of dye (1:1, SYTO® 9 nucleic acid 
stain, propidium iodide) for 15mins in the dark. Cultures were centrifuged at 14,000xg 
for 1min and re-suspended in 50µl 0.85% (w/v) NaCl before 5µl of each sample was 
transferred onto a Poly-L-lysine glass slide (Fisher Scientific, UK) and mounted under 
a coverslip using the provided mountant. 
 The bacteria were visualized by fluorescence microscopy (Olympus, UK) at x100 
magnification under oil emersion. Live (green) and dead (red) bacterial cells were 
subsequently counted using Image Pro-Plus software v6.0 (Media Cybernectics, 
USA). Individual bacteria in a minimum of 4 fields of view were counted per condition.  
3.2.3.2 Blocking OPG and Haptoglobin in Conditioned Media of OMLP-
PCs  
CM samples (90µl) from section 2.2.7 were incubated with 100CFU of Gram positive 
(E. faecalis and S. pyogenes) +/- 0.6µg/ml of human OPG neutralizing antibody 
(concentration sufficient enough to block ten times of the amount of OMLP-PC 
secreted OPG, calculated from EC50 value; R&D Systems) or with Gram negative 
(P. aeruginosa and P. mirabilis) bacteria +/- 24µg/ml of polyclonal rabbit anti-human 
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haptoglobin antibody (Sharpe-Timms et al., 2002); Dako, UK) in a 96 well plate for 
16hrs at 37°C/5% CO2. After 16hrs, bacterial cultures were serially diluted and spiral 
plated onto appropriate agar and incubated at 37°C overnight and the number of 
colonies grown on the agar plates were counted (as section 3.2.3). 
3.2.3.3 OPG Binding to Gram Positive Bacterial Cell Wall Components  
Surface plasmon resonance (SPR) was conducted using Biacore™ T200 (GE 
Healthcare, UK).  The surface of the gold plated chip (GE Healthcare, UK) was 
activated using 75mg/ml 1-ethyl-3-(3dimethylaminopropyl) carbodiimide (EDC: GE 
Healthcare, UK) and 11.5mg/ml  N-hydroxysuccinimide (NHS: GE Healthcare, UK) 
before 50µg/ml human OPG Antibody (R&D Systems, UK) in 20mM Sodium acetate 
at pH 4.5  was injected over the chip. The chip was then deactivated using 1M 
ethanolamine hydrochloride at pH 8.5. To immobilise rhOPG, 50µg/ml in PBS was 
injected over the antibody-bound chip. A second injection of the rhOPG was 
performed to ensure maximal binding was achieved. PGN (Sigma Aldrich, UK) and 
lipoteiochic acid (LTA; Sigma Aldrich, UK) were injected (0µg/ml – 50µg/ml in PBS) 
over different cells of the chip containing the immobilised rhOPG as well as chips 
containing no rhOPG or antibody (as a negative control) at a flow rate of 30µl/min. 
PGN or LTA were allowed to bind to the rhOPG for 40s with a further 3mins for the 
dissociation period.  Data was analysed using the BiacoreTM T200 Software v2.0 (GE 
Healthcare, UK). 
3.2.4 Statistical Analysis  
All statistical analysis was performed using SPSS statistics (IBM®, Version 20). 
Variance analysis was performed using Levene’s test, with significant variability 
assumed where P<0.05. Statistical analysis for comparing means was performed 
using a one-way analysis of variance (ANOVA) test with a post hoc Tukey test 
(where equal variance) or a Games-Howell test (where variances were unequal). 
Statistical significance was assumed where P<0.05.    
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3.3 Results 
3.3.1 OMLP-PCs Do Not Express LL37 
RNA was extracted from OMLP-PCs (n=4; +/- IFNγ) and EFs (n=3), which had been 
cultured with live bacteria and cDNA was synthesised. The molecular levels of LL37 
were subsequently determined using qPCR.  It was found that LL37 was not 
expressed in OMLP-PCs irrespective of IFNγ priming and/or bacterial exposure or 
within EFs (+/- bacterial exposure; Note that the cycle time [CT] values were > 37; 
Fig. 3.2 A-D). Unstimulated BM-MSC cDNA was also analysed as a positive control 
to ensure primers were functioning (Fig. 3.2 A-D). 
3.3.2 IDO is Induced by IFNγ, but not Modulated by the Presence of 
Bacteria in OMLP-PCs 
CM samples and extracted RNA was obtained from OMLP-PCs (n=4; +/- IFNγ) and 
EFs (n=3), which had been cultured with live bacteria. The molecular levels of IDO 
were determined using qPCR and IDO activity was assessed in the CM by 
measuring the metabolite L-kynurenine. Both the molecular expression (Fig. 3.3 A-D) 
and the activity (Fig. 3.4 A-D) of IDO were induced by IFNγ (P<0.05). IDO levels 
were undetectable in OMLP-PC samples at resting state or after exposure to bacteria 
in the absence of IFNy. Co-culturing IFNγ primed OMLP-PCs with live bacteria had 
no further effect on the IDO levels compared to IFNγ priming alone. IDO was not 
expressed in EF samples, irrespective of bacterial exposure (Fig. 3.3 A-D), however 
IFNγ stimulation of EFs did induce IDO expression and activity (P<0.05; Fig. 3.5 A-
B). Furthermore, the induced expression of IDO by IFNγ in EFs was significantly less 
compared to the induction of IDO by IFNγ in OMLP-PCs. 
3.3.3 PGE2 as an Antibacterial Mediator 
3.3.3.1 OMLP-PCs Express COX2 and Secrete PGE2  
CM samples and extracted RNA was obtained from OMLP-PCs (n=4) (+/- IFNγ) and 
EFs (n=3) generated in section 2.2.7, which had been cultured with live bacteria. 
cDNA was synthesised from the extracted RNA and the molecular levels of COX2 
were subsequently determined using qPCR. The secreted levels of PGE2 within the 
CM were determined using ELISA. COX2 was constitutively expressed in OMLP-PCs  
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Fig. 3.2: LL37 expression in OMLP-PCs (n=4) and EFs (n=3). Expression of LL37 in OMLP-PCs +/-IFNγ 
priming and/or exposure to (A) E. faecalis, (B) S. pyogenes, (C) P. aeruginosa or (D) P. mirabilis. LL37 
expression in BM-MSCs (n=3) as a positive control.  Data is expressed as average fold change to BM-
MSC, +/- SD of the mean.  
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Fig. 3.3: IDO expression in OMLP-PCs (n=4) and EFs (n=3). IDO expression in OMLP-PCs +/-IFNγ 
priming and/or exposure to (A) E. faecalis, (B) S. pyogenes, (C) P. aeruginosa or (D) P. mirabilis. Data 
is expressed as average fold change to OMLP-PCs, +/- SD of the mean. Statistics compared to OMLP-
PC. *P<0.05. 
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0                                                                                
  
Fig. 3.4: IDO activity in OMLP-PCs (n=3). IDO activity was assessed by measuring the metabolite L-
kynurenine in OMLP-PCs +/- IFNγ priming and/or exposure to (A) E. faecalis, (B) S. pyogenes, (C) P. 
aeruginosa or (D) P. mirabilis, +/- SD of the mean. Statistics compared to OMLP-PC (A-D) *P<0.05. 
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Fig. 3.5: IDO expression and activity in EFs +/- IFNγ. (A) The expression of IDO in EFs +/- IFNγ. OMLP-
PCs + IFNγ as a positive control. Data expressed as average fold change compared to EFs. (B) The 
activity of IDO measured by the IDO metabolite L-kynurenine in EF +/- IFNγ. All data +/- SD of the 
mean. **P<0.05, **P<0.01.  
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irrespective of IFNγ and/or Gram positive bacterial exposure (Fig. 3.6 A, B). 
However, exposure to Gram negative bacteria in combination with IFNγ priming, 
significantly increased the expression of COX2 within OMLP-PCs (P<0.05; Fig. 3.6 
C, D). COX2 expression was detected in EFs, at similar levels to the constitutive 
OMLP-PC expression (Fig. 3.6 A-D). Similarly to the expression profile of COX2, 
secreted levels of PGE2 were constitutively detected at an average of 1.57pg/ml, and 
significantly increased to an average of 7.7pg/ml (P<0.05) by a combination of IFNγ 
priming and Gram negative bacterial exposure to OMLP-PCs (Fig. 3.7 C, D). The 
constitutive secretion of PGE2 from EFs at an average of 0.15ng/ml was significantly 
less (P<0.05; Fig. 3.7 A-D) compared to that from the OMLP-PCs at 1.5ng/ml. 
3.3.3.2 PGE2 is Antibacterial Through a Bacteriostatic Mechanism 
PGE2 (0-100ng/ml, n=3) was incubated 150CFU/ml live bacteria, to assess the effect 
of PGE2 on bacterial growth. PGE2 significantly reduced the growth of both Gram 
positive bacteria, E. faecalis and S. pyogenes (P<0.05; Fig. 3.8 A, B) at 1ng/ml and 
the growth of the Gram negative P. mirabilis at 10ng/ml (P<0.05; Fig. 3.8 D). There 
was no effect on the growth of the Gram negative bacterium P. aeruginosa after 
incubation with PGE2 (P>0.05; Fig. 3.8 C). 
Cultures of E. faecalis, S. pyogenes or P. mirabilis incubated with 10ng/ml PGE2 
(antibacterial levels for all susceptible bacterium) from above were stained using the 
Live/Dead® BacLight™ Bacterial Viability Kit. Bacteria were counted and percentage 
viability calculated. PGE2 did not affect the bacterial viability (live:dead ratio) 
compared to bacteria only cultures (P>0.05; Fig. 3.9 A-C), confirming that PGE2 
suppresses bacterial growth through a bacteriostatic mechanism rather than a 
bactericidal mechanism.  
3.3.4 Haptoglobin as an antibacterial mediator  
3.3.4.1 Haptoglobin is Secreted by OMLP-PCs 
The levels of Haptoglobin within CM samples from section 2.2.7 were initially 
examined using ELISA. However, the levels fell below the first lower detection limit of 
the standard curve (3.13ng/ml) and were therefore not reliable (data not shown). 
Haptoglobin was therefore detected using Western blot analysis. The secretion of 
haptoglobin from OMLP-PCs and EFs was detected, and the presence of all β, α1 
and α2 chains were noted (Fig. 3.10). 
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Fig. 3.6: COX2 expression in OMLP-PCs (n=4) and EFs (n=3). The expression of COX2 in OMLP-PCs 
(+/- IFNγ) and EFs +/- exposure to (A) E. faecalis, (B) S. pyogenes, (C) P. aeruginosa and (D) P. 
mirabilis. Data expressed as the average fold change compared to OMLP-PCs, +/- SD of the mean. 
Statistics compared to OMLP-PC.  *P<0.05, **P<0.01 
 
0
1
2
3
4
5
6
7
C
O
X
2
 e
x
p
re
s
s
io
n
 /
 a
v
e
ra
g
e
 f
o
ld
 
c
h
a
n
g
e
 
0
1
2
3
4
5
6
7
C
O
X
2
 e
x
p
re
s
s
io
n
 /
 a
v
e
ra
g
e
 f
o
ld
 
c
h
a
n
g
e
 
0
5
10
15
20
25
30
35
40
C
O
X
2
 e
x
p
re
s
s
io
n
 /
 a
v
e
ra
g
e
 f
o
ld
 
c
h
a
n
g
e
 
0
5
10
15
20
25
30
35
40
C
O
X
2
 e
x
p
re
s
s
io
n
 /
 a
v
e
ra
g
e
 f
o
ld
 
c
h
a
n
g
e
 
** 
* 
A 
C D 
Chapter 3 Elucidating the Soluble Mechanisms Mediating the Antibacterial Effects of 
OMLP-PCs 
 
138 
 
 
 
 
 
 
Fig. 3.7: PGE2 secretion from OMLP-PCs (n=4) and EFs (n=3). The secretion of PGE2 from OMLP-
PCs (+/- IFNγ) and EFs +/- (A) E. faecalis, (B) S. pyogenes, (C) P. aeruginosa and (D) P. mirabilis, +/- 
SD of the mean. Statistics compared to OMLP-PCs.  *P<0.05 
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Fig. 3.8: The effect of PGE2 on bacterial growth (n=3). The growth of (A) E. faecalis, (B) S. pyogenes, 
(C) P. aeruginosa and (D) P. mirabilis after culturing with PGE2. Data expressed as percentage 
bacterial growth, +/- SD of the mean. Statistics compared to 0ng/ml. *P<0.05, **P<0.01, ***P<0.001 
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Fig. 3.9: The effect of PGE2 on bacterial viability (n=3). The viability (live [green]: dead [red] ratio) of (A) 
E. faecalis, (B) S. pyogenes, (C) P. mirabilis after culture with PGE2. Data expressed as percentage live 
or dead cells, +/- SD of the mean. 
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Fig. 3.10: Haptoglobin secretion by EFs (n=3) and OMLP-PCs (n=4). Western blot image demonstrating 
the presence of the β, α1 and α2 chains from both EFs and OMLP-PCs. Note that the both images are 
of the same membrane at different exposures. A positive control of Haptoglobin is represented in the 
CTRL lane.  
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3.3.4.2 Haptoglobin is Antibacterial Against Gram Negative Bacteria 
Through a Bacteriostatic Mechanism  
Haptoglobin (0-1µg/ml, n=3: Dako, UK) was incubated with 150CFU/ml live bacteria 
to assess its effects on bacterial growth. Haptoglobin had no effect on the growth of 
the Gram positive bacteria E. faecalis and S. pyogenes (P>0.05; Fig. 3.11 A, B). 
However, the growth of the Gram negative bacteria P. aeruginosa and P. mirabilis 
was significantly inhibited at 50pg/ml (P<0.001; Fig. 3.11 C, D).  
Gram negative bacterial cultures incubated with antibacterial levels of haptoglobin 
were stained using the Live/Dead® BacLight™ Bacterial Viability Kit. Haptoglobin 
had no significant effect on the bacterial viability (live:dead ratio) of the bacteria 
compared to bacteria only cultures (P>0.05; Fig. 3.12 A, B), demonstrating it’s 
bacteriostatic mechanism of action.   
3.3.4.3 Blocking Haptoglobin Restores the Growth of Bacteria 
CM samples from section 2.2.7 were incubated with 100CFU Gram negative bacteria 
(P. aeruginosa and P. mirabilis) +/- a haptoglobin blocking antibody. By blocking the 
secreted haptoglobin, the growth of both P. aeruginosa and P. mirabilis was fully 
restored, irrespective of whether the OMLP-PCs had previously been exposed to the 
bacteria or not (P<0.01; Fig. 3.13 A, B).  
3.3.5 OPG as an Antibacterial Mediator 
3.3.5.1 OPG is Constitutively Expressed by OMLP-PCs 
Transcriptional and secreted levels of OPG were assessed within samples generated 
in section 2.2.7. OPG gene expression was analysed using qPCR whilst secreted 
protein levels were assessed using ELISA.  OPG was constitutively expressed (Fig. 
3.14 A-D) and secreted (Fig. 3.15 A-D) by OMLP-PCs, irrespective of IFNγ priming 
and/or bacterial exposure (P>0.05). The expression and secretion of OPG was also 
noted in the EFs at similar levels to the OMLP-PCs (Fig. 3.14 A-D and Fig. 3.15 A-D), 
with mRNA expression further increased by Gram negative bacterial exposure to EFs 
(P<0.05; Fig. 3.14 C, D).  
 
Chapter 3 Elucidating the Soluble Mechanisms Mediating the Antibacterial Effects of 
OMLP-PCs 
 
143 
 
 
 
 
Fig. 3.11: The effect of haptoglobin (n=3) on bacterial growth. The growth of (A) E. faecalis, (B) S. 
pyogenes, (C) P. aeruginosa and (D) P. mirabilis after culture with haptoglobin. Data expressed as 
percentage bacterial growth, +/-SD. Statistics compared to 0pg/ml. *P<0.05, **P<0.01, **P<0.001. 
Statistics compared to 0pg/ml.  
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Fig. 3.12: The effect of haptoglobin on bacterial viability. The viability (live [green]: dead [red] ratio) of 
(A) P. aeruginosa and (B) P. mirabilis after culture with haptoglobin. Data expressed as percentage of 
live or dead cells, +/- SD of the mean. 
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Fig. 3.13: The effect of blocking haptoglobin in the CM of OMLP-PCs (n=4). The growth of (A) P. 
aeruginosa and (B) P. mirabilis after incubation with OMLP-PC derived CM +/- a haptoglobin blocking 
antibody and EF derived CM (n=3). Data expressed as percentage bacterial growth, +/- SD of the mean. 
Statistics compared to bacteria only controls (represented by the red dotted line), unless otherwise 
stated.  **P<0.01, ***P<0.001. 
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Fig. 3.14: OPG expression in OMLP-PCs (n=4) and EFs (n=3). The expression of OPG in OMLP-PCs 
(+/- IFNγ) and EFs +/- exposure to (A) E. faecalis, (B) S. pyogenes, (C) P. aeruginosa and (D) P. 
mirabilis. Data expressed as the average fold change compared to OMLP-PCs, +/- SD of the mean. 
Statistics compared to OMLP-PC, unless otherwise stated. *P<0.05, **P<0.01, ***P<0.001. 
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Fig. 3.15: OPG secretion from OMLP-PCs (n=4) and EFs (n=3). The secretion of OPG from OMLP-PCs 
(+/- IFNγ) and EFs +/- exposure to (A) E. faecalis, (B) S. pyogenes, (C) P. aeruginosa and (D) P. 
mirabilis, +/- SD of the mean.  
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3.3.5.2 OPG is Antibacterial against Gram Positive Bacteria Through a 
Bacteriostatic Mechanism  
OPG (0-100ng/ml, n=3) was cultured with 150CFU/ml live bacteria to assess its 
effect on bacterial growth. The growth of the Gram positive bacteria E. faecalis and 
S. pyogenes was significantly inhibited by OPG at 5ng/ml (P<0.001; Fig. 3.16 A, B). 
OPG had no significant effect on the growth of the Gram negative bacteria P. 
aeruginosa and P. mirabilis (P>0.05; Fig. 3.16 C, D).  
Gram positive bacterial cultures incubated with antibacterial levels of OPG from 
above were stained using the Live/Dead® BacLight™ Bacterial Viability Kit. Bacteria 
were counted and percentage viability calculated. The bacterial viability (live:dead 
ratio) was not affected by OPG compared to bacteria only cultures (P>0.05; Fig. 3.17 
A, B), demonstrating a bacteriostatic mechanism by OPG.   
3.3.5.3 Blocking OPG Partially Restores the Growth of Bacteria 
OMLP-PC CM samples from section 2.2.7 were incubated with 100CFU Gram 
positive bacteria (E. faecalis or S. pyogenes) +/- an OPG neutralising antibody. By 
blocking OPG within the CM, the growth of both E. faecalis (P<0.05; Fig. 3.18 A) and 
S. pyogenes (P<0.001; Fig. 3.18 B) was partially restored, irrespective of whether the 
OMLP-PCs had previously been exposed to the bacteria. 
3.3.5.4 OPG Does Not Act in an Additive or Synergistic Effect with 
Haptoglobin or PGE2  
It was investigated whether OPG acted in an additive or synergistic effect with 
haptoglobin or PGE2. Antibacterial levels of OPG were cultured with Gram positive 
and Gram negative bacteria +/- antibacterial levels of either haptoglobin or PGE2. As 
shown in Fig. 3.16, OPG significantly reduces the growth of Gram positive bacteria. 
The combined culture of OPG and haptoglobin or PGE2 had no further effect on the 
bacterial growth of either Gram positive or Gram negative bacteria compared to 
OPG, haptoglobin or PGE2 in culture alone (P>0.05; Fig. 3.19 A-D and Fig. 3.20 A-
D).  
3.3.5.5 OPG is Antibacterial against Oral Specific Strains  
To my knowledge this is the first study to demonstrate that OPG has antibacterial 
properties. To further extrapolate the potential effect to the oral cavity, OPG was  
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Fig. 3.16: The effect of OPG on bacterial growth (n=3). The growth of (A) E. faecalis, (B) S. pyogenes, 
(C) P. aeruginosa and (D) P. mirabilis after culture with OPG. Data expressed as percentage bacterial 
growth, +/-SD. Statistics compared to 0ng/ml. ***P<0.001. 
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Fig. 3.17: The effect of OPG on bacterial viability. The viability (live [green]: dead [red] ratio) of (A) E. 
faecalis and (B) S. pyogenes after culture with OPG. Data expressed as percentage of live or dead 
cells, +/- SD of the mean. 
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Fig. 3.18: The effect of blocking OPG in the CM of OMLP-PCs (n=4). The growth of (A) E. faecalis and 
(B) S. pyogenes after incubation with OMLP-PC derived CM +/- an OPG neutralising antibody and EF 
derived CM (n=3). Data expressed as percentage bacterial growth, +/- SD of the mean. Statistics 
compared to bacteria only controls (represented by the red dotted line), unless otherwise stated.  
**P<0.01, ***P<0.001. 
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Fig. 3.19: The effect of OPG and haptoglobin combined culture (n=3) on bacterial growth. OPG and 
haptoglobin cultured with (A) E. faecalis, (B) S. pyogenes, (C) P. aeruginosa and (D) P. mirabilis. Data 
expressed as percentage bacterial growth. +/- SD of the mean. ***P<0.001. 
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Fig. 3.20: The effect of OPG and PGE2 combined culture (n=3) on bacterial growth. OPG and PGE2 
cultured with (A) E. faecalis, (B) S. pyogenes, (C) P. aeruginosa and (D) P. mirabilis. Data expressed as 
percentage bacterial growth. +/- SD of the mean. *P<0.05, **P<0.01.  
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cultured with the Streptococcus species, S. salivarius and S. oralis, isolated from the 
oral mucosa of patients with oral squamous cell carcinoma. OMLP-PC CM 
demonstrated enhanced antibacterial effects against S. pyogenes (section 2.3.6), 
potentially due to in vivo priming. It was for this reason that orally isolated 
Streptococcus species were chosen to assess the antibacterial effects of OPG on 
oral specific bacteria. OPG significantly reduced the growth of both S. salivarius and 
S. oralis at 5ng/ml, comparable to the non-orally derived Gram positive bacteria 
(P<0.001 and P<0.05 respectively; Fig. 3.21A, B). 
3.3.5.6 Differences in the Secreted OGP from OMLP-PCs and EFs 
To assess why secreted OPG had an antibacterial phenotype when secreted by 
OMLP-PCs but not from EFs, levels of potential protein inhibitors from EFs were 
examined in addition to potential structural differences within the OPG proteins.  
3.3.5.6.1 OPG is Not Inhibited by Cellular Expression of TRAIL or RANKL 
by EFs 
The expression of TRAIL and RANKL were examined within cDNA samples 
generated from section 2.2.7 using qPCR. Secreted levels of TRAIL were also 
assessed in CM samples by ELISA. The mRNA expression of RANKL was not 
detected in either OMLP-PCs or EFs (data not shown). The expression and secretion 
of TRAIL was comparable between OMLP-PCs and EFs (P> 0.05; Fig. 3.22 A, B).  
3.3.5.6.2 OPG Secreted by OMLP-PCs and EFs Displays the Same 
Molecular Weight 
The secreted OPG within CM samples from section 2.2.7 was identified using 
Western blot analysis. Samples were examined under non-reducing, reducing and 
native conditions to assess any potential differences in the secreted OPG structure 
from OMLP-PCs and EFs, which would affect the migration during electrophoresis, in 
addition to performing 2D gel electrophoresis. OPG from OMLP-PCs and EFs 
demonstrated the same molecular weight when exposed to each of the above 
conditions, with dimers (non-reducing and native; Fig. 2.23 A, C) and monomers 
(reducing; Fig. 2.23 B) identified at the same molecular weight for OMLP-PCs and 
EFs. However, the charge of the OPG appears to shift to a more negative charge in 
the EFs compared with OPG secreted from OMLP-PCs as shown by the Western 
blot analysis of the 2D electrophoresis gels (Fig. 2.24 G).  
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Fig. 3.21: The effect of OPG on oral specific bacterial strains. OPG (n=3) cultured with Streptococcus 
salivaris (A) and Streptococcus oralis (B). Data expressed as percentage bacterial growth, +/-SD. 
Statistics compared to 0ng/ml. *P<0.05, **P<0.01, ***P<0.001. 
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Fig. 3.22: TRAIL expression in OMLP-PCs (n=4) and EFs (m=3). The mRNA expression (A) and 
secretion (B) of TRAIL in OMLP-PCs and EFs. mRNA expression data represented as the average fold 
change compared to OMLP-PCs. +/- SD of the mean. Note: ELISA sensitivity 0-1500pg/ml.  
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Fig. 3.23: Western blot detection of OPG in EFs (n=3) and OMLP-PCs (n=4). OPG detection in CM of 
OMLP-PCs and EFs subjected to (A) non-reducing, (B) reducing and (C) native conditions. A positive 
control of rhOPG is demonstrated in the CTRL lane.  
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3.3.5.7 OPG Binds Lipoteichoic Acid on the Surface of Gram Positive 
Bacteria  
To further examine the antibacterial mechanism of OPG, SPR was performed to 
investigate potential binding sites of OPG on the surface of Gram positive bacteria.  
Successful antibody binding to the gold plated chip and subsequent immobilisation of 
OPG was demonstrated (Fig. 3.25 A, B). Following OPG immobilisation, PGN or LTA 
was injected over the surface with binding to OPG measured. It was found that PGN 
did not bind to OPG (Fig. 3.26 A), whereas LTA bound to OPG in a concentration 
dependant manner (Fig. 3.26 B). Note that the molecular weight value for LTA was 
unavailable hence analysis of the binding kinetics could not be performed.   
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Fig. 3.25: OPG immobilisation for SPR. Successful antibody immobilisation (A) and 
OPG binding to the antibody (B) for SPR. 
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Fig. 3.26: OPG binding to Gram positive bacterial cell wall components. PGN (A) or LTA (B) binding to 
OPG.  
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3.4  Discussion 
It was demonstrated in chapter 2 that OMLP-PCs possess antibacterial properties 
and that this was mediated through the release of soluble factors. Within this chapter 
the role of several different soluble factors, secreted by OMLP-PCs, was confirmed 
with the potential to explain their antibacterial mechanism of action.  Additionally, it 
has been demonstrated that IDO and LL37, factors implicated in the BM-MSC 
mechanism (Krampera et al., 2006, Krasnodembskaya et al., 2010), are not involved 
in the OMLP-PC effects. This demonstrates that OMLP-PCs act by different 
mechanisms to those already identified for the BM-MSCs.  
3.4.1 PGE2  
The studies in this chapter demonstrate that in addition to the immunomodulatory 
properties, PGE2 is capable of directly affecting bacterial growth. At low levels, PGE2 
can decrease the growth of both Gram positive and Gram negative bacteria, through 
a bacteriostatic mechanism. However, PGE2 was unable to affect the growth of one 
of the Gram negative bacteria investigated, P aeruginosa. This could be due to the 
complex cell wall structure of P aeruginosa, its potential mucoid phenotype and 
ability to create biofilms (Rybtke et al., 2015), which may limit the ability of the PGE2 
lipid to penetrate the P. aeruginosa cell wall. The levels of PGE2 secreted from EFs 
are too low to demonstrate antibacterial effects. However, the secreted PGE2 from 
OMLP-PCs does not fully explain the antibacterial properties reported for OMLP-
PCs. Blocking the secreted PGE2 could further delinate the involvement of PGE2. 
Blocking studies during this study were not possible. The availability of the one direct 
PGE2 blocking antibody (Cayman Chemical, USA) is limited. It is possible to block 
the COX2 enzyme, however this would not block PGE2 production specifically. 
Blocking COX2 would have further effects on COX2 mediated processes such as the 
production of other prostaglandins. It would therefore not be possible to definitively 
interpret any data as a direct result of blocking PGE2, but the effects may be related 
to other COX2 mediated factors.  As not all of the antibacterial properties of OMLP-
PCs could be explained by PGE2, further factors were investigated.  
3.4.2 Haptoglobin 
This chapter demonstrated the secretion of haptoglobin from OMLP-PCs, and the 
presence of the higher activity α1 chain (Sadrzadeh and Bozorgmehr, 2004). 
Haptoglobin’s involvement in the antibacterial effects of OMLP-PCs was confirmed 
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when the secreted protein was blocked, preventing the direct antibacterial properties 
of OMLP-PCs on the Gram negative bacteria. However, the secretion of haptoglobin, 
along with the presence of the α1 chain was also detected in the non-antimicrobial 
EFs. The potent antibacterial activity of haptoglobin was recorded at 50pg/ml. The 
marginal differences in secreted levels of haptoglobin, which may account for the 
lack of antibacterial properties in EFs, are extremely difficult to quantify at such low 
levels. Commercial ELISA kits were unable to detect the secreted protein from either 
OMLP-PCs or EFs, with a sensitivity in the ng/ml range. Therefore it was not possible 
to undertake a direct comparison of the secreted levels of haptoglobin from OMLP-
PCs and EFs. It is hypothesised that the ratios of different isoforms of haptoglobin 
vary between OMLP-PCs and EFs, with a greater abdundance of the higher activity 
isoforms containing the α1 chain secreted by OMLP-PCs. This could be investigated 
using pull down assays with an antibody specific to the α1 chain to isolate the higher 
activity isoforms. 
Haptoglobin was shown to be antibacterial against Gram negative bacteria, with no 
effects on Gram positive bacteria, even at high levels. The bacteriostatic effects of 
haptglobin against E. coli, a Gram negative bacteria, through the depletion of iron 
have long been documented (Eaton et al., 1982). Whilst both Gram positive and 
Gram negative bacteria are dependant on iron, the levels and uptake mechanisms 
can vary dramatically between organisms. S. pyogenes is able to bind and transport 
ferric iron (Fe3+), a stable form of iron, through an ATP-binding cassette transporter. 
However, both the P. aeruginosa and P. mirabilis are able to sequester iron from iron 
complexes, particularly when iron availability is restricted. FpvA (Shen et al., 2005) 
and FpvB (Ghysels et al., 2004) are the outer membrane transporters involved in iron 
uptake in P. aeruginosa which are capable of sequestering iron from ferripyoverdine 
binding (Cornelis and Dingemans, 2013). P. mirabilis iron uptake is mediated by a 
64kDa iron-regulated outer membrane protein which is capable of sequestering iron 
from haem (Lima et al., 2007). As Gram positive bacteria lack the outer membrane, 
the outer membrane proteins involved in iron uptake during iron restriction are not 
present. The differences in iron uptake mechanisms could potentially explain the 
selective antibacterial properties of haptoglobin.  
3.4.3 OPG 
To my knowledge this is the first study to demonstrate that OPG possesses 
antibacterial properties, with decreased levels during inflammatory conditions 
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associated with infection such as periodontitis (Bostanci et al., 2007), potentially 
contributing to the disease. OPG decreased the growth of Gram positive bacteria in 
direct culture, with no effects observed on the growth of Gram negative bacteria. 
OPG was demonstrated to act in a bacteriostatic manner and was found to bind LTA 
on the surface of the Gram positive bacteria. This explains the lack of antibacterial 
effects against Gram negative bacteria, which do not express LTA on the surface of 
their cell wall, preventing binding of OPG to these bacteria. It was further shown that 
the antibacterial properties of OPG were not confined to the reference strains initially 
examined. OPG significantly reduced the growth of Gram positive, Streptococcus 
salivaris and Streptococcus oralis isolated from the oral mucosa of patients with oral 
squamous cell carcinoma, at the same level (5ng/ml) of the reference strains. These 
facultative anaerobes represent bacteria, which may lay near the surface of biofilms, 
due to the accessibility to oxygen. It is also known that OPG is detected within the 
oral fluids such as saliva (Buduneli et al., 2008) and grevicular fluid (Balli et al. 2015). 
With this knowledge and data from this study it is evident that OPG could affect 
bacteria on the surface of biofilms, highlighting the potential importance of OPG in 
maintaining the microflora of the oral cavity.  
The involvement of OPG in the antibacterial mechanism of OMLP-PCs was 
confirmed when the secreted OPG was neutralised, inhibiting some of the 
antibacterial effects of OMLP-PCs. However, the expression and secretion of OPG 
was also noted in EFs at comparable levels. It was hypothesised that the secreted 
OPG from EFs was either bound to an inhibitor, or that the structure/conformation of 
the secreted OPG was different, blocking the LTA binding site, compared to the 
OMLP-PCs. RANKL and TRAIL are known to bind OPG (Baud'huin et al., 2013), 
which could potentially block the LTA binding site. However the expression levels 
within OMLP-PCs and EFs did not vary, indicating that the release of these factors 
and subsequent binding to OPG, most likely, did not account for the lack in 
antibacterial activities by OPG secreted from EFs. Western blot analysis was 
performed to continue to investigate this hypothesis. It was found that under non-
reducing conditions, OPG secreted from EFs was not bound to a protein inhibitor 
(that was large enough to detect by Western blot analysis). It would not be possible 
to detect the molecular weight change in OPG if it was bound to a small protein or 
peptide. Further studies would be needed to fully rule out the possibility of a bound 
inhibitor to OPG secreted from EFs. For example, label transfer could be used to 
isolate proteins bound to OPG. The process would involve pre-labelled OPG which 
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would transfer its label (e.g. biotin) to an interacting protein. OPG could then be 
cleaved from the interaction and the OPG interacting protein isolated using the label. 
Isolated proteins could then be analysed using electrophoresis, protein sequence 
analysis or mass spectrometry.  
Under reducing and non-reducing conditions (including native), it was oberserved 
that the monomers and dimers (respectively) which make up OPG were the same 
between the OPG secreted by OMLP-PCs and EFs, confirming that no structural 
differences affecting molecular weight were present. The secreted OPG was also 
separated by charge in addition to size, using 2D gel electrophoresis. It was found 
that there were differences in the charge of the secreted OPG, with the protein 
secreted from EFs displaying a more negative charge compared with that secreted 
from OMLP-PCs. This may be explained by differing levels of glycosylation on the 
OPG secreted from EFs and OMLP-PCs, as the OPG protein contains several N-
glycosylation sites (Lerner, 2004). Glycosylation can affect both the molecular weight 
and isoelectric point of a protein, manifesting in differences during 2D gel 
electrophoresis. Further studies are required to determine any additional differences 
in the secreted OPG from the two different cell sources. Immunoprecipitation may be 
used to purify OPG from both the OMLP-PCs and EFs. The purified OPG could then 
be incubated with live bacteria to demonstrate the differences in antibacterial activity. 
Furthermore the isolated protein could be sequenced to identify differences in protein 
sequence and potential splice variants. Additionally crystallography could be 
undertaken to assess any differences in the crystal structure of OPG secreted from 
OMLP-PCs and EFs. Furthermore, crystallising the structure of OPG bound to LTA 
could identify the LTA binding site, and pinpoint any differences in bacterial binding 
capabilities of the secreted OPG. Crystallography is however a time consuming 
process and dependant on the sufficient levels of purified OPG. Purifying appropriate 
levels of OPG using immunoprecipitation may also prove a time consuming process 
with just 10ng/ml being secreted by both OMLP-PCs and EFs. It is also possible that 
by binding to an antibody during the immunoprecipitation process, OPG could 
change its structure. Whilst it is possible the structure could revert back to its original 
secreted structure when eluted, it is not guaranteed.   
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CM samples were stored at -80°C before thawing for analysis. It is important to 
consider the effect of freeze thawing on the samples and any possible degradation of 
potential antibacterial proteins or peptides sensitive to this process. Therefore further 
mechanisms must be considered and the presence of such proteins or peptides 
compared to freshly generated samples which have not undergone freeze thawing.  
3.5 Conclusion  
The aim of this chapter was to identify the soluble factors mediating the antibacterial 
effects of OMLP-PCs. It was demonstrated that several different factors were 
involved.  The factors identified in mediating the BM-MSC antibacterial effects, IDO 
and LL37, were not implicated in the OMLP-PC mechanism. This highlights the 
difference in the antibacterial mechanisms by the different cell populations, which 
could be attributed to the differences in the environment from which the cells were 
isolated.  
The direct antibacterial effects of PGE2, haptoglobin and for the first time OPG were 
reported in this study, with antibacterial levels secreted from OMLP-PCs. The lack of 
antibacterial effects of EFs, despite secreting active levels of OPG, is not fully 
understood. Differences in the charge of OPG secreted from EFs compared to 
OMLP-PCs was reported. Further studies are required to delineate the difference in 
OPG secreted by EFs and the antibacterial OMLP-PCs.  Greater understanding in 
the differences may be assessed after isolating the secreted OPG and examining the 
protein sequences and structure.  
Each antibacterial factor demonstrated selective antibacterial properties, with no one 
factor fully explaining the antibacterial properties of OMLP-PCs in vitro. It is likely that 
additional factors are involved in the antibacterial effects of OMLP-PCs. The oral 
cavity constantly displays a rich microbial diversity, and it is therefore essential that a 
diverse range of antibacterial factors is present within the oral cavity. This chapter 
highlights the potential involvement of OMLP-PCs in oral homeostasis by the 
secretion of several different antimicrobial factors.  
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4 Changes in the Antibacterial Potential of OMLP-PCs during 
Chronic GVHD 
  
4.1 Background 
GVHD develops when donor T cells within transplanted material (HSCT) become 
activated and mount an intense inflammatory/immune response within the recipient 
(Ferrara et al., 2009). The development of the disease results from a multi-staged 
process. Initial chemotherapy or radiotherapy before HSCT results in tissue damage 
in the patient and the release of bacterial products such as LPS from the gut 
microflora. Accumulation of such products results in a pro-inflammatory cytokine 
response and the migration of host APCs to secondary lymphoid organs. APCs 
within the lymph nodes become activated and present antigen to the donor T cells, 
leading to their activation and proliferation. This in turn stimulates the production of 
IFNy and IL-2 from the donor T cells. The activated T cells then migrate to the target 
tissues of the host such as the skin, gut, liver and oral cavity (in the case of chronic 
GVHD [cGVHD]) where cell apoptosis is initiated and further cytokine release is 
stimulated to perpetuate the process (Ferrara and Reddy, 2006).  
The disease is most associated with patients who receive HSCT with a mismatch in 
HLA proteins, with overall survival decreased with the increase in mismatched HLA 
proteins (Loiseau et al., 2007).  The disease is grouped into two classifications; acute 
GVHD (aGVHD) and cGVHD. The aGVHD form traditionally manifests itself within 
100 days of the transplantation, whereas cGVHD presents 100 post transplantation, 
potentially lasting the lifetime of the patient (Martin et al., 2015). 
Up to 83% of patients undergoing HSCT who develop cGVHD display oral symptoms 
(Mays et al., 2013). Symptoms include mucosal atrophy, ulceration, erythema, 
microbial infections and pain (Granitto et al., 2014).  Patients with oral cGVHD are 
thought to be more susceptible to infections such as candidiasis, potentially due to 
the steroid based treatment of the disease (Treister et al., 2012).  It has been further 
hypothesised that a dysfunction in the stromal cells of the oral cavity manifests after 
HSCT treatment, resulting in the decreased immunoregulatory capacity of the cells 
(Garming-Legert et al., 2015). A further lack of anti-microbial and anti-inflammatory 
factors resulting from the dysfunctional stromal tissue is predicted, leading to 
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increased infections and poor wound healing of the affected areas. With potential 
increases in microbial infections during HSCT and GVHD, it is important to consider 
the pathological changes, which may occur within the oral mucosa and the 
implications they may have on infections. Changes in the secretion of antimicrobial or 
immunomodulatory factors may contribute to oral GVHD and the increased infections 
observed.  
Chapters 2 and 3 have established the direct antibacterial properties of OMLP-PCs in 
healthy individuals. The increased microbial infections during GVHD may be 
attributed to the loss of antibacterial functions of the OMLP-PCs or a decrease in 
progenitor cell numbers in these patients. It is unknown whether potential changes in 
OMLP-PCs are modulated by GVHD, which therefore predisposes the oral cavity to 
infections. Furthermore, the oral cavity may be more vunerable to infections before 
the development of GVHD by the conditioning regimes prior to HSCT (Kedia et al., 
2013). Conditioning regimes such as chemotherapy and radiotherapy target the 
immune cells within the bone marrow, limiting the innate defence in these patients. 
Immunosuppressive treatment, to prevent HSCT rejection, further limits the innate 
immune system. Overall this limits the patient’s ability to overcome infection.  
Mucosal damage has been documented in the gastrointestinal tract following HSCT. 
Colitis, pneumatosis intestinalis, thickening of the mucosal layer and increased 
infections by micro-organisms such as Clostridium difficile have been reported (Lee 
et al., 2008). Furthermore, conditioning regimes will damage the mucosal linings 
(Ferrara and Reddy, 2006). Similar effects of HSCT and the conditioning regimes on 
the oral mucosa have been documented, with oral mucositis the predominant side-
effect reported. Oral mucositis is characterised by mucosal damage extending from 
mild inflammation to extensive ulcerations caused by epithelial cell apoptosis 
(Haverman et al., 2014). The resulting ulceration leads to a loss in mucosal integrity 
and facilitates microbial colonisation with further pro-inflammatory cytokine release 
initiated. Oral mucositis can cause severe pain and limited movement (limiting the 
patient’s ability to eat), which has a detrimental effect on the patient’s quality of life 
(Bellm et al., 2000). Whether the mucosal damage from HSCT results in the 
dysfunction of OMLP-PCs is unknown.    
The migration of innate immune cells to the site of infection is crucial to limit the 
damage caused during infections. Chemokines such as TNFα, IL-8 and IL-1β are 
secreted by tissue-resident cells such as epithelial cells, providing concentration 
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gradients for the migration of innate cells, such as neutrophils, to affected sites 
(Kolaczkowska and Kubes, 2013). The secretion of the chemoattractant factor, IL-8, 
is reported from BM-MSCs, nasal mucosal MSCs and human salivary gland MSCs 
(Jakob et al., 2010, Jakob et al., 2013) demonstrating the potential of these stem cell 
populations to recruit immune cells such as neutrophils.  
The release of stromal derived factor (SDF)-1 by bone marrow stromal cells ensures 
the retention of neutrophils within the marrow environment by binding the CXCR4 
receptor on the neutrophil surface (Summers et al., 2010). Potentially, the release of 
SDF-1 could lead to the immobilisation of neutrophils at the site of infection. 
Furthermore, MSCs are known to decrease neutrophil apoptosis through IL-6 
secretion (Raffaghello et al., 2008) and increase the phagocytosis of bacteria by 
neutrophils (Hall et al., 2013). Additionally neutrophil activation and chemotaxis is 
promoted by MSCs through the secretion of factors such as IL-8 (Chen et al., 2014).  
The beneficial effects of BM-MSCs in patients with sepsis, including reduced 
mortality and improved organ function, have been reported to be dependent on BM-
MSC effects on monocytes and macrophages (Németh et al., 2009). The secretion of 
factors such as prostaglandin E2 (PGE2) by BM-MSCs stimulates IL-10 secretion 
from monocytes and M2 macrophages. Depeletion of the monocyte and macrophage 
populations within a polymicorbial septic mouse model eliminated the beneficial 
effects of BM-MSCs. Furthermore, increased monocyte phagocytosis of bacteria 
such as Escherichia coli has been documented with BM-MSC treatment 
(Krasnodembskaya et al., 2012). It has also been reported that MSCs can modulate 
the phenotype of macrophages, shifting the population from the pro-inflammatory M1 
to the anti-inflammatory M2 phenotype (Dayan et al., 2011, Nakajima et al., 2012, 
Melief et al., 2013). Overall, the effects of MSCs on innate immune cells enhances 
the anti-microbial properties of cells such as neutrophils and monocytes through 
direct effects on bacterial phagocytosis, chemotaxis and shifts in the inflammatory 
cytokine release, leading to beneficial effects during infections such as sepsis. It is 
hypothesised that OMLP-PCs may contribute to oral homeostasis in a similar manner 
with both direct antibacterial effects demonstrated in chapter 2, and indirect effects 
through modulating cells of the innate immune system.  
This study aims to investigate the direct antibacterial potential of OMLP-PCs isolated 
from oral cGVHD patients. The ability of the cells to express and secrete cyto- and 
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chemokines relevant to the attraction of innate immune cells will also be examined, 
and whether this is altered during oral cGVHD.  
 
4.1.1 Aims 
1. To compare the antibacterial potential of oral cGVHD patient derived OMLP-
PCs to those isolated from healthy donors. 
 
2. To assess the involvement of OMLP-PCs in innate defence during GVHD by 
comparing the expression and secretion of antibacterial and chemoattractant 
factors from GVHD patient derived OMLP-PCs to those derived from healthy 
donors.   
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4.2 Materials and Methods 
Cell isolation and the generation of CM and cDNA samples was performed by Dr 
Lindsay Davies and Dr Gregory Tour, Karolinska Institute as part of an on-going 
collaborative project. ELISAs (except PGE2) were carried out by Dr Gregory Tour, 
Karolinska Institute. All flow cytometry cell characterisation, qPCR, IDO activity 
assays, PGE2 quantification, haptoglobin Western blot analysis and antibacterial 
assays were carried out by myself, Emma Board-Davies, in addition to all data 
analysis.     
 
All tissue culture reagents were purchased from Life Technologies Europe BV 
(Stockholm, Sweden) unless otherwise stated.  
4.2.1 Isolation of OMLP-PCs and EFs from Healthy and GVHD patients 
OMLP-PCs and EFs were isolated and expanded from healthy donors (hOMLP-PCs 
and hEFs) and moderate-severe grade oral cGVHD patients (gOMLP-PCs and gEFs) 
as described in section 2.2.1. The study was approved by Karolinska University 
Hospital, Stockholm Ethical Committee and conducted in accordance with the 
Declaration of Helsinki.  All donors provided written consent. All GVHD patients were 
classified as having severe cGvHD using global severity scoring according to the 
National Institute of Health (NIH) Consensus Working Group for Diagnosis and 
Staging of cGvHD. Furthermore all patients included had a cGvHD organ score of 3/3 
within the oral cavity, with evidence of non-healing oral lesions of the buccal mucosa. 
Five millimeter punch biopsies were taken from an area of the buccal mucosa 
unaffected by lesions.   
4.2.2 Characterisation of OMLP-PCs and EFs from Healthy Donor and 
GVHD Patients 
Flow cytometry was used to ensure that the cells from both healthy and GVHD 
donors displayed the same cell surface expression for the previously defined stem 
cell markers (Davies et al., 2010). OMLP-PCs and EFs from healthy donors (n=4, 
n=3 respectively) and OMLP-PCs and EFs from GVHD patients (n=6, n=3 
respectively) were cultured in DMEM supplemented with 10% (v/v) FCS, 2mM L-
glutamine and antibiotics/antimycotics (100 U/ml penicillin G, 100 µg/ml streptomycin 
sulphate and 0.25 µg/ml amphotericin B) herein referred to as complete medium to 
90% confluence. Cells were subsequently removed from the plastic using Accutase® 
before pelleting cells at 500xg for 5mins. Cells were resuspended in 800µl complete 
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medium and aliquoted into 8 flow cytometry tubes (100ul/tube). Cells were stained 
with CD105-fluorescein isothiocyanate (FITC) (Clone SN6h, Ancell, USA; 5µl), CD73-
phycoerythrin (PE) (500257, BD Bioscience, Sweden; 5µl), CD90-FITC (Clone 5E10; 
BD Bioscience, 2.5µl), CD14-PE/CD45-FITC Simultest™ (clone MφP9 and clone 
2D1 respectively; BD Bioscience, Sweden; 5µl), CD31-FITC (Clone WM59 BD 
Bioscience; 2.5µl), HLAI-RPE (Clone W6/32, Dako, Sweden; 3.5µl) and HLAII-FITC 
(Clone CR3/43 Dako, Swden; 5µl) were added. BD Simultest™ Control γ1/γ2a (IgG1 
FITC/IgG2a PE; 5ul) served as controls. All tubes were incubated for 15mins in the 
dark at room temperature before washing in 1ml PBS.  Cells were pelleted at 500xg 
for 5mins and the supernatant aspirated. Cells were resuspended in 300µl fridge cold 
PBS + 0.1% (w/v) BSA and analysed on a BD FACSCalibur™ (BD Bioscience, 
Sweden) with 10,000 gated events recorded per sample. Data was analysed using 
FlowJo version 7.6 (Tree Star Inc., Ashland, OR). 
4.2.3 Stimulation of OMLP-PCs and EFs with LPS 
OMLP-PCs and EFs from healthy donors and GVHD patients were stimulated with 
LPS to assess the effect on their antibacterial potential. OMLP-PCs and EFs from 
healthy donors (n=4, n=3 respectively) and cGVHD patients (n=6, n=3 respectively) 
were seeded into 24 well culture plates (1x105 /well) in DMEM supplemented with 
10% (v/v) FCS and 2mM L-glutamine and incubated overnight at 37°C/5% CO2 to 
allow cells to adhere. Medium was aspirated and replaced with RPMI supplemented 
with 10% (v/v) FCS, 2mM L-glutamine, 20% (v/v) BHI +/- 10ng/ml LPS (Sigma).  
Samples were incubated for 1hr or 7hrs at 37°C/5% CO2. Cells from the 1hr and 7hr 
time points were lysed in RLT buffer containing 1% (v/v) 2β-mercaptoethanol and 
samples stored at -80°C (RNeasy Kit, Qiagen, Sweden). CM was harvested from the 
7hr samples, centrifuged at 500xg for 5mins to remove any cellular debris before 
storage at -80°C.  
4.2.4 Susceptibility Testing of GVHD CM and Blocking of Identified 
Antibacterial Mediators  
CM (90µl) derived from hOMLP-PCs (n=4), hEFs (n=3), gOMLP-PCs (n=6) and gEFs 
(n=3) were incubated with 100CFU of Gram positive bacteria (E. faecalis and S. 
pyogenes) +/- 0.6µg/ml of human osteoprotegerin neutralizing antibody (R&D 
Systems) or Gram negative bacteria (P. aeruginosa and P. mirabilis) +/- 24µg/ml of 
polyclonal rabbit anti-human haptoglobin antibody (Dako, UK) for 16hrs at 37ºC/5% 
CO2 in a 96 well plate. Bacterial cultures were serially diluted and spiral plated (Don 
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Whitley Scientific Limited, UK) onto TSA or CLED (P. mirabilis) agar and incubated at 
37°C overnight. The number of colonies grown on the agar plates was counted and 
bacterial CFU/ml was calculated from the counting table (WASP 2 User Manual 
Section 15.1, Don Whitely Scientific Limited, UK) as per section 2.2.4.   
4.2.5 RNA Isolation 
RNA was isolated from OMLP-PCs and EFs from healthy donors and GVHD patients 
+/- LPS from section 4.2.3, using the RNeasy kit (Qiagen, Sweden). Briefly, cells 
stored in the lysis solution were homogenised by vortexing samples for 1min. An 
equal volume of 70% (v/v) ethanol was added to each sample, mixed and directly 
added to a RNeasy spin column provided. Columns were centrifuged at 8000xg for 
15s before 700µl of the buffer RW1 was added to the column.  Columns were again 
centrifuged at 8000xg for 1min before 500µl of buffer RPE was applied. A 
centrifugation step at 500xg for 1min was carried out to wash the membrane of the 
column before a further 500µl of buffer RPE was applied, before a further 8000xg 
centrifugation for 2mins. RNA was then eluted into a clean tube using 50µl RNase-
free water and centrifuged at 8000xg for 1min. RNA was quantified using a Nanodrop 
2000C (Thermo Scientific, Sweden) and stored at -80ºC. 
4.2.6 cDNA Synthesis 
cDNA was generated from 200ng of RNA using the High-Capacity cDNA Reverse 
Transcription Kit (Life Technologies Europe BV, Sweden). A reaction mix was 
prepared as per the manufacturer’s protocol, with 2µl x10 RT buffer, 0.8 µl x25 dNTP 
mix, 2 µl x10 RT random primers, 1µl MultiScribe™ Reverse Transcriptase and 4.2 µl 
nuclease-free water. Two hundred ng of RNA, made up to a 10µl volume using 
nuclease-free water, was added to the reaction mix and incubated using a thermal 
cycler at 25ºC for 10mins, 37ºC for 2hrs, 85ºC for 5mins and held at 4ºC. 
Synthesised cDNA was diluted 1 in 10 with nuclease-free water and stored at -20ºC.  
4.2.7 Quantitative-Polymerase Chain Reaction (qPCR) 
Two µl for the diluted cDNA from section 4.2.6 was added to 0.25µl of 10 µmol 
forward and reverse primer mix (Table 4.1), 5µl SYBR green Fast SYBR® Green 
Master Mix (Life Technologies, Sweden) and 2.75µl nuclease-free water. Samples 
were incubated using a thermal cycler at 95ºC for 20s before 40 cycles of 95ºC for 3s 
and 60ºC for 30s were applied.  
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Table 4.1: Primer sequences utilised for qPCR analysis of OMLP-PCs and EFs +/- LPS treatment. All 
primers were sourced from (MWG Biotech, Germany) 
Primer target Primer sequence 
 
β actin 
(as per section 
2.2.1.3) 
 
F: 5’ AGG GCA GTG ATC TCC TTC TGC ATC CT 3’ 
R: 5’ CCA CAC TGT GCC CAT CTA CGA GGG GT 3’ 
 
IDO 
(as per section 
2.2.1.3) 
 
F: 5’ GCG ATG TTG GAA ATA GCT TC 3’ 
R: 5’ CAG GAC GTC AAA GCA CTA AA 3’ 
 
OPG 
(as per section 
2.2.1.3) 
 
F: 5’ GAA GGG CGC TAC CTT GA GAT 3’ 
R: 5’ GCA AAC TGT ATT TCG CTC TGG 3’ 
 
COX2 
(as per section 
2.2.1.3) 
 
F: 5’ CTT CAC GCA TCA GTT TTT CAA G 3’ 
R: 5’ TCA CCG TAA ATA TGA TTT AAG TCC AC 3’ 
 
SDF-1a 
 
F: 5’ CCA AAC TGT GCC CTT CAG AT 3’ 
R: 5’ TGG CTG TTG TGC TTA CTT GTT TTG G 3’ 
 
IL-1β 
 
F: 5’ CAC GAT GCA CCT GTA CGA TCA 3’ 
R: 5’ GTT GCT CCA TAT CCT GTC CCT  3’                  
 
IL-8 
 
F: 5’ TTG CCA AGG AGT GCT AAA GAA 3’ 
R: 5’ GCC CTC TTC AAA AAC TTC TCC 3’ 
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Data was analysed using the Δ ΔCT method, by which each sample was compared 
to its own β-actin level, before being compared to the control sample group (hOMLP-
PCs, - LPS).   
4.2.8 Examining the Levels of Antibacterial Factors 
4.2.8.1 Quantification of IDO Activity in Conditioned Media from OMLP-
PCs from Healthy Donors and GVHD Patients 
The concentration of the IDO metabolite, L-kynurenine, was determined as a 
measure of IDO activity as per section 3.2.2.1, on CM samples generated in section 
4.2.3.   
4.2.8.2 Quantification of PGE2 Secretion from OMLP-PCs from Healthy 
Donors and GVHD Patients 
The secretion of PGE2 was determined using the Prostaglandin E2 Parameter Assay 
Kit (R&D Systems, UK) as per section 3.2.2.3, on CM samples generated in section 
4.2.3.   
4.2.8.3 Detection of Haptoglobin in the Secretome of OMLP-PCs from 
Healthy Donors and GVHD Patients 
Total protein concentrations were determined in CM samples generated from section 
4.2.3 using a bicinchoninic acid (BCA) protein assay (Pierce: Life Technologies, UK) 
as per section 3.2.2.4.1. Twenty five µg total protein was separated through a 4–15% 
Mini-PROTEAN® TGX™ Gel (Biorad, UK) as per section 3.2.2.4.1 with Western blot 
analysis performed to detect the secretion of haptoglobin as per section 3.2.2.4.4. 
4.2.8.4 Quantification of OPG, IL-8, IL-1β and SDF-1a Secretion in 
Conditioned Media from OMLP-PCs from Healthy Donors and 
GVHD Patients 
Secreted levels of OPG, IL-8, IL-1β and SDF-1αwere determined in CM samples 
generated in section 4.2.3 using an enzyme-linked immunosorbent assay (ELISA: 
R&D Systems, UK) as per section 3.2.2.2.  
 Chapter 4 Changes in the Antibacterial Potential of OMLP-PCs during Chronic GVHD 
 
177 
 
4.2.8.5 Statistical Analysis  
All statistical analysis was performed using SPSS statistics (IBM®, Version 20). 
Variance analysis was performed using Levene’s test, where significant variability 
was assumed at P<0.05. Statistical analysis for comparing means was performed 
using a one-way ANOVA with a post hoc Tukey test (where equal variance) or a 
Games-Howell test (where variances were unequal). Statistical significance was 
assumed where P<0.05.    
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4.3 Results  
 
4.3.1 OMLP-PCs and EFs in culture  
Healthy OMLP-PCs (n=4) and EFs (n=3) and GVHD patient derived OMLP-PCs 
(n=6) and EFs (n=3) were expanded in complete media. All cell types demonstrated 
a typical bipolar, fibroblast-like morphology (Fig. 4.1 A-D).  
4.3.2 Cell Surface Expression of GVHD Patient Derived Cells Mirror that 
of Healthy Donor Derived Cells   
All OMLP-PC clones were phenotyped for their cell surface expression of CD73, 
CD105, CD90 and HLA I. The negative expression of the haematopoietic markers 
CD45 and CD34 and the endothelial marker CD31 was also examined, in addition to 
negative expression of CD14, CD80 and HLA II. OMLP-PCs from both healthy and 
GVHD sources expressed the typical stem cell markers above, with the lack of the 
expression of the haematopoietic markers noted (Fig. 4.2 - Fig. 4.5).  
4.3.3 Investigating the Antibacterial Factors Secreted from GVHD 
Patient Derived OMLP-PCs  
The expression and secretion of potential antibacterial factors was analysed in cells 
derived from healthy donors and GVHD patients to assess potential differences in the 
antibacterial secretome of these cells. 
4.3.3.1 IDO is Not Expressed in OMLP-PCs Derived from Either Healthy 
Donors or GVHD Patients after Stimulation with LPS  
Molecular expression of IDO and its activity was determined using qPCR and an 
activity assay respectively, in samples generated from section 4.2.3. Both the 
molecular expression (Fig. 4.6 A) and protein activity (Fig. 4.6 B) of IDO were 
undetectable in hOMLP-PCs and gOMLP-PCs after stimulation with LPS, irrespective 
of 1hr or 7hr initial culture period. A positive control of hOMLP-PCs primed with IFNγ 
was used. 
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Fig. 4.1: Representative photomicrographs of (A) hOMLP-PC, (B) hEF, (C) gOMLP-PC and (D) gEF, 
PD 24-30. Bar = 10µM. 
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J I Fig. 4.2: Representative cell surface expression of 
(A) CD45, (B) CD14, (C) CD31, (D) CD73, (E) 
CD105, (F) CD34, (G) CD90, (H) HLA I, (I) HLA II 
and (J) CD80 in hOMLP-PC clones. Red line 
represents the Ig control, whilst the blue line 
demonstrates the cell surface expression of the 
sample.   
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Fig. 4.3: Representative cell surface expression of 
(A) CD45, (B) CD14, (C) CD31, (D) CD73, (E) 
CD105, (F) CD34, (G) CD90, (H) HLA I, (I) HLA II 
and (J) CD80 in hEFs. Red line represents the Ig 
control, whilst the blue line demonstrates the cell 
surface expression of the sample.  .  
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Fig. 4.4: Representative cell surface expression of 
(A) CD45, (B) CD14, (C) CD31, (D) CD73, (E) 
CD105, (F) CD34, (G) CD90, (H) HLA I, (I) HLA II 
and (J) CD80 in gOMLP-PC clones. Red line 
represents the Ig control, whilst the blue line 
demonstrates the cell surface expression of the 
sample. 
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J I Fig. 4.5: Representative cell surface expression of 
(A) CD45, (B) CD14, (C) CD31, (D) CD73, (E) 
CD105, (F) CD34, (G) CD90, (H) HLA I, (I) HLA II 
and (J) CD80 in gEFs. Red line represents the Ig 
control, whilst the blue line demonstrates the cell 
surface expression of the sample.   
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 Fig. 4.6: IDO expression in OMLP-PCs and EFs. The expression (A) and activity (B) of IDO in hEFs 
(n=3), hOMLP-PCs (n=4), gEFs (n=3) and gOMLP-PCs (n=6) +/- LPS.  Molecular expression data (A) 
expressed as average fold change compared to hOMLP-PCs. IDO activity determined in CM at 7hrs. All 
data +/- SD of the mean. Statistics compared to all other samples. ***P<0.001. 
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4.3.3.2 GVHD Causes the Expression of COX2 to Increase in OMLP-PCs, 
but Not the Secretion of PGE2  
RNA isolated from section 4.2.3 was synthesised into cDNA and levels of COX2 
determined by qPCR. Secreted levels of PGE2 in CM samples from section 4.2.3 
were analysed using the Prostaglandin E2 Parameter Assay Kit (R&D Systems, UK). 
No significant differences were observed by LPS stimulus to any of the cell 
populations demonstrated at 1hr (P>0.05). The baseline expression of COX2 at 7hrs 
was significantly higher in gOMLP-PCs than the expression in hOMLP-PCs 
(P<0.001; Fig. 4.7 A). LPS stimulation significantly increased the expression of COX2 
in hOMLP-PCs and gOMLP-PCs at 7hrs (P<0.01; Fig. 4.7, A). The expression of 
COX2 was significantly greater in OMLP-PCs compared to EFs in samples derived 
from GVHD patients at 7hrs (P<0.05; Fig. 4.7 A). No differences in expression were 
observed between hOMLP-PCs and hEFs +/- LPS stimulation (P>0.05; Fig. 4.7 A).  
The secretion of PGE2 was unaffected by LPS stimulation in both OMLP-PCs and 
EFs from either healthy donors for GVHD patients (P>0.05; Fig. 4.7 B). Both hOMLP-
PCs and gOMLP-PCs displayed the same levels of secreted PGE2 (P>0.05; Fig. 4.7 
B), which were significantly higher than the secretion from hEFs or gEFs (P<0.001; 
Fig. 4.7 B).    
4.3.3.3 Haptoglobin is Secreted from OMLP-PCs from Both Healthy 
Donors and GVHD Patients 
The secretion of haptoglobin was investigated using Western blot analysis. The 
presence of the secreted protein was found in OMLP-PCs and EFs from both healthy 
donors and GVHD patients (Fig. 4.8). 
4.3.3.4 OPG Expression is Constitutive  
OPG expression and secretion in samples from section 4.2.3 were determined by 
qPCR and ELISA respectively. No statistical differences in either the mRNA 
expression or protein secretion of OPG were observed between hOMLP-PCs and 
gOMLP-PCs or EFs, irrespective of LPS stimulation (P>0.05; Fig. 4.9 A, B).   
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Fig. 4.7: Expression of COX2 and PGE2 secretion from OMLP-PCs and EFs. The expression of COX2 
(A) and secretion of PGE2 (B) in hEFs (n=3), hOMLP-PCs (n=4), gEFs (n=3) and gOMLP-PCs (n=6), +/- 
LPS.  Molecular expression data (A) expressed as average fold change compared to hOMLP-PCs. All 
data +/- SD of the mean, **P<0.01 ***P<0.001. 
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Fig. 4.8: Secretion of haptoglobin from OMLP-PCs and EFs. Haptoglobin secretion from healthy donor 
derived OMLP-PCs and EFs (A) and GVHD patient derived OMLP-PCs and EFs (B).  A positive control 
of Haptoglobin is represented in the CTRL lane.  
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Fig. 4.9: OPG expression and secretion from OMLP-PCs and EFs. The expression (A) and secretion 
(B) of OPG from OMLP-PCs and EFs from healthy donors (n=3, n=4 respectively) and GVHD patients 
(n=3, n=6 respectively) +/- LPS. The molecular data was expressed as average fold change compared 
to hOMLP-PCs. All data +/- SD of the mean.  
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4.3.4 OMLP-PCs Derived from GVHD patients do not Display 
Antibacterial Properties 
The fact that gOMLP-PCs (in a similar way to hOMLP-PCs) produced/secreted the 
antibacterial factors PGE2, haptoglobin and OPG, led to an investigation into the 
potential antibacterial properties of the disease cells. CM samples generated from 
section 4.2.3 were cultured with 100CFU of Gram positive and Gram negative 
bacteria to assess their effect on bacterial growth.  As demonstrated in section 2.3.6, 
CM from hOMLP-PCs significantly reduced the growth of both Gram positive 
(P<0.001; Fig. 4.10 A, B) and Gram negative bacteria (P<0.05; Fig. 4.11 A, B). Prior 
stimulation of the cells with LPS had no further effect on the ability of the CM to 
reduce the bacterial growth. However, CM derived from gOMLP-PCs had no effect 
on the growth of any bacteria tested (P>0.05; Fig. 4.10 A, B and Fig. 4.11 A, B) 
irrespective of LPS stimulation. EF derived media from both healthy donors and 
GVHD patients had no effect on bacteria growth (P>0.05; Fig. 4.10 A, B and Fig. 4.11 
A, B) irrespective of stimulation by LPS. 
Blocking OPG or haptoglobin in hOMLP-PC CM significantly increased the growth of 
Gram positive or Gram negative bacteria respectively (P<0.01; Fig. 4.10 A, B and 
P<0.05; Fig. 4.11 A, B). Blocking OPG or haptoglobin within gOMLP-PCs CM 
samples had no effect on bacterial growth (P>0.05; Fig. 4.10 A, B and Fig. 4.11 A, 
B).   
4.3.4.1 IL-8 Expression but not Secretion is Upregulated by LPS in 
OMLP-PCs Derived from GVHD Patients 
To analyse the potential of OMLP-PCs to recruit innate immune cells such as 
neutrophils, the chemoattractant IL-8 was analysed. The expression of IL-8 was 
determined using qPCR and secretion by ELISA in samples produced in section 
4.2.3. At 7hrs, mRNA IL-8 expression was significantly increased by LPS stimulation 
in both OMLP-PCs and EFs (P<0.01; Fig. 4.12 A), irrespective of the patient source, 
with no difference between disease and normal cells (P>0.05). The secretion of IL-8 
was significantly increased in hOMLP-PCs by LPS (P<0.01; Fig. 4.12 B).  However, 
LPS had no effect on the IL-8 secretion from gOMLP-PCs or either source of EFs 
(P>0.05; Fig. 4.12). 
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Fig. 4.10: The effect of CM on the growth of Gram positive bacteria. CM +/- LPS from hEFs (n=3), 
hOMLP-PCs (n=4), gEFs (n=3) and gOMLP-PCs (n=6) cultured with (A) E. faecalis and (B) S. 
pyogenes, +/- a neutralising antibody to OPG. Data expressed as percentage bacterial growth, +/- SD of 
the mean. Statistics compared to bacterial only controls (represented by the red dotted line), unless 
otherwise stated. #P<0.01, §P<0.001. 
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Fig. 4.11: The effect of CM on the growth of Gram negative bacteria. CM +/- LPS from hEFs (n=3), 
hOMLP-PCs (n=4), gEFs (n=3) and gOMLP-PCs (n=6) cultured with (A) P. aeruginosa and (B) P. 
mirabilis, +/- a blocking antibody to haptoglobin. Data expressed as percentage bacterial growth, +/- SD 
of the mean. Statistics compared to bacterial only controls (represented by the red dotted line), unless 
otherwise stated. *P<0.05, §P<0.001. 
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Fig. 4.12: IL-8 expression and secretion in OMLP-PCs and EFs. The expression (A) and secretion (B) of 
IL-8 from OMLP-PCs and EFs from healthy donors (n=3, n=4 respectively) and GVHD patients (n=3, 
n=6 respectively) +/- LPS. The molecular data expressed as average fold change compared to hOMLP-
PCs. All data +/- SD of the mean. *P<0.05.  
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4.3.4.2 The Expression of IL-1β is increased by LPS in hOMLP-PCs but 
not in gOMLP-PCs 
To analyse the potential of OMLP-PCs to recruit innate immune cells such as 
neutrophils, the chemoattractant IL-1β was analysed. IL-1β expression was analysed 
in synthesised cDNA samples generated from section 4.2.3. LPS stimulation 
significantly increased the expression of IL-1β in hOMLP-PCs (P<0.05; Fig. 4.13) but 
not in gOMLP-PCs (P>0.05; Fig. 4.13). These findings did not translate to the protein 
level, with no secretion of IL-1β detected in any samples analysed.  
4.3.4.3 Baseline Secreted Levels of SDF-1α are significantly higher in 
Healthy Donor Compared to GVHD Patient Cells  
The levels of SDF-1α were analysed as potential mechanism for neutrophil retention. 
The expression and secretion of SDF-1α was analysed using qPCR and ELISA 
respectively, from samples generated in section 4.2.3. There were no significant 
differences in the expression of SDF-1 α +/-LPS treatment (P>0.05; Fig. 4.14, A).  
However, the secretion of SDF-1α was significantly higher from hOMLP-PCs 
compared to gOMLP-PCs +/- LPS treatment (P<0.01; Fig. 4.14 B). LPS treated 
hOMLP-PCs secreted significantly more SDF-1α compared to LPS treated hEFs 
(P<0.05; Fig. 4.14 B).  No other differences between OMLP-PCs and EFs were 
observed from either healthy donors or GVHD patients (P>0.05).  
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Fig. 4.13: IL-1β expression in OMLP-PCs and EFs. The expression of IL-1β from OMLP-PCs and EFs 
from healthy donors (n=3, n=4 respectively) and GVHD patients (n=3, n=6 respectively) +/- LPS. 
Molecular data expressed as average fold change compared to hOMLP-PCs. All data +/- SD of the 
mean.  
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Fig. 4.14: SDF-1α expression and secretion in OMLP-PCs and EFs. (A) The expression SDF-1α from 
OMLP-PCs and EFs from healthy donors (n=3, n=4 respectively) and GVHD patients (n=3, n=6 
respectively) +/- LPS. Data expressed as average fold change compared to hOMLP-PCs 1hr.  (B) The 
secretion of SDF-1a from hOMLP-PCs (n=4) and gOMLP-PCs (n=6). All data +/- SD of the mean. 
*P<0.05, ***P<0.001.  
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Table 4.2: Summary of findings, a comparison between hOMLP-PCs and gOMLP-PCs 
 hOMLP-PCs gOMLP-PCs 
IDO None detected (+/- LPS) None detected (+/- LPS) 
COX2  Baseline expression lower than 
gOMLP-PCs 
Expression increased by LPS 
Baseline expression higher than hOMLP-
PCs  
Expression increased by LPS  
PGE2 Constitutive secretion Constitutive secretion 
Haptoglobin Constitutive secretion Constitutive secretion 
OPG Constitutive expression and 
secretion 
Constitutive expression and secretion 
Antibacterial 
effects 
Significantly reduces bacterial 
growth 
No effects on bacterial growth 
IL-8 Expression increased by LPS 
Secretion increased by LPS 
Expression increased by LPS 
No effect of LPS on secretion 
IL-1β Expression increased by LPS No effect of LPS on expression 
SDF-1α Secretion higher than gOMLP-PCs Secretion lower than hOMLP-PCs 
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4.4 Discussion 
Oral GVHD is associated with an increase in microbial infections (Treister et al., 
2012), but the underlying reasons as to why are not fully understood. Both HSCT and 
the prior conditioning regimes can result in increased infections (Kedia et al., 2013). 
The conditioning regimes such as chemotherapy and radiotherapy target the bone 
marrow, eradicating the immune cells limiting the patient’s ability to overcome 
infection. Furthermore, immunosuppressive therapy is given to patients before HSCT 
to prevent immune rejection of the stem cell therapy, which further limits the patient’s 
immune system (Kedia et al., 2013). The HSCT and associated conditioning regimes 
may predispose the patient to increased infections, which further manifest during the 
development of GVHD post-HSCT treatment.  
Mucosal surfaces are commonly affected by GVHD. Mucosal damage following 
HSCT (Lee et al., 2008) has been documented, predisposing these areas to 
developing GVHD. Changes in the microflora and increased infections are known in 
the gastrointestinal tract following HSCT (Lee et al., 2008). One study demonstrated 
that during allogeneic HSCT the bacterial diversity within the gut is decreased. It was 
demonstrated that Enterococcus species commonly dominated the gut of the patients 
(40%), with a further 37% of patients displaying a dominant Streptococcus species 
(Taur et al., 2012). Further studies have demonstrated that conditioning regimes 
such as chemotherapy have additional effects on the gut microflora (Montassier et 
al., 2014). Chemotherapy has been reported to reduce the bacterial diversity with a 
decrease in the abundance of Faecalibacterium species and an increase in 
Escherichia species associated with chemotherapy. The importance of the change in 
Faecalibacterium organisms has been highlighted with the reported anti-inflammatory 
effects of the bacteria in vitro and in vivo (Sokol et al., 2008). With the documented 
reduction in this bacterium following chemotherapy conditioning it has been 
hypothesised that chemotherapy results in a decrease of anti-inflammatory bacterial 
species within the gut, limiting the gut’s ability to regulate the intestinal environment, 
thereby pre-disposing the gut to the inflammatory condition, mucositis (Montassier et 
al., 2014).  The imbalance in the microbial populations following HSCT and the 
conditioning regimes have been linked to the development of GVHD (Jenq et al., 
2012). Inflammation resulting from the development of GVHD has been associated 
with major shifts in microbial populations within both the human and murine intestine. 
After the development of GVHD, a loss of bacterial diversity has been reported. The 
elimination of Lactobacillales species prior to the transplantation therapy resulted in 
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the development of GVHD within murine models, with the reintroduction of the 
Lactobacillales species alleviating the disease (Jenq et al., 2012). This published 
study demonstrates the direct effects of microbial changes on the development of 
GVHD.   
Oral mucositis is a common complication with both HSCT and GVHD.  It could be 
hypothesised that this inflammatory condition is attributed to changes in the oral 
microbiome, with decreases in anti-inflammatory species directly affecting the oral 
mucosa. This chapter has demonstrated the loss of antibacterial properties of OMLP-
PCs derived from GVHD patients. The resulting loss in antibacterial potential within 
the oral mucosa may further potentiate the effects of the remaining dominant 
bacterial species. With the potential loss in anti-inflammatory species and the 
decrease in antibacterial potential, a significant dysregulation within the oral mucosa 
may be present, inciting infections within the oral cavity.   
In chapters 2 and 3, OMLP-PCs from healthy donors were shown to possess direct 
antibacterial properties through the release of soluble factors. As part of this results 
chapter, it was demonstrated that OMLP-PCs derived from patients with oral GVHD 
did not share this quality. CM from gOMLP-PCs had no effect on bacterial growth 
with any of the bacteria tested. Further studies would be needed to ensure gOMLP-
PCs do not have any antibacterial properties as they may, for example, act through 
contact dependant mechanisms.  Co-culture of gOMLP-PCs and live bacteria during 
this chapter was however, not possible due to logistical problems in the transfer of 
the gOMLP-PCs from the Karolinska Institutet to Cardiff University School of 
Dentistry microbiology laboratory.  With changes in the oral cavity well documented 
during HSCT and the prior conditioning regimes, it is plausible that the OMLP-PCs 
lose antibacterial potential prior to developing GVHD. This loss of function may be 
attributed to mucosal damage during the conditioning regimes, further predisposing 
the oral cavity to the effects of GVHD. Examining the antibacterial effects of OMLP-
PCs isolated from patients undergoing conditioning regimes, those undergoing HSCT 
and those who have developed chronic oral GVHD may determine the time at which 
the OMLP-PCs lose their antibacterial function.  
The secretion of previously identified antibacterial factors (from Chapter 3) involved 
in the hOMLP-PCs mechanism of action were also investigated in gOMLP-PCs. 
PGE2 secretion was the same from OMLP-PCs isolated from both healthy donors 
and GVHD patients. It has been demonstrated that PGE2 can act in a synergistic 
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manner with TNFα. The ability of PGE2 to induce IL-12 production in human dendritic 
cells is significantly increased by TNFα (Rieser et al., 1997). It may be possible that 
PGE2 secreted by hOMLP-PCs functions as an antibacterial factor in synergy with 
another factor not present in the secretome of gOMLP-PCs. The expression of COX2 
however, was significantly higher in gOMLP-PCs than hOMLP-PCs at 7hrs. This may 
indicate that other COX2 dependant factors, such as prostaglandin D2 (PGD2), may 
be regulated by the COX2 expressed in gOMLP-PCs. PGD2 has been shown to 
display immunomodulatory properties through its ability to act as a chemoattractant 
to monocytes and alter dendritic cell maturation (Gosset et al., 2003), but its effects 
compared to PGE2 are not well defined. Preliminary studies have demonstrated that 
PGD2 is not secreted by hOMLP-PCs (data not shown), eliminating any role within 
the antibacterial effects of hOMLP-PCs. Further studies are warranted to examine 
the secretion of PGD2 from gOMLP-PCs. 
Haptoglobin secretion was demonstrated from both OMLP-PCs derived from healthy 
donors and those from GVHD patients. Concentrations of the OMLP-PCs derived 
protein are difficult to measure due to the low levels of secretion (pg/ml). It is possible 
that gOMLP-PCs secrete sub-active levels of haptoglobin, whilst hOMLP-PCs 
secrete above the antibacterial level of 50pg/ml (section 3.3.4.1). There are three 
isoforms of haptoglobin, with the differences between each isoform attributed to the 
differing α chains. Each isoform is comprised of either two α1 chains, two α2 chains 
or one α1 and one α2 chains. It is the α1 chain that conveys the highest level of 
activity, with the isoform containing two α1 chains demonstrating the greatest activity 
(Eaton et al., 1982). It is plausible that differences in the ratios of these isoforms 
explain the differences in antibacterial potential of the secreted haptoglobin from 
hOMLP-PCs and gOMLP-PCs. The resolution of the α chains was poor using 
Western blot analysis. A more specific technique, such as mass spectrometry, could 
be used to identify the chains present and the isoforms secreted by the cells.   
The secretion of another identified antibacterial factor, OPG, was also investigated. 
The secreted of OPG was also noted to be the same from both gOMLP-PCs and 
hOMLP-PCs. It is possible that the OPG secreted from the gOMLP-PCs is secreted 
in a different conformation, blocking the bacterial binding site, or bound to an inhibitor 
(see section 3.4.3) hence resulting in the lack of gOMLP-PC antibacterial activity that 
was observed. 
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Both OMLP-PCs and EFs significantly increase the expression of the 
chemoattractant IL-8 in response to LPS, irrespective of whether the cells were 
derived from healthy donors or GVHD patients. However, the secretion of IL-8 was 
only upregulated by LPS in hOMLP-PCs and was impaired in gOMLP-PCs and EF 
populations. This suggests that the OMLP-PCs and EFs from both sources are able 
to sense the LPS stimulus and upregulate the expression of IL-8, however, the 
secretion of the protein in response to LPS is not realised by the gOMLP-PCs and 
EFs by 7hrs.  This suggests that either the IL-8 protein is not translated in these cell 
populations, the secretion is impaired, or the protein is degraded. The expression of 
IL-1β was also significantly increased by LPS stimulation of hOMLP-PCs, but not of 
gOMLP-PCs, however secretion from neither hOMLP-PCs nor gOMLP-PCs was 
detected. The lack of secretion of the chemoattractant IL-8 by gOMLP-PCs in 
response to LPS could have potential downstream effects, preventing the gOMLP-
PCs from recruiting innate immune cells, such as neutrophils (Kolaczkowska and 
Kubes, 2013) after bacterial exposure. The change in ratio of IL-8 and potentially 
other chemoattractants during GVHD may lead to compromised immune cell 
recruitment. The tissues targeted by GVHD are associated with an infiltration of 
immune cells such as T cells, monocytes and macrophages, which leads to tissue 
damage (Martin, 2008).  
Oral cGVHD is also associated with an infiltration of immune cells such as 
lymphocytes within the oral mucosa (Soares et al., 2005). This could be a result of 
the differential expression in the chemoattractant factors within the oral mucosa, 
specifically the OMLP-PCs, leading to a dysregulation in immune cell recruitment. 
This chapter suggests that the recruitment of neutrophils by IL-8 and the retention by 
SDF-1α is impaired, leading to an imbalanced immune cell infiltration. LPS activation 
(Ward et al., 2009), and rhinovirus stimulation (Stokes et al., 2011) have been 
demonstrated to induce IL-1β in monocytes, demonstrating the ability of both 
bacterial and viral infections to induce IL-1β. IL-1β has been further identified as the 
factor controlling IL-8 release, a factor also known to be a potent neutrophil 
chemoattractant (Stokes et al., 2011). IL-8 is thought to activate neutrophils, 
facilitating their adhesion to the endothelium during neutrophil migration (Williams et 
al., 2011). The expression of IL-1β was increased by LPS in the healthy, but not 
GVHD OMLP-PCs. While the secretion of the protein was not detected even in 
healthy OMLP-PCs, it is possible that intracellular levels of IL-1β within OMLP-PCs 
may regulate the molecular levels and proteomic release of IL-8. The lack of IL-1β 
expression with gOMLP-PCs may lead to a dysregulation in the release of IL-8 and 
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therefore neutrophil recruitment with the oral cavity during GVHD. To further examine 
the importance of IL-8 secretion from OMLP-PCs, chemotaxis/cell migration assays 
(such as Boyden chambers) could be used to assess the ability of hOMLP-PC or 
gOMLP-PC CM to cause immune cell migration, such as neutrophils. The 
chemoattractive properties of BM-MSCs in addition to human salivary gland MSCs 
have been documented, with the induction of neutrophil chemotaxis reported from 
both cell types (Brandau et al., 2014). Direct neutralisation or blocking of the secreted 
IL-8 can be performed to investigate the role of this cytokine in the OMLP-PC 
mediated chemotaxis.   
The retention of neutrophils within the bone-marrow environment is mediated by the 
release of SDF-1 by the BM-MSCs (Summers et al., 2010). Secreted SDF-1 binds 
the CXCR4 receptor on the surface of neutrophils, immobilising the immune cells. It 
can be hypothesised that the secretion of SDF-1 by OMLP-PCs would retain 
neutrophils after recruitment to the oral mucosa, facilitating bacterial clearance during 
infection. The expression and secretion of SDF-1α was observed from OMLP-PCs, 
however, the secretion was significantly higher from hOMLP-PCs compared with 
gOMLP-PCs. This demonstrates the greater potential of hOMLP-PCs to immobilise 
innate immune cells at the site of infection compared to gOMLP-PCs. The secretion 
of SDF-1α was reported irrespective of LPS stimulation, demonstrating the 
constitutive ability of the hOMLP-PCs to modulate neutrophil immobilisation.  The 
expression of CXCR4 has also been reported on the surface of monocytes (Caulfield 
et al., 2002), with homing of monocytes to the bone-marrow by CXCR4 mediated 
mechanisms demonstrated (Wang et al., 2009). This further establishes the potential 
of hOMLP-PCs mediated SDF-1 α secretion to immobilise innate immune cells, such 
as neutrophils and monocytes, within the oral cavity. 
 
4.4.1 Conclusion 
The antibacterial properties of OMLP-PCs previously demonstrated in chapter 2 are 
absent in OMLP-PCs derived from GVHD patients who demonstrate oral symptoms. 
The development of oral GVHD and the increased infections during the disease may 
in part be attributed to the loss of antibacterial function of the OMLP-PCs, with the 
oral mucosa unable to regulate the oral microbiome during GVHD.   
 Chapter 4 Changes in the Antibacterial Potential of OMLP-PCs during Chronic GVHD 
 
202 
 
The loss of IL-8 and SDF-1α may prevent the migration and immobilisation of innate 
immune cells within the oral cavity during infection. With a lack of innate cell 
presence the immune response to bacterial challenge will be compromised, further 
potentiating the symptoms observed during oral GVHD.  
The loss of direct antibacterial properties of OMLP-PCs, in addition to the loss of 
indirect properties (innate cell effects), may cause a severe dysregulation within the 
oral mucosa during GVHD. These changes may contribute to the increased infection 
rate in GVHD patients and limit the host innate immune responses.   
This study demonstrates the loss of antibacterial function of OMLP-PCs isolated from 
GVHD patients, which may explain the increased infections during the disease.  
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5 General Discussion 
5.1 Background 
With over 700 different bacterial species identified in the human oral cavity 
(Kawamura and Kamiya, 2012) it is surprising that infections, particularly after 
invasive dental procedures for example, are rare (Parahitiyawa et al., 2010). The oral 
cavity harbours a dynamic microbial defence system vital for healthy homeostasis. 
The innate immune system, comprising of both cellular and protein components, 
provides a rapid but non-specific defence against pathogens. Innate immune cells 
are recruited to sites of infection by chemotactic stimuli such as cytokine gradients 
(Kolaczkowska and Kubes, 2013). Once at the infected site, innate immune cells 
exert their effects by the secretion of pro-inflammatory cytokines and phagocytosis 
(Fournier and Philpott, 2005). AMPs provide a further line of defence during the initial 
stages of infection; disrupting the phospholipid bacterial membrane, a structure vital 
to each bacterium (Teixeira et al., 2012).  The mechanism of action for AMPs can 
vary, with many reducing the available nutrients such as iron, zinc or tryptophan to 
bacteria (Ellison and Giehl, 1991, Dale and Fredericks, 2005, Hucke et al., 2004). 
Over 45 AMPs have been identified in the oral cavity (Gorr, 2009), highlighting their 
importance in oral microbial defence. The diverse presence of factors such as 
defensins, histatins, LL37, lactoferrin and lysozyme demonstrates the multifactorial 
antimicrobial defence in the oral cavity. The secretion of AMPs have been identified 
from oral epithelial cells, neutrophils & salivary glands (Gorr, 2009), demonstrating 
the secretion of AMPs by cells found facing the external environment. However, little 
research has focused on the secretion of AMPs from cells residing within the deeper 
tissue, which may play a role when the epithelial layer is penetrated or disrupted. The 
secretion of AMPs from tissue resident stem cell populations within the oral cavity 
has also not been investigated. The secretion of one AMP, LL37, has been reported 
from a tissue resident stem cell population found within the bone marrow; the BM-
MSCs (Krasnodembskaya et al., 2010). LL37 is thought to explain in part the 
antibacterial effects observed by BM-MSCs. No further literature has investigated the 
secretion of AMPs from BM-MSCs, which mediate the direct antibacterial properties 
of these cells.  
Several stem cell populations, including the orally derived gingival mesenchymal 
stem cells (GMSCs), dental pulp-MSCs (DP-MSCs), periodontal ligament stem cells 
(PDLSCs) and OMLP-PCs have identified immunosuppressive properties (Zhang et 
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al., 2009, Tomic et al., 2011, Wada et al., 2009, Davies et al., 2012). The 
immunomodulatory properties of the stem cell populations are mediated by secreted 
factors such as PGE2 and IDO (Zhang et al., 2009, Wada et al., 2009). Many of 
these immunomodulatory factors, such as IDO, also have identified antibacterial 
properties (Hucke et al., 2004).  
The aim of this thesis was to investigate the role of the OMLP-PCs in oral microbial 
defence. The low rate of infection within the oral cavity, despite a diverse microbial 
population is thought to result from a multifactorial antibacterial response which 
maintains a healthy homeostasis (Gorr, 2009). The role of oral stem cells within host 
defence is yet to be explored, in addition to the role of cells residing in the deeper 
tissue. It is not known whether the disruption of the epithelial layer and subsequent 
deeper infection may elicit an antimicrobial response from cells within the deeper 
tissue, or whether the response is confined to the surfaces of the oral cavity. The 
ability of the OMLP-PCs to modulate bacterial load was assessed to investigate any 
potential antibacterial effects in addition to identifying secreted antimicrobial factors, 
which may play a role in the antibacterial mechanism. To examine whether systemic 
disease disrupts the antibacterial effects of OMLP-PCs, cells isolated from oral 
cGVHD patients were also investigated.  
 
5.2 The Antibacterial Properties of OMLP-PCs 
This study demonstrates for the first time the direct antibacterial properties of OMLP-
PCs, a property currently only investigated in a limited number of other stem cell 
populations, BM-MSCs and cord blood MSCs (Krasnodembskaya et al., 2010, Sung 
et al., 2016). Whilst similarities in the broad spectral antibacterial effects have been 
noted between the MSCs and OMLP-PCs, with both stem cell sources decreasing 
the growth of Gram positive and Gram negative bacteria, distinct differences in the 
mechanism of action are evident. Each of these stem cell populations mediate their 
antibacterial effects in vitro through the release of antimicrobial factors. Both the 
studies involving BM-MSCs and cord-blood MSCs demonstrated that MSCs must be 
exposed to bacteria before the cells secreted such factors to display an antibacterial 
phenotype (Krasnodembskaya et al., 2010, Sung et al., 2016). However, during this 
study it was demonstrated that OMLP-PCs constitutively secrete antimicrobial 
factors, making them ideal for cell based therapies where an antibacterial component 
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is required, with no modulation to the cells needed to display the full antibacterial 
phenotype.  
Whilst it appears that the cells may unnecessarily expend energy by producing 
antibacterial factors in the absence of bacteria, the constitutive secretion may be 
explained through prior in vivo priming. OMLP-PCs are isolated from the buccal 
mucosa of human donors. The oral cavity is rich in microbial species (Kawamura and 
Kamiya, 2012), hence the OMLP-PCs may be primed by bacteria in vivo. This may 
also explain the increase in the directed migration of OMLP-PCs compared to the 
control EFs in control conditions. In vivo, the possible exposure to bacterial (or their 
products) gradients may have resulted in the stimulation of migration in OMLP-PCs. 
This would allow OMLP-PCs to migrate to the site of infection, leading to a more 
effective antimicrobial response by the cells. A positive migratory stimulus of FCS 
was not able to further enhance the migration of OMLP-PCs, potentially due to the 
stimulation of a maximal migratory phenotype resulting from the in vivo priming.  
The antibacterial effects of OMLP-PCs have been demonstrated against both Gram 
positive and Gram negative bacteria, however only a limited number of bacteria were 
examined. A large panel of bacteria are required to fully assess the antibacterial 
potential of OMLP-PCs and confirm the broad spectral effects. The antibacterial 
effects against bacteria such as oral commensals, oral pathogens, non-orally derived 
bacteria and bacterial biofilms would determine the full spectrum of the OMLP-PC 
effect. This could determine whether OMLP-PCs elicit an antimicrobial effect against 
all bacteria, or whether the effect is confined to a subset of bacteria.  
Currently the antibacterial properties of both BM-MSCs (Krasnodembskaya et al., 
2010, Sung et al., 2016) and OMLP-PCs have focussed on the effects against 
aerobic or facultative anaerobic bacteria. These bacteria may represent the bacteria 
near the surface of biofilms, due to the accessible oxygen. However, anaerobic 
bacteria would be found deeper within biofilms (Thurnheer et al., 2015). To assess 
whether OMLP-PCs could affect anaerobic bacterial growth and therefore disrupt 
deeper layers of a biofilm, a co-culture with the OMLP-PCs and anaerobic bacteria 
could be used. The experimental system to co-culture stem cells and aerobic 
bacteria is simple, with both OMLP-PCs and microorganisms remaining healthy at 
37ºC in 5% CO2. However, a direct co-culture of OMLP-PCs and anaerobic bacteria 
is not possible with the current experimental setup. Under the current experimental 
conditions (5% CO2) it would not be possible to culture anaerobic bacteria, whilst the 
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anaerobic conditions required for these bacteria would prevent the healthy culture of 
the progenitor cell populations causing cell death. While direct co-culture is difficult, 
susceptibility testing for the conditioned media (CM) may be more plausible. CM 
derived from OMLP-PCs could potentially be cultured in anaerobic conditions in the 
presence of bacteria. A redesign of the susceptibility testing protocol would be 
needed, as the current protocol would not allow the culture of anaerobic bacteria. 
These bacteria require a rich medium to grow and the CM does not provide the 
bacteria with such nutrients. However, by growing bacteria in biofilms, the growth of 
both aerobic bacteria on the surface and anaerobic bacteria deeper within the biofilm 
is facilitated. It is possible that OMLP-PCs could then be seeded on top of the biofilm 
and the diffusion of the OMLP-PC secretome could penetrate through to the 
anaerobic compartment of the biofilm. Using this system, potential interplay between 
a complex bacterial ecosystem and the OMLP-PCs could be investigated, rather than 
single bacterial species, allowing a more physiologically relevant approach. 
 
5.3 Antibacterial Proteins and Peptides 
The involvement of antibacterial soluble factors in the OMLP-PC effect was 
confirmed as a mechanism of action throughout the study, with the antibacterial 
properties retained within the CM of the cells. Krasnodembskaya et al., 2010 
demonstrated that LL37 in-part mediates the antibacterial properties of BM-MSCs, 
with neutralisation of LL37 abolishing the antibacterial effects. The secretion of IDO, 
an antibacterial  protein, is well established from MSCs after IFNγ stimulation (Wada 
et al., 2009). As BM-MSCs are the gold standard stem cell population for cell-based 
therapies, the BM-MSC identified LL37 and IDO expression and secretion was 
assessed in OMLP-PCs. A more recent study suggesting an involvement of hBD-2 
(Sung et al., 2016) could steer future investigations to examine the role of the 
defensins in the OMLP-PC mediated antibacterial effects. The presence of hBD-2 
has been identified in human saliva, in addition to hBD-1 and -3 and the α-defensins 
(HNP)-1,2 and 3 (Gorr, 2009). LPS activation of TLR4 and PGN activation of TLR2 
has been demonstrated to induce the expression hBD-2 in intestinal epithelial cells 
(Vora et al., 2004). The TLR4 ligand LPS also stimulates granulocyte-colony 
stimulating factor (G-CSF) production in nasal mucosal MSCs (Jakob et al., 2010) in 
addition to the chemoattractant factor IL-8 (Jakob et al., 2013). The secretion of G-
CSF by endothelial cells and immune cells such as monocytes is known to promote 
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the proliferation and differentiation of myeloid cells. This gives further evidence of the 
ability for bacterial stimuli, such as LPS, to modulate the immunomodulatory and 
antibacterial phenotype of immunomodulatory cell populations. The induction of 
human defensins during oral microbial infection has also been demonstrated (Sawaki 
et al., 2002, Wehkamp et al., 2004), suggests a role for defensins within the oral 
cavity. Examining the secretion of defensins from OMLP-PCs may further evaluate 
the role of these cells during infection. Investigating the surface expression of TLRs 
on OMLP-PCs may elucidate to the potential pathways regulating the antibacterial 
mechanisms.  
This thesis has established that neither LL37 nor IDO are involved in the antibacterial 
effects of OMLP-PCs. OMLP-PCs demonstrated constitutive antibacterial effects with 
no expression of LL37 detected in OMLP-PCs, whilst the induction of IDO was 
dependent on IFNγ stimulation. This demonstrates that the antibacterial mechanism 
of OMLP-PCs differs from that reported for the BM-MSCs. This study identified three 
factors which mediate the antibacterial effects of the OMLP-PCs; PGE2, haptoglobin 
and OPG.  
The immunomodulatory effects of PGE2 are well documented, with 
immunosuppressive effects on both innate and adaptive immune cells such as 
macrophages (Aronoff et al., 2004) and lymphocytes (Kalinski, 2012). The direct 
effects of PGE2 on bacterial growth have not fully been investigated. The literature 
suggests that PGE2 has a positive effect on bacterial growth through its 
immunosuppression (Agard et al., 2013). It is thought that PGE2 impairs the 
antibacterial functions of cells such as the phagocytosis of macrophages (Aronoff et 
al., 2004), thereby promoting bacterial infection. However, these studies examined 
the effects of PGE2 at 1µM (350ng/ml) (Serezani et al., 2007, Aronoff et al., 2004). 
The constitutive secretion of PGE2 from OMLP-PCs was reported at levels up to 
2ng/ml or less, with increased levels induced by Gram negative bacteria and IFNγ to 
8ng/ml. At the constitutive levels secreted by OMLP-PCs, PGE2 demonstrates 
antibacterial properties, decreasing the growth of bacteria. It is therefore likely that 
PGE2 acts in a biphasic manner, where at high concentrations the lipid induces 
imunosuppression and promotes bacterial growth, whereas at low concentrations 
PGE2 directly reduces bacterial growth. It is likely that the promotion of bacterial 
growth at high concentrations of PGE2 is an indirect result of the 
immunosuppression. With the innate immune system dampend due to the 
immunosuppession, a limited microbial defence from such innate cells would exist. 
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Further studies are needed to assess the direct antibacterial effects of PGE2 at 
concentrations above those already examined. The co-culture of peripheral blood 
PBMCs, OMLP-PCs and bacteria may indicate the potential interplay between the 
level of immunosupression and the level of antibacterial effects and whether these 
properties are inversely related. 
The antibacterial effects of haptoglobin have long been established (Eaton et al., 
1982). The chelation of iron by haptoglobin/haemoglobin binding limits the available 
iron to bacteria, an essential growth nutrient (Barclay, 1985). Although haptoglobin 
was detected in the secretome of the OMLP-PCs and blocking its activity restored 
bacterial growth, it was also detected in the secretome of the non-antibacterial EFs. 
There are 3 different human isoforms of haptoglobin, differing in the alpha chain 
composition (Sadrzadeh and Bozorgmehr, 2004). Each isoform contains two alpha 
chains, either two alpha 1 chains, two alpha 2 chains, or one alpha 1 and one alpha 2 
chain. It is the alpha 1 chain which conveys the highest level of activity to the protein, 
with the isoform containing two alpha 1 chains demonstrating the greatest activity 
(Eaton et al., 1982). Whilst both the alpha 1 and alpha 2 chains of haptoglobin in the 
secretome of OMLP-PCs and EFs were detected, it is not possible to determine 
which isoforms each chain was associated with from the Western blots performed. 
The lack of antibacterial effects of EFs, despite the presence of haptoglobin, may be 
attributed to differing ratios of the three isoforms secreted by OMLP-PCs and EFs. 
Mass spectrometry could be used to identify the haptoglobin isoforms (Garibay-
Cerdenares et al., 2014) present in the secretome of OMLP-PCs and EFs in further 
studies.   
This is the first study to demonstrate the antibacterial effects of OPG. Normally 
associated with bone-remodelling (Jin et al., 2015), it has been demonstrated in this 
thesis that OPG can reduce the growth of Gram positive bacteria in vitro. Its 
involvement within the immune system has been investigated, with the inhibition of 
TRAIL-induced lymphocyte apoptosis by OPG known (Emery et al., 1998). OMLP-
PCs are known to suppress lymphocyte proliferation (Davies et al., 2012) however, 
lymphocyte apoptosis was not reported. The secretion of OPG by OMLP-PCs may 
prevent lymphocyte apoptosis during OMLP-PC-mediated immunosuppression. 
Further immunomodulatory effects of OPG have been described, with an involvement 
in B cell development (Emery et al., 1998) and monocyte chemotaxis reported 
(Mosheimer et al., 2005). Additionally, the decrease in OPG during the inflammatory 
disease periodontitis is well documented (Bostanci et al., 2007, Mogi et al., 2004, Liu 
Chapter 5 General Discussion 
 
210 
 
et al., 2003, Balli et al., 2015). Periodontitis is associated with the bacterium P. 
gingivalis, but the correlation between the disease and OPG levels has not been fully 
explored. OPG levels during periodontitis are compared to levels of its ligand RANKL 
and their involvement in bone-remodelling. No study has investigated the potential 
direct effect of OPG on bacterial growth and whether the decrease in OPG levels 
pre-disposes patients to bacterial infection.  
This study investigated the potential mechanism for the OPG-mediated antibacterial 
effects. A bacteriostatic effect was confirmed, by the lack of bacterial cell death after 
OPG incubation, while its binding site on Gram positive bacteria was identified. OPG 
binds to LTA embedded in the peptidoglycan layer on the surface of these bacteria. 
Gram negative bacteria lack the peptidoglycan layer (Labischinski et al., 1991) and 
therefore surface expression of LTA, explaining the lack of antibacterial effects of 
OPG on these bacteria. This finding has an important effect on the way OPG should 
be analysed during periodontitis. It is well known that OPG is decreased during the 
disease, but the knowledge that it has direct bacterial effects was not known, until 
this study. Whether a decrease in OPG leads to the increased infections during 
diseases such as periodontitis has not been examined.  
Further investigations are warranted to fully characterise the OPG binding to 
bacteria, with crystallography able to identify the binding domain of OPG. To further 
assess the antibacterial mechanism of OPG, gene array analysis could be performed 
on the bacterial genome to assess the changes in gene expression after OPG 
binding. This may provide an insight into the downstream effects on bacterial growth 
by OPG.   
It has been demonstrated that the antibacterial effects of OMLP-PCs are mediated by 
different factors to those already identified for BM-MSCs (LL37 and IDO). Further 
investigations are needed to assess whether the factors identified in this study play a 
role in the antibacterial effects of BM-MSCs. With such limited literature available in 
this new research area, it has been important to validate the effects that we see with 
pure peptide/protein for each of our factors of interest. This is the first study to 
demonstrate the secretion of haptoglobin by a stem cell population hence its 
involvement in the BM-MSC mediated antibacterial effect is also unknown. The 
secretion of PGE2 has been documented from BM-MSCs and it’s 
immunosuppressive phenotype confirmed (Yañez et al., 2010). BM-MSCs are 
reported to secrete approximately 500pg/ml (Yañez et al., 2010, (Naderi et al., 2015), 
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which is increased to 1ng/ml with LPS stimulation (Yañez et al., 2010). The LPS 
stimulated PGE2 secretion is thought to mediate the immunosuppression by BM-
MSCs, but direct effects on bacteria have not been assessed.  
It has been reported that BM-MSCs secreted levels of OPG between 10-20ng/ml 
(Oshita et al., 2011, Le Blanc et al., 2004) however, neutralisation of OPG does not 
affect the immunosuppressive properties of the BM-derived cells. Further 
investigations are needed to assess whether OPG mediates any of the antibacterial 
effects demonstrated by MSCs in vitro. The negative control cells used in this study, 
EFs, were found to secrete similar levels of OPG to OMLP-PCs, yet did not display 
an antibacterial phenotype. The protein sequence of OPG should be analysed in 
future studies to determine if there are differences in this sequence between the 
OPG secreted from OMLP-PCs and that from EFs. Raman spectroscopy has been 
identified as a useful tool in detected changes in protein profiles in recent studies 
(Michael et al., 2014, Vrensen et al., 2015). A molecular fingerprint of the secreted 
OPG could therefore be investigated through the application of Raman spectroscopy, 
detecting any differences in the biochemical fingerprint between the secreted OPG 
from OMLP-PCs and EFs. It is possible that OPG secreted from the EFs may be 
conformationally different, blocking the LTA binding site, preventing antibacterial 
activity. The conformation and activity of BM-MSC secreted OPG would need to be 
assessed. Conformational differences may be attributed to differences in the 
glycosylation of the protein secreted from the different cell populations. Differences in 
the charge of the OMLP-PC and EF secreted OPG protein were alluded to through 
the 2D gel electrophoresis performed within this study, which may be explained by 
differences in the protein glycosylation. It is important to consider these differences 
when examining the potential antibacterial effects of OPG secreted from BM-MSCs.  
 
5.4 In vivo potential of OMLP-PCs 
This thesis has reported on the antibacterial effects of OMLP-PCs in vitro, 
demonstrating the potential therapeutic effects of a cell-based therapy. However, it is 
questionable as to whether the effects seen in in vitro would translate into clinical 
benefit. The significant reduction in the growth of bacteria demonstrated in vitro by 
OMLP-PCs may not be sufficient to clear a bacterial infection in vivo. However, it is 
likely that OMLP-PCs would have further antimicrobial effects in vivo due to the 
potential immunomodulatory properties of the cells. The immunomodulatory effects 
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on lymphocyte proliferation have been characterised for OMLP-PCs (Davies et al., 
2012) and many other stem cell populations (Zhang et al., 2009, Tomic et al., 2011, 
Wada et al., 2009). Further immunomodulatory effects have been confirmed for stem 
cell populations, which have yet to be investigated for OMLP-PCs. BM-MSCs have 
been reported to increase the phagocytosis of immune cells, which have 
demonstrated encouraging potential as a cell-based therapy to treat polymicrobial 
sepsis. In a model of polymicrobial sepsis, the reduction of P. aeruginosa in the blood 
has been attributed to the increase in blood monocyte phagocytosis 
(Krasnodembskaya et al., 2012). It was demonstrated that isolated monocytes from 
MSC-treated mice displayed a higher phagocytic activity compared to those isolated 
from non-treated mice. No changes in the phagocytic activity in the isolated 
neutrophils was observed. These effects were seen in the absence of inflammatory 
cytokine (e.g. TNFα) or immunomodulatory factor (e.g. PGE2) changes, 
demonstrating the effect was directly mediated by the phagocytosis of the 
monocytes.  Other studies however, have demonstrated effects of MSCs on the 
phagocytosis of neutrophils. BM-MSCs and human salivary gland MSCs were 
reported to increase the phagocytic activity of neutrophils in vitro, as demonstrated 
by the increase in intracellular bacterial uptake (Brandau et al., 2014) and BM-MSCs 
in vivo in a mouse model of polymicrobial sepsis (Hall et al., 2013). No phagocytosis 
has been observed from the BM-MSCs directly. However, these studies did not 
examine further effects on monocyte phagocytosis.  
The effects of OMLP-PCs on immune cell phagocytosis are yet to be examined, but it 
is hypothesised that this may be another trait that OMLP-PCs share with BM-MSCs. 
Evaluating the effects of OMLP-PCs on innate immune cells will begin to examine the 
potential indirect antibacterial effects of OMLP-PCs in vivo. The ability of OMLP-PCs 
to cause innate cell migration and activation should be examined in addition to direct 
effects of OMLP-PCs on immune cells. MSCs, from both the bone-marrow and the 
salivary glands have been reported to induce neutrophil chemotaxis (Brandau et al., 
2014), with LPS stimulation of MSCs enhancing the chemotactic effect. Furthermore, 
the secretion of CCL4, a pro-inflammatory cytokine involved in macrophage 
recruitment, from the neutrophils was induced by LPS stimulated BM-MSCs. The 
ability of OMLP-PCs to mediate changes in the monocyte and/or mature macrophage 
populations could lead to further antibacterial effects in vivo. Macrophages cultured 
with MSCs demonstrate an increased M2 phenotype charaterised by IL-10 and IL-6 
secretion (Kim and Hematti, 2009). It is thought that M2 macrophages resolve the 
inflammation caused by infection to prevent tissue damage (Sica et al., 2015). The 
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ability of MSCs to induce an M2 phenotype suggests MSCs may be involved in the 
resolution of inflammation and infection. Shifts in the pro-inflammatory M1 and anti-
inflammatory M2 macrophage phenotype by OMLP-PCs are yet to be explored, in 
addition to the effects of OMLP-PCs on monocyte differentiation into macrophage 
phenotypes. Future studies could examine the effects of OMLP-PCs on monocyte 
and macrophage populations, in addition to the effects on innate cell phagocytosis. 
The antibacterial effects of OMLP-PCs may be further enhanced in vivo due to 
indirect antimicrobial effects through the modulation of innate immune cells.  
 
5.5 OMLP-PCs as a New Cell Source for Stem Cell Therapies 
While BM-MSCs do display properties making them an ideal for a cell-based therapy 
such as the ability to home to sites of injury (Wei et al., 2013) and immune-privileged 
phenotype (Lee et al., 2011),  the invasive procedure to obtain BM-MSCs prevents 
extensive harvesting. A bone marrow aspiration can cause a large amount of 
discomfort and pain for the donor (Chen et al., 2013), therefore identifying an 
alternative cell source with limited discomfort to the donor is needed. OMLP-PCs are 
harvested during a minimally invasive procedure, which can be carried out during 
routine dental procedures. The mucosa is easily accessible and pain to the donor is 
limited. Due to the rapid healing within the oral mucosa, donors display a rapid 
recovery with no scarring. The mucosa is therefore an ideal source of progenitor cells 
for stem cell-based therapies.  
This study has demonstrated the constitutive antibacterial properties of OMLP-PCs, 
thought to be a result from in vivo priming. The effects of in vivo priming may offer 
further advantages of OMLP-PCs as a cell-based therapy compared to BM-MSCs. 
The exposure of OMLP-PCs to S. pyogenes resulted in an enhanced antibacterial 
effect against this bacterium. With Streptococcus species, including S. pyogenes 
(Ramachandran, 2014), regularly the causative organism of sepsis, OMLP-PCs may 
provide a distinct advantage over other stem based cell therapies. OMLP-PCs share 
the immune-privileged phenotype with BM-MSCs demonstrated by the low 
expression of HLA molecules (Davies et al., 2010). Additional studies are required to 
demonstrate further shared qualities, which make BM-MSCs ideal as a cell-therapy, 
such as the ability for OMLP-PCs to home to sites of injury. The secretion of SDF-1 is 
known to facilitate the retention of neutrophils within the bone-marrow. SDF-1 
produced by BM-MSCs binds to its ligand, CXCR4, expressed on the neutrophil 
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surface (Summers et al., 2010), immobilising the neutrophils. Furthermore, the SDF-
1/CXCR4 axis has been implicated in stem cell homing. The expression of CXCR4 
on MSCs directly correlates to the increased migration and engraftment observed by 
during MSC therapy (Chen et al., 2012). The overexpression of CXCR4 in BM-MSCs 
used for the treatment of skin injuries enhances the migration of the BM-MSCs to the 
site of injury and reduces the wound healing time (Yang et al., 2013). The recruitment 
of BM-MSCs to the site of injury and the wound healing capacity of the tissue is 
diminished when CXCR4 is blocked (Xu et al., 2013). Moreover, the treatment of a 
GVHD murine model with MSCs overexpressing CXCR4 improves the mortality rate 
of the mice in addition to reducing the GVHD clinical scores (Chen et al., 2012). The 
expression of CXCR4 on the surface of OMLP-PCs (personal communication Dr 
Lindsay Davies, Karolinksa Institutet) and the secretion of SDF-1 demonstrated in 
chapter 4 suggests that OMLP-PCs are able to recruit further OMLP-PCs to sites of 
infection. The secretion of SDF-1α by OMLP-PCs has the potential to bind to the 
CXCR4 expressed on the surface of the OMLP-PCs, immobilising further OMLP-PCs 
at the site of infection. The loss of CXCR4 expression on OMLP-PCs isolated from 
cGVHD patients (personal communication Dr Lindsay Davies, Karolinksa Institutet) 
indicates the lack of homing capabilities of these cells during disease.  
 
5.6 OMLP-PCs Lose their Antibacterial Effects during Oral GVHD 
GVHD is an immune disorder, which can develop in patients who have undergone 
HSCT. During GVHD, immune-competent cells such as lymphocytes within the 
transplanted material become activated, giving rise to an immune response against 
the host recipient (Ferrara et al., 2009). Complications of GVHD are known to affect 
several different organs such as the skin, liver and GI tract (Margaix-Muñoz et al., 
2015). The oral cavity can also be affected in up to 70% of patients who develop 
chronic GVHD (Pavletic et al., 2005) with pain, mucositis and increased bacterial 
infections, particularly gingivitis, reported (Margaix-Muñoz et al., 2015).  
Patients undergoing HSCT are predisposed to changes in the microbial flora and 
increased bacterial infections due to the effects of the treatment and conditioning 
regimes. Patients are given immunosuppressive therapy prior to HSCT to limit 
immunorejection (Ferrara et al., 2009). Additionally, radiation targeting the bone-
marrow may be prescribed to prevent immunorejection. However, dampening of the 
patient’s immune system and the irradiation of immune cells in the marrow results in 
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a decreased ability to fight infection. Furthermore, neutropenia, a decrease in 
neutrophil numbers, has been observed in patients undergoing HSCT, further limiting 
microbial defence bacteria (Young et al., 2015).  The effects of HSCT and the 
conditioning regimes may predispose the oral cavity to increased bacterial infections, 
with a reduction in the microbial diversity reported after chemotherapy (Ye et al., 
2013) for example. Furthermore, the oral mucosa has a diminished ability to 
effectively manage the changes in the bacterial flora and changes in bacterial load 
through the loss of antibacterial effects of the OMLP-PCs demonstrated here. The 
CM from OMLP-PCs isolated from oral GVHD patients failed to reduce the growth of 
bacteria, compared to those isolated from healthy patients. This may further explain 
the increased infections and gingivitis seen in oral cGVHD patients. It is not known 
whether the loss of OMLP-PCs antibacterial properties occurs during the 
development of GVHD, or prior to the disease development during the HSCT and 
conditioning regimes. Isolation of cells and determination of antibacterial potential 
from patients at each stage can further determine the point at which these properties 
are lost. 
The secretion of identified antibacterial factors from chapter 2 were assessed, 
however no changes in these factors were reported from OMLP-PCs isolated from 
GVHD patients compared to healthy donors. This suggests that there are further 
antibacterial mechanisms mediating the antibacterial effect of OMLP-PCs isolated 
from healthy donors. It may also be possible that the CM derived from OMLP-PCs 
isolated form GVHD patients contains an inhibitory factor(s), preventing the 
antibacterial effects of the secreted factors.   
This study demonstrates the potential to re-introduce OMLP-PCs isolated from 
healthy patients into GVHD patients as a treatment. One case study has 
demonstrated the potential benefits of a stem cell treatment for chronic oral GVHD 
(Garming-Legert et al., 2015). Locally injected BM-MSCs reduced the redness and 
ulceration wound in a 59 year old male. OMLP-PCs may provide a further benefit, by 
contributing towards the regeneration of a ‘normal’ oral microbial defense.    
 
5.7 Future Directions 
This study has demonstrated the direct antibacterial effects of OMLP-PCs. Future 
studies should further define the OMLP-PC secretome and identify additional 
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antibacterial factors involved in the antimicrobial mechanism. The recent reports of 
hBD-2 involvement in the antibacterial effects of cord blood MSCs (Sung et al., 2016) 
and it’s known presence within the oral cavity (Gorr, 2009) warrant the investigation 
of hBD-2 secretion from OMLP-PCs. A large scale analysis of the secretome is 
required to identify all factors involved in the antibacterial mechanism. A screening 
protocol may be established, with initial investigations focused on AMPs known to be 
present within the oral cavity such as defensins and histatins (Gorr, 2009). 
A large scale study to examine the spectrum of antibacterial effects of OMLP-PCs 
should be undertaken to assess the antibacterial effects against further Gram 
positive and Gram negative bacteria. It is important to assess the effects against oral 
commensals, oral pathogens and non-oral bacteria to ascertain which subsets of 
bacteria are affected by OMLP-PCs and those which could be potential targets for an 
OMLP-PC based therapy. The effect on pathogenic oral anaerobic bacteria such as 
P. gingivalis should be evaluated to assess the therapeutic potential of OMLP-PCs in 
diseases caused by such bacteria such as periodontitis.  
Importantly, future investigations should focus on the effect of OMLP-PCs on innate 
immune cells to evaluate the antibacterial potential of the cells in vivo. The 
chemotactic effect of OMLP-PCs on several immune cells such as monocytes and 
neutrophils using migration assays (such as boyden chambers) could be investigated 
in addition to the effect of OMLP-PCs on innate cell function. The secretion profiles of 
innate cells could be assessed to evaluate the effect of OMLP-PCs on innate cell 
cytokine release. Phagocytic assays could analyse the effects of OMLP-PCs on 
innate cell phagocytosis, and assess whether OMLP-PCs can affect the antibacterial 
mechanisms of the innate cells. The phenotype of differentiated monocytes or mature 
macrophages could be assessed after OMLP-PCs co-culture to evaluate the 
macrophage M1 pro- or M2 anti-inflammatory phenotype. Surface expression of M1 
or M2 markers such as CD86 and CD163 respectively can be analysed to assess the 
macrophage phenotype in addition to the secretion of M1 and M2 related factors 
such as TNFα and IL-10 respectively. The ability of OMLP-PCs isolated from patients 
with oral cGVHD to modulate innate cells should also be considered, to assess 
whether it is only the direct antibacterial effects which are eradicated during the 
disease or whether the immunomodulatory capacity of the PCs is also affected.  
Future investigations into the OMLP-PCs antibacterial secretome and innate cell 
effects will hope provide further evidence for the suitability of OMLP-PCs as a cell 
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based-therapy. The advantages over the gold-standard BM-MSCs have been 
discussed, including the ease of access to the cells. Further studies will examine 
whether the beneficial immunomodulatory properties of MSCs are also observed in 
OMLP-PCs, such as the increased innate cell phagocytosis during polymicrobial 
sepsis (Hall et al., 2013).  
 
5.8 Conclusion  
In conclusion this thesis generated new knowledge concerning the antibacterial 
properties of OMLP-PCs, with the constitutive property thought to be a result of in 
vivo priming. The effect is mediated by soluble factors secreted from the OMLP-PCs, 
as demonstrated by the ability of the CM to decrease the growth of bacteria, as with 
the cells directly. This illustrates the potential role of OMLP-PCs in the oral host 
defence, with the ability of the OMLP-PCs and their secretome to decrease the 
growth of both Gram positive and Gram negative bacteria. Three factors were 
identified to play a role in the OMLP-PC mediated antibacterial effects (PGE2, OPG 
and haptoglobin) highlighting the differences in the mechanism of action between 
OMLP-PCs and BM-MSCs. This is the first study to illustrate the antibacterial effects 
of OPG, with OPG binding to a Gram positive bacterial cell wall component, LTA, 
beginning to decipher its mechanism of action.  
The antibacterial effects of OMLP-PCs isolated from oral GVHD patients did not 
demonstrate an antibacterial response, with the CM having no effect on bacterial 
growth. This may in part explain the increased infections observed during GVHD 
which may lead to inflammation and the symptoms of oral GVHD. Changes in the 
microbiome of the oral cavity prior to the development of GVHD may pre-dispose the 
patient to oral infections, which is potentiated by the loss of functional antibacterial 
OMLP-PCs. Changes in the antibacterial potential of the cells in GHVD were 
observed in the absence of any changes in the levels of the secreted antibacterial 
factors PGE2, OPG and haptoglobin. This suggests there are further mechanisms 
mediating the antibacterial effects of OMLP-PCs.  
The importance of OMLP-PCs in the regulation of bacterial populations to help 
maintain a healthy homeostasis has been suggested in this study, with a loss of 
antibacterial functions potentially leading to the dysregulation of the oral mucosa and 
an increased infections during diseases such as oral cGVHD. OMLP-PCs and their 
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secretome demonstrate antibacterial properties against a range of bacteria, 
illustrating the potential for OMLP-PCs as a novel cell based or soluble factor based 
therapy for conditions with a bacterial involvement such sepsis.   
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7 Supplementary Data 
7.1 Bacterial growth profiles 
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Figure S1: The growth profile of E. faecalis in BHI, RPMI + 10%FCS (+/- 5-20% 
BHI) from a 1:100 of a 0.5 McFarland. 
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Figure S2: The growth profile of E. faecalis in BHI, RPMI + 20%FCS (+/- 5-20% 
BHI) from a 1:100 of a 0.5 McFarland. 
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Figure S3: The growth profile of E. faecalis in BHI, RPMI + 10%FCS (+/- 5-20% 
BHI) from 150CFU. 
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Figure S4: The growth profile of E. faecalis in BHI, RPMI + 20%FCS (+/- 5-20% 
BHI) from 150CFU. 
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Figure S5: The growth profile of S. pyogenes in BHI, RPMI + 10%FCS (+/- 5-20% 
BHI) from a 1:100 of a 0.5 McFarland.. 
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Figure S6: The growth profile of S. pyogenes in BHI, RPMI + 20%FCS (+/- 5-20% 
BHI) from a 1:100 of a 0.5 McFarland. 
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Figure S7: The growth profile of S. pyogenes in BHI, RPMI + 10%FCS (+/- 5-20% 
BHI) from 150CFU. 
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Figure S8: The growth profile of S. pyogenes in BHI, RPMI + 20%FCS (+/- 5-20% 
BHI) from 150CFU. 
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Figure S9: The growth profile of P. aeruginosa in BHI, RPMI + 10%FCS (+/- 5-
20% BHI) from a 1:100 of a 0.5 McFarland. 
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Figure S10: The growth profile of P. aeruginosa in BHI, RPMI + 20%FCS (+/- 5-
20% BHI) from a 1:100 of a 0.5 McFarland. 
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Figure S11: The growth profile of P. aeruginosa in BHI, RPMI + 10%FCS (+/- 5-
20% BHI) from 150CFU. 
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Figure S12: The growth profile of P. aeruginosa in BHI, RPMI + 20%FCS (+/- 5-
20% BHI) from 150CFU. 
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Figure S13: The growth profile of P. mirabilis in BHI, RPMI + 10%FCS (+/- 5-20% 
BHI) from a 1:100 of a 0.5 McFarland. 
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Figure S14: The growth profile of P. mirabilis in BHI, RPMI + 20%FCS (+/- 5-20% 
BHI) from a 1:100 of a 0.5 McFarland. 
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Figure S15: The growth profile of P. mirabilis in BHI, RPMI + 10%FCS (+/- 5-20% 
BHI) from 150CFU. 
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Figure S16: The growth profile of P. mirabilis in BHI, RPMI + 20%FCS (+/- 5-20% 
BHI) from 150CFU. 
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Tissue-Specific Progenitor and Stem Cells
Oral Mucosal Lamina Propria-Progenitor Cells Exert
Antibacterial Properties via the Secretion of
Osteoprotegerin and Haptoglobin
EMMA BOARD-DAVIES,a,b RACHAEL MOSES,a,b ALASTAIR SLOAN,a,b PHIL STEPHENS,a,b LINDSAY C. DAVIESa,b,c
Key Words. Oral mucosa x Progenitor cell x Antibacterial agents x Osteoprotegerin x Haptoglobin
ABSTRACT
The oral cavity possesses a diverse microflora, yet recurrent infections within healthy individuals are
rare. Wound healing within the buccal mucosa is preferential, potentially because of the presence of
oral mucosal lamina propria-progenitor cells (OMLP-PCs). In addition to their multipotency, OMLP-
PCs demonstrate potent immunosuppressive properties. The present study investigated whether
OMLP-PCspossessantibacterial properties, directly interactingwithmicroorganismsandcontributing
to the maintenance of a balanced oral microflora. Gram-positive and -negative bacteria were cocul-
tured with OMLP-PCs, buccal mucosal fibroblasts, or their respective conditioned media (CM). Bac-
terial growth was significantly inhibited when cocultured with OMLP-PCs or their CM. No
antibacterial activity was apparent within the fibroblasts. Analysis of the OMLP-PC CM indicated con-
stitutive secretion of osteoprotegerin (OPG) andhaptoglobin (Hp). Exposure of the bacteria toOPGor
Hpdemonstrated their differential antibacterial properties,with neutralization/blocking studies con-
firming that the growth of Gram-positive bacteria was partially restored by neutralizing OPG within
OMLP-PC CM; blocking Hp restored the growth of Gram-negative bacteria. The present study dem-
onstrates, for the first time, the broad-spectrum antibacterial properties of OMLP-PCs. We report
the direct and constitutive antibacterial nature of OMLP-PCs, with retention of this effect within
the CM suggesting a role for soluble factors such as OPG and Hp. Knowledge of the immunomodula-
tory and antibacterial properties of these cells could potentially be exploited in the development of
novel cell- or soluble factor-based therapeutics for the treatment of infectious diseases such as pneu-
monia or ailments such as chronic nonhealing wounds. STEMCELLS TRANSLATIONALMEDICINE 2015;
4:1–11
SIGNIFICANCE
Oral mucosal lamina propria-progenitor cells (OMLP-PCs) are a cell source with known immunomod-
ulatory properties. The present report demonstrates the novel finding thatOMLP-PCs possess potent
antibacterial properties, halting the growth of Gram-positive and -negative bacteria through the se-
cretion of soluble factors. OMLP-PCs constitutively secrete osteoprotegerin (OPG) and haptoglobin
(Hp) at levels high enough to exert antibacterial action. OPG, a glycoprotein not previously known to
be antibacterial, can suppress Gram-positive bacterial growth. Hp is only active against Gram-
negative microorganisms. These findings indicate that OMLP-PCs could offer great potential in the
development of novel cell- or soluble factor-based therapies for the treatment of infectious illness,
such as bacterial pneumonia, through systemic infusion and of chronic wounds through local
administration.
INTRODUCTION
Oral soft tissues are continually exposed to the
external environment and are thus a critical
entry point for potentially harmful bacteria
[1]. However, chronic infections are rare, po-
tentially because of antimicrobial factors se-
creted by resident cells within tissues such as
the salivary glands [2]. A decrease in specific
antimicrobial factors has been linked to the
onset of oral diseases such as periodontitis
and deficiencies in the human cathelicidin pro-
tein LL-37 [3].
Oral mucosal lamina propria-progenitor cells
(OMLP-PCs) are isolated from buccal mucosal
biopsies by differential adhesion to fibronectin
[4]. These cells are clonally expanded and are
CD44+CD90+CD105+CD166+ andCD342CD452.
They are of neural crest origin (Slug+, Snail+,
Sox10+, and Twist+) and aremultipotent (mesen-
chymal and neural lineages) [4]. In addition to
their plasticity, OMLP-PCs demonstrate potent
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immunosuppressive properties, suppressing lymphocyte prolif-
eration in a contact- and dose-independent manner, indicating
the importance of secreted factors inmediating their mechanism
of action [5].
The immunosuppressive properties of bone marrow-
derived mesenchymal stem cells (BMMSCs) are well docu-
mented [6]. BMMSCs require licensing to an anti-inflammatory
phenotype, termed “MSC2,” by exposure to proinflamma-
tory cytokines, such as interferon-g (IFN-g), to display these
properties [7]. IFN-g induces the expression of indoleamine
2,3-dioxygenase (IDO), the enzyme responsible for depleting
tryptophan, an essential factor in suppressing lymphocyte
proliferation [8].
Immunosuppressive factors, such as IDO, are also known to
have prominent antibacterial actions. This enzyme also inhibits
tryptophan-dependent bacteria such as group B streptococci
[9] and Escherichia coli [10, 11] by the depletion of tryptophan.
This knowledge has led to the hypothesis that stem cells can
act with dual properties, displaying both immunomodulatory
and antibacterial characteristics. However, limited studies have
been reported with respect to the potential antibacterial proper-
ties of stem/progenitor cells. BMMSCs have been demonstrated
to decrease the growth of a restricted number of bacteria in vitro
by the secretion of antibacterial factors such as LL-37 [12]. In vivo
studies have also documented the antibacterial nature of
BMMSCs for the treatment of conditions suchas sepsis. For exam-
ple, BMMSCs stimulate bacterial clearance within the blood in
both polymicrobial [13] and Gram-negative sepsis mousemodels
[14], potentially owing to an increase in the phagocytosis of
bacteria.
Haptoglobin (Hp) is a multifunctional glycoprotein with
knownantibacterial and immunomodulatory properties affecting
both the innate and the adaptive immune systems [15]. It is com-
posed of two a and two b chains, with the type of a chain (a1 or
a2) conveying the level of Hp activity. Three human forms are
known: Hp1-1, Hp2-1, and Hp2-2. Hp1-1with twoa1 chains dem-
onstrating the highest level of activity. Its ability to effectively
bind hemoglobin and thereby deplete iron from the environment
provides Hp with excellent antibacterial effects against multiple
bacterial and fungal pathogens [10].Normally associated asapos-
itive acute phase protein, produced by the liver and found in in-
creasing concentrations within the plasma as inflammation
occurs, no association with stem/progenitor cells has yet been
reported [16].
Osteoprotegerin (OPG) is a glycoprotein predominantly de-
scribed as a decoy receptor for the receptor activator of nuclear
factor kB ligand (RANKL), preventing nuclear kB activation. Ac-
tivation of this pathway is central to the regulation of a number
of key immune pathways and the process of osteoclastogenesis
[17].OPG is known tobe a componentof theBMMSCsecretome,
although it has been reported to not play a significant role in
MSC-mediated immunosuppression [18], but rather in regulat-
ing bone resorption [19]. Numerous reports have highlighted
a correlation among bone resorption, OPG, and periodontitis;
a condition associated with the bacteria Porphyromonas
gingivalis [20–22].
In thepresent report, we demonstrate, for the first time, the
broad-spectrum antibacterial properties of OMLP-PCs. These
findings suggest that this is an inherent and distinct property
of this PC population that does not extend to stromal fibro-
blasts. We demonstrate that OMLP-PC-mediated antibacterial
activity is through the constitutive secretion of soluble factors,
including Hp and OPG, confirming that the OMLP-PC secretome
is able to directly modulate bacterial growth in the absence of
immune cell involvement. To our knowledge, this is the first re-
port documenting the antibacterial properties of OPG and its
ability to inhibit Gram-positive bacterial growth through a bac-
teriostatic mechanism. Future investigations will focus on iden-
tifying the potential for OMLP-PC usage as a cell- or soluble
factor-based therapeutic in the treatment of infectious
diseases.
MATERIALS AND METHODS
Isolation and Maintenance of OMLP-PCs and Enriched
Fibroblasts in Culture
Disease-free buccal mucosa biopsies (n = 4) were obtained from
healthy donors undergoing orthognathic surgery at Cardiff and
Vale University Health Board (Cardiff, U.K.). The local research
ethical committee had previously approved the present study,
and thedonorswere informed in accordancewith theDeclaration
of Helsinki.
Single cell suspensionsof the laminapropriawereobtainedby
enzymatic digestion of the biopsy specimens, and OMLP-PCs
were isolated and characterized as previously described [4, 23].
In brief, OMLP-PCs were separated from the lamina propria cell
suspension by differential adhesion to fibronectin and expanded
inmonolayer culture. Cells remaining in suspension aftermultiple
adhesion steps on fibronectin (i.e., the OMLP-PC-depleted stro-
mal fraction) were termed “enriched fibroblasts” (EFs) and used
as a control oral fibroblast cell population throughout the present
study.
OMLP-PCs and EFs were maintained at 37°C in a 5% CO2
humidified atmosphere in Dulbecco’s modified Eagle’s medium
supplemented with 10% (vol/vol) fetal calf serum (FCS), 2 mM
L-glutamine, and antibiotics/antimycotics (100 U/ml penicillin
G, 100mg/ml streptomycin sulfate, and 0.25mg/ml amphotericin
B; Life Technologies, Paisley, U.K., http://www.thermofisher.
com). To remove cells from plastic for subsequent experimental
procedures, 0.05% (wt/vol) trypsin/0.53 mM EDTA (Life Technol-
ogies) was used, unless otherwise stated.
Maintenance of Microbiology Stocks
Enterococcus faecalis (NCTC 775), Pseudomonas aeruginosa
(ATCC 15692), and Staphylococcus pyogenes (NCTC 8198) were
maintained on tryptone soya agar (TSA; Oxoid Ltd., Basingstoke,
U.K., http://www.oxoid.com). Proteus mirabilis (NCTC 11938)
was maintained on cysteine lactose electrolyte deficient (CLED;
Oxoid Ltd.) agar to prevent swarming of the bacteria. Bacteria
were subcultured onto fresh agar plates weekly and grown over-
night at 37°C. Agar plates were then stored at 4°C.
Coculture of OMLP-PCs, EFs, OPG, and Human Hp With
Live Bacteria
OMLP-PCs and EFs (n = 4 donors) were used at 24–30 popula-
tion doublings for the following experiments. OMLP-PCswere
treated 6100 U/ml recombinant human IFN-g (Sigma-Aldrich,
Gillingham, U.K., http://www.sigmaaldrich.com) for 7 days
before coculture with bacteria to induce an anti-inflammatory
phenotype as confirmed by quantification of the IDO-inducing
metabolite L-kynurenine [5].
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OMLP-PCs with or without IFN-g and EFs were seeded into
24-well plates at a density of 1 3 105 cells per well in Roswell
Park Memorial Institute (RPMI) medium supplemented with
10% (vol/vol) FCS and 2mM L-glutamine. The cells were allowed
to adhere overnight at 37°C in 5% CO2. Subsequent to adhesion,
the culture medium was removed and exchanged for RPMI sup-
plemented with 10% (vol/vol) FCS, 20% (vol/vol) brain heart in-
fusion broth, and 2mM L-glutamine with or without inoculation
with 150 colony-forming units (CFUs) of bacteria. For the OPG
and human Hp coculture experiments, recombinant human
OPG (rhOPG; R&D Systems, Abingdon, U.K., http://www.
rndsystems.com) or Hp (Sigma-Aldrich) was added to 150 CFU
bacteria in suspension at 1–100 ng/ml or 10 pg/ml to 1 mg/ml,
respectively.
The CFUs of each bacterium were previously calculated from
10- or 20-ml (S. pyogenes only) overnight cultures derived from
single colonies. Cultures were spiral plated using a Whitley auto-
matic spiral plater (Don Whitley Scientific, Shipley, U.K., http://
www.dwscientific.co.uk) onto appropriate agar after 16 hours
(for cocultures) and 23 hours (for susceptibility testing) at 37°C
(and 5% CO2 for S. pyogenes). The bacterial colonies were subse-
quently counted in accordance with the manufacturer’s instruc-
tions, and the dilution for 150 CFUs was determined for each
culture period.
The cocultures were incubated at 37°C and 5% CO2 for the
calculated time to reach the mid-log phase for the control cul-
tures (individual mid-log time points were previously deter-
mined for each bacterium using growth curves starting from
an inoculation of 150 CFUs). Bacteria and OMLP-PC/EF-only cul-
tures served as controls. The conditioned media (CM) was re-
moved, serially diluted, and spiral plated onto TSA or CLED
agar (P.mirabilis) and incubated overnight at 37°C before count-
ing the bacterial colonies. The remaining CM was centrifuged at
500g for 5 minutes to remove any cell debris. For samples con-
taining bacteria, the CMwas further centrifuged at 14,000g for 2
minutes through a Pall NanosepMF centrifugal device, Bio-Inert
pore size of 0.2 mm (Sigma-Aldrich) to remove bacteria, and
stored at 280°C.
Susceptibility Testing of Live Bacteria With
OMLP-PC Secretome
A total of 100 CFUs of bacteria in phosphate-buffered saline was
added to 90ml of CM from the above coculture experiments. The
cocultureswere then incubated at 37°C and5%CO2 for 16 hours.
The bacterial cultures were serially diluted, spiral plated onto
TSA or CLED (P. mirabilis) agar, and incubated overnight at
37°C before the bacterial colonies were counted as described
above. The experiments were repeated with the addition of
0.6 mg/ml of human osteoprotegerin/TNFRSF11B neutralizing
antibody (R&D Systems) or 24 mg/ml of the polyclonal rabbit
anti-human Hp antibody (Dako, Ely, U.K., http://www.dako.
com).
Quantification of OPG Gene Expression by OMLP-PCs
Total RNA was extracted from the OMLP-PCs after coculture
with bacteria using the Illustra RNAspin Mini RNA isolation kit
(GE Healthcare Life Sciences, Little Chalfont, U.K., http://
www.gelifesciences.com) and stored at 280°C before use.
cDNA was synthesized from 0.5 mg of total RNA using random
hexamer primers and Moloney murine leukemia virus reverse
transcriptase in accordancewith themanufacturer’s instructions
(Promega, Southampton, U.K., http://www.promega.com). The
genomic level of OPG (forward: 59-GAAGGGCGCTACCTTGAGAT-
39 and reverse: 59-GCAAATGTATTTCGCTCTGG-39) and b-actin
(forward: 59-AGCTACGAGCTGCCTGAC-39 and reverse: 59-AAGG-
TAGTTTCGTGGATGC-39) within OMLP-PCs was determined by
quantitative reverse transcription-polymerase chain reaction
(qRT-PCR) using Fast SYBR Green Master Mix (Life Technologies)
according to the manufacturer’s instructions.
Quantification of OPG Level in OMLP-PC Secretome
The protein levels of secreted OPG were determined in CM
samples from the coculture experiments using the human
osteoprotegerin/TNFRSF11B DuoSet enzyme-linked immunosor-
bent assay (ELISA) (R&D Systems). The concentration of OPG in
the samples was assessed using a standard curve of rhOPG from
0 to 4000 pg/ml.
Detection of Hp in OMLP-PC Secretome
CM derived from OMLP-PCs cultured with and without 100 U/ml
IFN-g for 7 days was combined with Laemmli buffer (62 mM Tris-
HCL [pH 6.8], 10% [vol/vol] glycerol, 5% sodium dodecyl sulfate,
0.005% bromophenol blue, and 5% b-mercaptoethanol) and re-
duced by heating to 100°C for 2 minutes. The total protein con-
centration was determined using the bicinchoninic acid protein
assay (ThermoFisher) to ensure equal loading.
Samples (35mg) of total protein were separated on NuPAGE
Novex 4%–12% Bis-Tris gels (Life Technologies). A positive con-
trol of 1 mg human Hp was added to one well (Sigma-Aldrich).
The proteins were transferred to nitrocellulose membrane
(HybondECL; GE Healthcare Life Sciences) overnight at 4°C, be-
fore rinsing the membrane in deionized water. The membrane
was placed in 5% (wt/vol) nonfat milk for 1 hour at room tem-
perature with agitation before probing with polyclonal rabbit
anti-human Hp (1.2 mg/ml; Dako) diluted in 2% (wt/vol) nonfat
milk in phosphate-buffered saline (PBS) with 0.1% Tween20
(PBS-T) for 1 hour at room temperaturewith agitation. Themem-
branewaswashed inPBS-Tbeforebeing incubatedwithhorseradish
peroxidase-conjugated polyclonal swine anti-rabbit immunoglobu-
lins (0.1mg/ml; Dako) in 2% (wt/vol) nonfatmilk diluted in PBS-T for
1 hour at room temperature. The membrane was washed in PBS-T
before development using ECL Prime and exposure to Hyperfilm
(GE Healthcare Life Sciences).
AssessingEffectofOMLP-PCSecretome,OPG, andHpon
Bacterial Viability
Bacteria were assessed for viability after exposure to OMLP-PC
CM, rhOPG, and Hp, as detailed above. Bacteria were stained
using the LIVE/DEAD BacLight Bacterial Viability Kit (Life Tech-
nologies) as per the manufacturer’s instructions. Bacteria were
stained for 15 minutes before mounting onto poly-L-lysine
microscope slides under a coverslip, using the BacLight mount-
ingoil provided. Thebacteriawerevisualizedusinga fluorescent
microscope at 3100 objective under oil immersion (Olympus,
Southend-on-Sea, U.K., http://www.olympus-lifescience.com).
Live (green) and dead (red) bacterial cells were subsequently
counted using Image Pro-Plus software, version 6.0 (Media
Cybernectics, Bethesda, MD, http://www.mediacy.com). Individ-
ual bacteria in a minimum of four fields of view were counted
per condition.
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Statistical Analysis
All statistical analyses were performed using SPSS statistics, ver-
sion 20 (IBM Corp., Armonk, NY, http://www-01.ibm.com/
software/analytics/spss/). Statistical analysis to compare mean
values was performed using one-way analysis of variance with
post hoc Tukey test (equal variances assumed) or a Games-
Howell test (unequal variances determined). Variance analysis
was performed using Levene’s test. Significance was assumed
at p # .05.
RESULTS
OMLP-PCs Significantly Reduce Growth of Both
Gram-Positive and Gram-Negative Bacteria
OMLP-PCs were cultured with Gram-positive (E. faecalis and
S. pyogenes) and Gram-negative (P. aeruginosa and P. mirabilis)
bacteria to the calculated mid-log time point. The growth of
each bacterium, both Gram-positive (p , .001; Fig. 1A, 1B)
and Gram-negative (p, .001; Fig. 1C, 1D), was significantly re-
duced when cocultured with OMLP-PCs. No further inhibitory
effect was evident with previous IFN-g licensing of the PCs
(confirmation of IDO activity on IFN-g licensing shown in
supplemental online Fig. 1). Coculturing of the PC-depleted
EFs with bacteria had no significant effect on the growth of
any bacterium (Fig. 1A–1D).
OMLP-PC Secretome Constitutively Reduces Growth of
Gram-Positive and Gram-Negative Bacteria
CM from OMLP-PCs significantly reduced the growth of each
bacterium (p , .001; Fig. 2A–2D). No further inhibitory effect
was demonstrated with CM derived from OMLP-PCs previously
licensed with IFN-g or primed by pre-exposure to the bacte-
rium, with the exception of S. pyogenes. CM derived from
OMLP-PCs previously exposed to S. pyogenes further sup-
pressed the growth of this bacterium compared with CM de-
rived from unprimed OMLP-PCs (p , .001; Fig. 2B). CM from
EFs with or without previous exposure to each bacterium had
no significant effect on the growth of any of the bacteria (Fig.
2A–2D).
OPG Is Constitutively Expressed and Secreted by OMLP-
PCs
mRNA expression levels of OPG from OMLP-PCs were examined
using qRT-PCR, and the secreted levelswithin CMweremeasured
using ELISA. OPG was constitutively expressed (Fig. 3A–3D) and
secreted (average secretion of 13 ng/ml in resting OMLP-PCs;
Figure 1. OMLP-PCs demonstrate broad-spectrum antibacterial
effects in coculture with bacteria. OMLP-PCs significantly reduced
the growth of Gram-positive E. faecalis (A) and S. pyogenes (B) and
Gram-negative P. aeruginosa (C) and P.mirabilis (D) bacteria. This ef-
fect was observed irrespective of OMLP-PCs prestimulation with
IFN-g or not. EFs had no effect on bacterial growth. Data are ex-
pressed as the percentage of growth6 SEM, with bacteria-only cul-
tures set to 100%. ppp, p # .001. Abbreviations: EFs, enriched
fibroblasts; IFN-g, interferon-g; OMLP-PCs, oral mucosal lamina
propria-progenitor cells.
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Fig. 3E–3H) by OMLP-PCs, with IFN-g and/or bacterial exposure
having no further effect on these levels.
OPG Exerts Antibacterial Activity Against Gram-
Positive Bacteria
Bacteria were incubated with rhOPG at concentrations relevant
to those secreted by OMLP-PCs to examine whether OPG pos-
sesses antibacterial properties. OPG significantly decreased
the growth of Gram-positive bacteria (E. faecalis significant at
5 ng/ml, p # .01; Fig. 4A; and S. pyogenes significant at
5 ng/ml, p # .001; Fig. 4B). However, OPG demonstrated no sig-
nificant effect on the growth of either Gram-negative bacteria
(Fig. 4C, 4D).
Neutralizing OPG Partially Inhibits Antibacterial
Properties of OMLP-PCs Against Gram-Positive Bacteria
CM derived from OMLP-PCs (with or without previous bacterial
exposure) was incubated with live, Gram-positive bacteria in
the presence or absence of an OPG-neutralizing antibody. Neu-
tralization of the OMLP-PC (with or without bacterial exposure)
secreted OPG significantly increased the growth of E. faecalis
(OMLP-PC CM, p # .01, and bacterially exposed OMLP-PC CM,
p # .05; Fig. 4E) and S. pyogenes (OMLP-PC CM, p # .001,
and bacterially exposed OMLP-PC CM, p # .001; Fig. 4F) com-
pared with CM that had not been neutralized. However, neither
the growth of E. faecalis nor the growth of S. pyogenes was fully
restored to control levels by neutralization of OPG (p # .01, Fig.
4E; and p # .001, Fig. 4F, respectively).
Hp Is Constitutively Secreted by OMLP-PCs
Hp secretion fromOMLP-PCs was detected in the CMbyWestern
blot, with all three chain variants detected, suggesting the consti-
tutive secretionof thehigher activity forms,Hp1-1andHp2-1 (Fig.
5A). Hp was secreted from OMLP-PCs, irrespective of IFN-g stim-
ulation of the cells.
Hp Exerts Antibacterial Activity Against Gram-
Negative Bacteria
Bacteria were incubated with Hp to examine its antibacterial
properties. Hp significantly decreased the growth of both
Gram-negative bacteria (P. aeruginosa was significant at
50 pg/ml, p # .001 [Fig. 5B] and P. mirabilis was significant at
50 pg/ml, p # .001 [Fig. 5C]). However, Hp demonstrated no sig-
nificant effect on the growth of either Gram-positive bacterium
(Fig. 5D, 5E).
Figure 2. OMLP-PCs exert antibacterial effects through the secre-
tion of soluble factors. Conditioned media (CM) derived from
OMLP-PCs significantly reduced the growth of Gram-positive
E. faecalis(A) and S. pyogenes (B) and Gram-negative P. aeruginosa
(C) and P. mirabilis (D) bacteria. CM from EFs had no significant effect
onbacterial growth.Data areexpressed as thepercentageof growth6
SEM, with bacteria-only cultures set to 100%. ppp, p # .001. Abbrevi-
ations: EFs, enriched fibroblasts; IFN-g, interferon-g; OMLP-PCs, oral
mucosal lamina propria-progenitor cells.
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Figure 3. OMLP-PCs constitutively express and secrete OPG. OPG expression and secretion was unchanged by IFN-g priming of OMLP-PCs
and/or exposure to Gram-positive E. faecalis (A, E) and S. pyogenes (B, F) or Gram-negative P. aeruginosa (C, G) and P. mirabilis (D, H) bacteria.
Genomic expression data are presented as the fold change from resting OMLP-PCs6 SEM and OPG secretion data as ng/ml6 SEM. Abbrevia-
tions: EFs, enriched fibroblasts; IFN-g, interferon-g; OMLP-PCs, oral mucosal lamina propria-progenitor cells; OPG, osteoprotegerin.
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Blocking Hp Inhibits Antibacterial Properties of OMLP-
PCs Against Gram-Negative Bacteria
CM derived from OMLP-PCs (with or without previous bacterial
exposure) was incubated with live, Gram-negative bacteria in
the presence or absence of an anti-human Hp antibody. By block-
ing the secretedHp in theCMsamples ofOMLP-PCs (with orwith-
outbacterial exposure), thegrowthofP. aeruginosa (p # .001 for
both, with or without bacterial exposure; Fig. 5F) and P. mirabilis
(p # .01 forboth,withorwithoutbacterial exposure; Fig. 5G)was
significantly increased compared with samples in which Hp had
not been blocked. The growth of P. aeruginosa and P. mirabilis
was fully restored to control levels by blocking Hp.
OMLP-PC-Mediated Antibacterial Action
Is Bacteriostatic
Bacterial cultures were incubatedwith CMderived fromOMLP-
PCs, rhOPG (Gram-positive bacteria), or Hp (Gram-negative
bacteria), as previously stated. Subsequent to incubation, the
bacterial cultures were stained using the LIVE/DEAD BacLight
staining kit. Bacterial viability was not compromised when bac-
teria were incubated with CM with or without bacterial expo-
sure, rhOPG, or Hp (Fig. 6A–6D).
DISCUSSION
We have previously reported the potent immunomodulatory po-
tential of OMLP-PCs and their mode of action through the release
of soluble factors [5]. In addition to their immunosuppressive
properties, BMMSCs have recently been reported to display an-
tibacterial properties [12, 24], leading to the hypothesis that im-
munomodulatory OMLP-PCs might also exhibit equivalent or
potentially enhanced antibacterial properties because of their
anatomical site of origin. The present study has demonstrated a re-
producible direct antibacterial action by OMLP-PCs against both
Gram-positive and Gram-negative bacteria in a bacteriostatic
manner through the constitutive release of the differentially act-
ing soluble factors, OPG and Hp.
Figure 4. OPG demonstrated antibacterial properties against Gram-positive bacteria. OPG reduced the growth of Gram-positive bacteria
E. faecalis (A) and S. pyogenes (B) only (no effect on Gram-negative bacteria [C, D]). Blocking OPG within the conditioned media of OMLP-
PCs significantly restored thegrowthofGram-positive E. faecalis (E)andS. pyogenes (F)bacteria.Dataareexpressedas thepercentageofgrowth
6 SEM, with bacteria-only cultures set to 100%. p, p # .05; pp, p # .01; ppp, p # .001. Abbreviations: EFs, enriched fibroblasts; IFN-g,
interferon-g; OMLP-PCs, oral mucosal lamina propria-progenitor cells; OPG, osteoprotegerin.
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To date, limited evidence of stem cell-mediated antibacte-
rial action has been documented. Both IDO and LL-37 have been
implicated in the BMMSC mechanism of action [12, 24]. Within
the present study, we found evidence for the importance of
soluble factors in OMLP-PC-mediated antibacterial activity.
However, in contrast to the BMMSC reports, no expression of
LL-37 was seen within the OMLP-PCs (data not shown), and
IDO, as we have previously reported, is only inducible by
Figure 5. Haptoglobin is constitutively secreted byOMLP-PCs and demonstrates antibacterial properties against Gram-negative bacteria. (A):Hp
was constitutively detected in the conditionedmedia (CM)ofOMLP-PCs (n=3donors; lanes2, 4, and6, irrespectiveof IFN-g stimulationof the cells
[lanes 1, 3, 5]). Lane 7 indicates theHp-positive control. Hp reduced the growth of P. aeruginosa (B) andP.mirabilis (C) bacteria only (no effectwas
seen on Gram-positive bacteria [D, E]). Blocking Hp in the CM restored the growth of the Gram-negative P. aeruginosa (F) and P. mirabilis (G)
bacteria. Data are expressed as the percentage of growth6 SEM, with bacteria-only cultures set to 100%. p, p # .05; pp, p # .01; ppp, p # .001.
Abbreviations: EFs, enriched fibroblasts; Hp, haptoglobin; IFN-g, interferon-g; OMLP-PCs, oral mucosal lamina propria-progenitor cells.
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inflammatory stimuli and not constitutively expressed, as per
the antibacterial effect shown [5].
Similar antibacterial effects ofMSCs have been noted inmu-
rine models, with an increase in bacterial clearance on MSC
treatment of sepsis [25] and E. coli-induced pneumonia [26],
with lipocalin 2 thought to play a role in the latter. Our data have
demonstrated that OMLP-PCs are antibacterial via the release
of soluble factors. Additionally, we have shown that CM from
OMLP-PCs is antibacterial through a bacteriostatic mechanism,
ruling out soluble factors, which act in a bactericidal manner,
such as the family of defensins and LL-37 [27]. The constitutive
antibacterial nature of OMLP-PCs also differs from the reported
mechanism seen in BMMSCs, for which exposure to bacteria is
necessary for the cells to exert their effect by secreting soluble
factors [12]. These differential modes of action among sources
of stem cells is to be expected, and we hypothesize that in vivo
priming and the niche environment from which the cells are
derived will have a significant effect on their antibacterial
properties.
OPG is vital in bone remodeling, regulating the process by acting
as a decoy receptor for RANKL and influencing osteoclastogenesis
[28]. The major bacterium involved in periodontal disease,
P. gingivalis [29], is known to be capable of inducing OPG in human
cells. The inductionofOPGbyP. gingivalishasbeendemonstrated in
both endothelial cells [30] and gingival fibroblasts fromboth healthy
and periodontitis patients, with the varying levels potentially corre-
lating with disease status [31]. Patients with periodontitis display
lower levels of OPG within the gingival crevicular fluid [20, 21] and
gingival tissue [22] compared with healthy controls. However, each
published study todatehas comparedOPGtoRANKLwithin the con-
text of bone remodeling and osteoclastogenesis. The clinical impor-
tance of OPG alone regarding bacterial infection during periodontal
disease has not yet been explored.
We have demonstrated, for the first time, the novel anti-
bacterial properties of OPG, which exerts a direct antibacterial
action specifically against Gram-positive bacteria, through
a bacteriostatic mechanism. OPG is constitutively secreted
by OMLP-PCs at concentrations high enough to exert antibac-
terial effects. Furthermore, neutralization of OPG within the
CM significantly restored the growth of the Gram-positive
bacteria tested. However, because complete restoration in
the growth of either bacterium to control levels was not
Figure 6. OMLP-PCs exert their antimicrobial actions via bacteriostatic mechanisms. LIVE/DEAD staining of E. faecalis (A), S. pyogenes (B),
P. aeruginosa (C), and P. mirabilis (D) cultures after incubation with OMLP-PC conditioned media with or without bacterial exposure, recombi-
nant human OPG and haptoglobin. No bactericidal effect was seen with any of the test conditions. Data are expressed as the percentage of
live/dead cells 6 SEM. Black bars indicate the percentage of live cells; and checkered bars, the percentage of dead cells. Abbreviations:
EFs, enriched fibroblasts; IFN-g, interferon-g; OMLP-PCs, oral mucosal lamina propria-progenitor cells; OPG, osteoprotegerin.
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observed, we hypothesize that OPG is not the only factor in-
volved in this antibacterial mechanism against S. pyogenes
and E. faecalis.
In contrast to the other Gram-positive bacteria used in
the present study, the antibacterial effect of the CM was
greater against S. pyogenes when previous exposure of the
OMLP-PCs to the bacteria had occurred. We hypothesize that
thismight be a consequence of in vivo priming. OMLP-PCswill
have been exposed to streptococcal species in vivo, because
these are one of the predominate bacterial genera within the
oral cavity [32]. This could explain the heightened response
of the primed CM to S. pyogenes, because the cells might
have been sensitized to recognize this genus. Further inves-
tigations will determine whether the CM acts in a similar
manner to other bacteria commonly found within the oral
cavity.
Hp has long been known to display antibacterial proper-
ties against the Gram-negative bacterium E. coli [11]. Hp’s
mechanism of action is simple, sequestering iron and, there-
fore, reducing the iron available for bacteria [10]. Impor-
tantly, iron is crucial for bacterial growth, with a deficiency
causing bacterial growth inhibition [33]. Although iron is es-
sential for most bacteria, the levels required and uptake
mechanisms vary considerably between microorganisms.
Generally, Gram-negative bacteria recognize iron sources
via an outer membrane receptor. The iron is then trans-
ported into the cell by an ATP-binding cassette transporter
within the inner membrane [34]. Because Gram-positive bac-
teria lack an outer membrane, iron uptakemechanisms differ
from that of the Gram-negative bacteria. The differences in
iron uptake mechanisms are the likely reason Hp only demon-
stratedantibacterial propertiesagainst theGram-negativebacteria
examined. The studies confirmed the efficacy of Hp’s antibac-
terial properties, with bacteriostatic effects evident down to
levels as low as 50 pg/ml. Western blot analysis identified mul-
tiple isoforms of Hp constitutively expressed within the secre-
tome of the OMLP-PCs, with the presence of the a1 chain
suggesting the production of the higher affinity Hp1-1
and/or Hp2-1 isoforms. Blocking of this protein was sufficient to
completely restore bacterial growth, suggesting this is the ma-
jor mechanism of OMLP-PC antibacterial action against Gram-
negative bacteria.
Wound healing within the oral mucosa is well documented
to be preferential, characterized by rapid re-epithelialization,
remodelingof theextracellularmatrix, and rapid transition through
the inflammatory phase [23, 35–38]. Our previous work suggested
a potential role for immunomodulatory OMLP-PCs resident within
the lamina propria in orchestrating this healing response [4, 5]. The
finding that this cell source possesses additional innate antibacte-
rialpropertiessupportsthehypothesis thatOMLP-PCsoffer anovel
cell source for the development of cell- or soluble factor-basedlocal
treatment of chronic nonhealing wounds or systemic infusions for in-
fectious disorders such as bacterial pneumonia.
Additionalstudiesarerequiredtoexaminefurthertheantibacterial
factors secreted by the OMLP-PCs, particularly against Gram-positive
bacteria as the presence of OPG did not fully explain the antibacterial
properties of the cells. Future work will concentrate on investigating
the potential factors involved in these antibacterial mechanisms and
how these findings can be exploited for clinical translation.
CONCLUSION
Within the present study, we have demonstrated, for the
first time, the broad spectrum antibacterial properties of
OMLP-PCs. These PCs constitutively secrete antimicrobial soluble
factors with bacteriostatic activity against both Gram-positive
and Gram-negative bacteria. Analysis of the OMLP-PC secretome
confirmed a role forOPG in the suppression ofGram-positive bac-
terial growth and for Hp in inhibiting Gram-negative bacteria. The
findingswehave reported illustrate thepotential forOMLP-PCs in
the development of novel antibacterial cell- or soluble factor-
based therapies for conditions such aspneumonia or chronic non-
healing wounds.
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